"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Good morning, and welcome to the Fourth Quarter 2014 Earnings Conference Call. [Operator Instructions] I will now hand today's call over to Regina Nethery. Please go ahead.",27,"Good morning, and welcome to the Fourth Quarter 2014 Earnings Conference Call. [Operator Instructions] I will now hand today's call over to Regina Nethery. Please go ahead."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Humana's senior management team will discuss our fourth quarter and full year 2014 results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be: Bruce Broussard, Humana's Pr",343,"Thank you, and good morning. In a moment, Humana's senior management team will discuss our fourth quarter and full year 2014 results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be: Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Senior Vice President and Chief Financial Officer. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts.
Joining Bruce and Brian for the Q&A session will be: Jim Mary, Executive Vice President and Chief Operating Officer; and Christopher Todoroff, Senior Vice President and General Counsel.
We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. This call is also being simulcast via the Internet along with a virtual slide presentation. An Adobe version of today's slide deck has been posted to the Investor Relations section of Humana's website.
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in this morning's earnings press release, as well as in our filings with the Securities and Exchange Commission. Today's press release, our historical financial news releases and our filings with the SEC are all available on Humana's Investor Relations website.
Call participants should also note that today's discussion and slide presentation include financial measures that are not in accordance with Generally Accepted Accounting Principles. Management's explanation for each of these non-GAAP measures is included in today's slide presentation, including a reconciliation of GAAP to non-GAAP financial measures. Finally, any references to earnings per share or EPS made during this morning's call refer to diluted earnings per common share.
With that, I'll turn the call over to Bruce Broussard."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Good morning, everyone, and thank you for joining us. This morning, Humana reported full year adjusted earnings per share for 2014 of $7.51, in line with our 2014 guidance. This past year was particularly dynamic across the sector and presented a number o",1359,"Good morning, everyone, and thank you for joining us. This morning, Humana reported full year adjusted earnings per share for 2014 of $7.51, in line with our 2014 guidance. This past year was particularly dynamic across the sector and presented a number of challenges, as well as some new opportunities. Humana continues to rise to these challenges through our consumer-focused strategy and integrated care delivery model while simultaneously investing in new growth areas. As a result, we are reiterating our guidance for 2015 earnings of $8.50 to $9 per share, a growth rate of approximately 17% at the mid-point. 
As we outlined in our Investor Day this past December, Humana's investment thesis is driven by our customer-focused, integrated care delivery model and the related results. This thesis includes 4 key elements: Continued robust organic membership and revenue growth; proven superior clinical operating performance; disciplined capital allocation, which all lead to a sustainable, competitive advantage.
I'll begin our discussion this morning with a focus on our membership and revenue growth. We recently raised our net Medicare Advantage membership growth expectations for 2015 to 300,000 to 350,000, primarily as a result of a strong sales during -- results of strong sales during a recently completed annual election period or AEP.
And looking at the January enrollment data from CMS, Humana continues to lead the industry in membership growth for individual Medicare Advantage plans. The CMS data indicates that Humana accounted for nearly 70% of the individual MA net enrollment growth across the sector. In fact, approximately 52% of our individual gross sales during the AEP came from competitor Medicare Advantage offerings.
From a geographic perspective, we did not see strong specific concentration with this growth, but did experience our highest membership gains in North Carolina. We are pleased with this individual MA growth as it complements the group MA membership increase we experienced in that state in 2014, making this a very important Humana market.
With a large base of Medicare members, we are now able to bring other Humana offerings, like HumanaOne, to the state. As you'll see from Slide 8, approximately 73% of our individual MA net growth was in HMO offerings, including current Humana members who chose to move to an -- into an HMO in 2015. This compares to 64% in 2014. 
Our HMO offerings continue to provide the highest level of engagement from both a member and provider perspective and also have the highest retention rate of our Medicare products. Over the past few years, we've discussed our integrated care delivery model and its 3 core elements: Improve the consumer experience by simplifying the interaction resulting in a trusting relationship; based on the trusting relationship, engage members and clinical programs; and offering assistance to providers and transitioning from fee-for-service to value-based reimbursement. 
This strategy has provided superior clinical operating performance resulting in a sustainable competitive advantage. Over the past few years, membership growth in Star scores provide evidence of the success of this strategy. We believe there are 5 key points of influence that drive our superior clinical operating performance. Although I will not go through all the detail on the slide today, I did want to highlight how we are already been working with our new 2015 members, allowing us to begin to get to know them and allow for timely enrollment in the proper clinical programs.
I'll begin with wellness and prevention. Staying in tune with the health of our members is a major focus of our wellness and prevention efforts. This all begins with our new member welcome calls. This call begin shortly after the onset of the AEP this past October. This outreach efforts have already resulted in the completion of over 160,000 health risk assessments. Data from the welcome calls, health risk assessments and our sophisticated predictive modeling have already come together to identify more than 46,000 of our members for referrals to our Humana At Home.
Our wellness efforts have a strong focus on gaps-in-care. In 2014, we closed approximately 4.3 million gaps-in-care for our members, driven by improvement in preventative screenings. Better still, we are very pleased that approximately 1.3 million of our members across all lines of business received preventative treatment on schedule.
Turning to the primary care point of influence. We are pleased to report that approximately 55% of our net membership growth during the AEP is for members associated with providers and value-based arrangements. Remember that we offer providers a continuum of opportunities to increase the integration of care. This includes performance bonuses, shared savings and shared risk relationships.
We see HHS announcement last week on its move to paying providers based on value as further validation that our integrated care delivery strategy is on track. We look forward to working with HHS in developing new payment models and continuing to assist providers in the transition to value-based payment.
Health care @Home will also be an important element of the care for many of our new members. As we've shared with you in the past, our Humana At Home programs did a terrific job of providing members with clinical support and care that often results in a significantly higher number of days they spend at their homes instead of in an acute care facility. 
Importantly, as we evaluate each of the points of influence I've just described, as well as our pharmacy interactions with our members, we utilize advanced analytics, including sophisticated predictive models, to provide insights that are both actionable and drive value for our members. All these metrics are indicative of the solid value proposition we continue to offer Medicare beneficiaries in the phase of rate reductions. Successfully engaging our members in clinical programs is proving we can assist our members with their health needs. This is allowing us to offer stability in their premiums and benefits, and reduce the complexity of navigating the health care system and helps produce the robust organic growth we are sharing with you today.
Looking at our other offerings. Humana's stand-alone PDP membership continues to experience strong growth with the bulk of the growth in our low-priced Walmart offering. This, together with growth in our Medicare Advantage membership, drives higher use of the services in our Healthcare Services segment, benefiting the enterprise overall.
Turning to our HumanaOne membership. As we evaluate recent health care exchange enrollment data, we believe it comports well with the pricing assumptions we made for 2015. As we've indicated on prior calls, our 2015 pricing appropriately assume the ultimate elimination of 2 of the 3Rs. We continue to be pleased with the mix of our membership, both across the metal tiers and by age distribution. We also believe that the 55 to 64 age ranges are opportunity to develop relationship with these members before they age into Medicare Advantage.
I also would want to highlight for you today something innovative we are doing in the Employer Group business. In the latter part of 2013, we introduced to our employer customers a product we call Total Health, which turns any standard medical plan of the employers choosing into an integrated health and well-being solution that encourages participation in HumanaVitality, health coaching and clinical programs. Employee participation results in employer discounts, which is resulting in the shift of our single year contract to a multi-year relationship that is creating employer solutions to not only cost, but also productivity.
Employer receptivity to the Total Health product is line with membership now at approximately 100,000 versus less than 400,000 at the end of 2013. We anticipate in the future these wellness programs and services will be complementary to employers choosing private and public exchange models. 
In conclusion, we continue to be pleased with our prospects for 2015 and beyond. The engagement of our associates and focus on the consumer through our integrated care delivery model has never been stronger. We believe that will result in the continuation of our superior clinical operating performance and a sustainable, competitive advantage for quite some time to come. 
With that, I'll turn the call over to Brian for a more detailed discussion of our financials and our commitment to disciplined capital allocation."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. As Bruce said in his remarks, 2014 was an unusually dynamic year full of opportunities and challenges. The growth in our Medicare business was substantial and was supplemented by the power of our Healthcare Se",1299,"Thank you, Bruce, and good morning, everyone. As Bruce said in his remarks, 2014 was an unusually dynamic year full of opportunities and challenges. The growth in our Medicare business was substantial and was supplemented by the power of our Healthcare Services segment, which has prospered while making a truly positive difference in our member's lives. Our Employer Group business capitalized on the way 2013 rollout of an exciting new offering in the form of total health, while also ending the year on a high note in terms of financial performance. All these transpired while we invested heavily in new growth opportunities, both HumanaOne and our state-based businesses, which we believe will generate significant returns for our shareholders down the road.
We are pleased that our full year adjusted EPS came in just above the mid-point of our guidance at $7.51 per share. As we close out the year, there were a few items that adversely affected our 2014 results, but we do not see any of these significantly impacting our 2015 guidance. 
Our Retail segment pretax earnings finished the year below our guidance range. This was primarily attributable to the severity of the flu season, slightly higher investment spending for our rules and state-based contracts and deterioration in the results for our Puerto Rico Medicare business, which continues to be a difficult market for us.
With regard to the flu, hospital inpatient admissions peaked in late December, early January, but have since abated and have returned to more normalized levels. I should hasten to add that utilization more broadly remains benign and within expectations.
With regard to the duals, we continue to build out our for structure and are well-positioned heading into 2015 to significantly reduce our investments, which we have committed to do.
Turning to the Employer Group segment. Our 2014 earnings results ended meaningfully above the upper end of our guidance range. While the flu did have some adverse impact on the Employer Group results, these were more than offset by lower medical claims utilization that we saw in both our commercial and Group Medicare businesses. It is also important to note the effort that our Employer Group team has made to reduce administrative costs, which was also a significant driver of the segment's full year results.
Finally, our effective tax rate came in above the range of our previous guidance. There were several factors driving this, including the associated tax ramifications of higher losses in our Puerto Rico Medicare operations, which are non-deductible for U.S. income tax purposes, as well as lower tax exempts investment income. We've evaluated each of these factors closely and have confidence that the 2015 guidance points we shared with you this morning encompass any continuing impact of each of these items.
Turning now to 2015. The majority of the guidance points we shared with you last quarter are unchanged. This slide summarizes the more significant changes since our last earnings call.
As we disclosed in a Form 8-K filing last month, we revised our Medicare Advantage and stand-alone PDP enrollment guidance to reflect the results of the 2015 AEP. Our higher projection for Medicare Advantage enrollment resulted in an increase to our revenue guidance that more than offset the revenue impact of the lower expectations for stand-alone PDP membership. As we have discussed in the past, the higher membership in our MA plans from the annual enrollment process will have a nominal impact on our Retail insurance segment performance this year. While there will be a favorable impact on the Healthcare Services segment home-based business from the higher Medicare Advantage membership, this will be offset by the impact of the revised stand-alone PDP membership will have on Humana pharmacy, as PDP members in our low price point offering tend to use our wholly owned mail order and Specialty pharmacies at rates slightly higher than our MA members.
One other element of our 2015 guidance points that we updated today is our projected accruals for the premium stabilization programs, commonly called the 3Rs. As Bruce shared in his remarks, we now have more color around the mix of our membership distribution, among the metal tiers and by age range. Having evaluated that data, we're comfortable lowering our projection for full year accruals for the 3Rs by approximately $50 million at the mid-point. We now expect the net receivables for 2015 to be less than half of the level they were compared to the balances we accrued at the end of 2014.
As we've noted in prior calls, our pricing strategy for 2015 included significantly lowering reliance on the 3Rs, and we are still on track for 2015 to achieve at a minimum breakeven results.
With regard to the risk corridors. We believe that the 2014 $51 million net receivable that we disclosed this morning is indeed collectible based on statutory and administrative actions. Further, any 2014 amounts must first be satisfied before subsequent years are paid. Finally, for 2015, the risk corridor receivable that we are currently forecasting is insignificant.
Turning to our operating cash flows. We have been around 1.5x net income for some time now, and we anticipate maintaining that quality of earnings metric again in 2015. This morning, we raised our guidance for operating cash flows by approximately $200 million, driven primarily by the timing of certain working capital items. While our days claims payable declined sequentially by 2.8 days to 44.7, this was primarily due to the increasing capitation payments as we continue to grow the number of providers under risk-based contracts, as well as the growth in our long-term support services business, whose providers get paid monthly. 
Additionally, our normal December decline in claims inventories, driven by the holiday season and higher staffing associated with preparing for new members coming on January 1, was magnified by the relatively late HumanaOne enrollment and the associated pended claims, which we paid down in the fourth quarter.
I'll now turn to our view of the quarterly breakdown of earnings for 2015. Though we do not divide specific quarterly guidance, we did want to give you a sense for the key drivers of performance among the quarters, as we've done in prior years. Given our expectations that our health care exchange business will at least breakeven and our investments in state-based contracts will begin to mitigate, we've layered in the impact of those newer businesses across the quarters. The results is that we again project the third and fourth quarters to experience the most pressure in light of the quarterly progression of health benefit ratios and the timing of marketing and Open Enrollment across our lines of business.
I'll conclude my discussion this morning with a few words around capital allocation. As Bruce said in his remarks, disciplined capital allocation is a key component of Humana's investment thesis. At the time of our third quarter release, we announced a significant increase in our share repurchase authorization and a commitment to accelerate our buyback activity. We've held true to that commitment and maintained our expectation to buy back $1 billion in stock by June of this year with approximately $630 million of that already completed. We would also expect to continue share repurchases in the back half of the year.
Aside from share repurchase activity, we are continuing to evaluate all of our businesses to ensure that they fit strategically within our portfolio and our earning the cost of capital will have a convincing plan to do so. To the extent, if business does not meet this criteria, that business will be restructured or divested. We expect to continue to update you on the progress of this review over the coming months.
With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] Your first question comes from the line of Justin Lake with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Justin Lake with JPMorgan."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Question around the retail results. You laid out a few headwinds to the quarter. Can you put some numbers around them? And also, give us some color on your positioning in Puerto Rico Medicare and how much money you're losing there right now?",43,"Question around the retail results. You laid out a few headwinds to the quarter. Can you put some numbers around them? And also, give us some color on your positioning in Puerto Rico Medicare and how much money you're losing there right now?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Sure. So the flu is a major driver. It was around $45 million all in for the company, but [ph] 3/4 of that was driven in the Retail segment. With regard to Puerto Rico, I rather not go into the details of the numbers there, but we are losing money in that",166,"Sure. So the flu is a major driver. It was around $45 million all in for the company, but [ph] 3/4 of that was driven in the Retail segment. With regard to Puerto Rico, I rather not go into the details of the numbers there, but we are losing money in that market. We lost more this quarter than we expected. And really, that's driven by the fact that the dynamics in that market are different. The medical management of those members is different. We got hit by uncompensated care adjustments that we had to take into our results that weren't in the bids because they came after the bids. And so 2014 was a very difficult year for that market. On the duals side, we're continuing to build up that infrastructure. As we think about investments for 2014, I would say the duals came in slightly higher. Individual came in slightly lower. So that's sort of how I'd calibrate those results on the Retail segment."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Kevin Fischbeck with Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck with Bank of America."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Just wanted to follow up on that, I guess, last comment before the Q&A about evaluating certain businesses, making sure that they are you guys talking a lot about this before. Is there -- are there significant business lines that are currently being evalu",79,"Just wanted to follow up on that, I guess, last comment before the Q&A about evaluating certain businesses, making sure that they are you guys talking a lot about this before. Is there -- are there significant business lines that are currently being evaluated? And I think you mentioned either the deduction number or fixing. Is there anything in the guidance that would contemplate some potential cost of fixing of this that's one that return that you are copying?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, our guidance really incorporates all of our current businesses as they stand today. We are very focused on continuing to drive down admin cost and, as you saw that in the Employer Group segment this year. We'll continue to work on that, but we're ev",102,"Well, our guidance really incorporates all of our current businesses as they stand today. We are very focused on continuing to drive down admin cost and, as you saw that in the Employer Group segment this year. We'll continue to work on that, but we're evaluating all the lines of business. I think we've been very clear that all the businesses over time need to earn their cost of capital, and we're going to make sure that, that occurs. And we're being very disciplined about it. So I don't want to comment on any specific businesses, but we're evaluating our entire portfolio."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So I guess, maybe is there a way to frame it? Are we talking about things are on the edges or are there decent sized parts of the business that are being evaluated?",33,"So I guess, maybe is there a way to frame it? Are we talking about things are on the edges or are there decent sized parts of the business that are being evaluated?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Again, I'd say all of our business are being evaluated. I think we feel very good about our core businesses. So I wouldn't see any major change in that regard. But there are a number of businesses that need to hit their returns, and we'll focus on that.",48,"Again, I'd say all of our business are being evaluated. I think we feel very good about our core businesses. So I wouldn't see any major change in that regard. But there are a number of businesses that need to hit their returns, and we'll focus on that."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Josh Raskin with Barclays.",12,"Your next question is from the line of Josh Raskin with Barclays."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","The question is around that Medicare Advantage growth and the source and the drivers. I think I heard you say 52% had come from competitors. I guess I was a little surprised to hear that, that I know last year was a little bit of anomaly. But I was just y",97,"The question is around that Medicare Advantage growth and the source and the drivers. I think I heard you say 52% had come from competitors. I guess I was a little surprised to hear that, that I know last year was a little bit of anomaly. But I was just yours of worry that trend in the past. And as you think about the overall MA growth, how much of that is coming from previously fee-for-service Medicare life, how many are aging, how many are PDP conversions, and maybe any other buckets just overall that MA growth?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, this is Jim Murray, as we look across the various markets that we grew, and there were probably 10 or 12 markets that we would point to, we're seeing the beneficial impact of our higher Stars rating, we believe, having a favorable impact in the way t",206,"Yes, this is Jim Murray, as we look across the various markets that we grew, and there were probably 10 or 12 markets that we would point to, we're seeing the beneficial impact of our higher Stars rating, we believe, having a favorable impact in the way that we're able to position ourselves relative to the competition. Bruce earlier talked about North Carolina, and that's the market where we have 4.5 stars, and some of the competitors that were there before didn't have as high as Star score. And we think that, that come in terms of the premium and benefits that we're able to put on The Street helps to position us better. So I would say that that's 1 aspect that we're you're seeing play itself. We're obviously very pleased about that. As respects, the number of members that we get from competitors versus fee-for-service, I would tell you that, that number, as we look at, is about 50-50. Agents generally, a significant part of the agent growth occurs during the as opposed during the AEP itself. A lot of favorable dynamics. And again, as Brian and Bruce both pointed out, we're pretty pleased with the way the this AEP played out for us."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Josh, one thing I would add to that is as you -- as we've discussed, we have got great growth in our HMO area and our strategy has always been is create a relationship through the PPO product and then evolve them over. And we just see that strategy contin",69,"Josh, one thing I would add to that is as you -- as we've discussed, we have got great growth in our HMO area and our strategy has always been is create a relationship through the PPO product and then evolve them over. And we just see that strategy continuing to be strong, which both helps us on retention, but also the engagement and helping them with their health."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And just a follow-up on that. So one, are you seeing any material impact from PDP conversions in the AEP? And then, I guess, I'm just looking that sort of competitive impact you're using, is that different than what you've seen in previous years? Is the i",69,"And just a follow-up on that. So one, are you seeing any material impact from PDP conversions in the AEP? And then, I guess, I'm just looking that sort of competitive impact you're using, is that different than what you've seen in previous years? Is the impact of stars more important now? Or you're doing better, vis-Ã -vis, the competition in the differently that you've seen in previous years?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I think last year, we have the same circumstance. I just -- we sound like a broken record, but our clinical platform has allowed us to offer stable benefits in the marketplace. And that clinical platform is not only helping us with stars scores, but it's",137,"I think last year, we have the same circumstance. I just -- we sound like a broken record, but our clinical platform has allowed us to offer stable benefits in the marketplace. And that clinical platform is not only helping us with stars scores, but it's also helping beach individuals and getting them in the right clinical programs, which is ultimately lowering the cost of the medical side, which is then turn around and allowing us to offer the proper benefits. So I think it all sort of fits together. It's just not stars. I would say that that's a contributor in the individual marketplaces, but I wouldn't look away from the call them and say that's our competitive advantage. Our competitive advantage is really the clinical programs that drives both lower medical costs and better quality."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of A.J. Rice with UBS.",13,"Your next question is from the line of A.J. Rice with UBS."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I might just ask you about 2 items that were in your walk forward to guidance last quarter. I think you had in there about a $0.35 tailwind from lower investments and exchange state based contracts. And Brian, you mentioned that a little bit in your prepa",118,"I might just ask you about 2 items that were in your walk forward to guidance last quarter. I think you had in there about a $0.35 tailwind from lower investments and exchange state based contracts. And Brian, you mentioned that a little bit in your prepared remarks. I wondered if there's an update on what you're thinking terms of investments and the timing. And then the other one I was going to ask you about was Hep C. You had a $0.45 tailwind in your guidance there. And since then, I know you provide -- you've done your vendor contract with Gilead, and I wondered, did that $0.45 contemplate that contract or is there now potential upside?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","So with regard to the first question on the investments. I would say it's similar to what we discussed last call in terms of what we're expecting. Again H1, we expect to breakeven or hopefully, do better than that. On the Medicaid duals side, we're expect",139,"So with regard to the first question on the investments. I would say it's similar to what we discussed last call in terms of what we're expecting. Again H1, we expect to breakeven or hopefully, do better than that. On the Medicaid duals side, we're expecting to reduce our investments, let's say, pretty significantly. I would think about it sort of as a $0.25 investment, plus or minus, on the Medicaid dual side for 2015. For Hep C, it really is early to tell. Let's see what happens for 2015. Clearly, the unit price discount helps. But we still need to see where utilization ultimately plays out and we're watching that very closely, and we'll see over the next few months where we stand. I would say, as it looks today, we feel pretty good, but it's still early."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Scott Fidel with Deutsche Bank.",13,"Your next question comes from the line of Scott Fidel with Deutsche Bank."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Just interested if you can give your thoughts on the CMS value-based contracting initiative for fee-for-service and whether we would view that as far as a positive or a risk for MA. And just thinking about from a reinvestment perspective, if you think the",89,"Just interested if you can give your thoughts on the CMS value-based contracting initiative for fee-for-service and whether we would view that as far as a positive or a risk for MA. And just thinking about from a reinvestment perspective, if you think there's any risk that MA rates could be pressured in the intermediate long-term if CMS does assume lower unit cost and lower cost trends in fee-for-service and whether that gets translated in the per capita growth rate assumption that they make for the MA business."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I think, overall, our view is this transition, the value-based reimbursement and getting more providers in those reimbursement is the best for, I think, the industry as a whole. I think we look at that as an opportunity for us both in the helping provider",176,"I think, overall, our view is this transition, the value-based reimbursement and getting more providers in those reimbursement is the best for, I think, the industry as a whole. I think we look at that as an opportunity for us both in the helping providers and at the same time, continuing to advance the Medicare Advantage positioning. In regards to does it affect the benchmark, I think, is where you're getting to. Over time, it will sell not benchmark and I think there's any kind of there that's lowering the cost in Medicare and it gets effective. But I do think, long term, the Medicare Advantage offers significantly better advantage as you look at the comprehensive nature of them. It's just not about the price. It also what we found is about integration of the services and the system that's provided there. But at the same time, we realized that we have to be better than the competition in our clinical programs, and that competition is both within Medicare Advantage and also Medicare as a whole."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Andy Schenker with Morgan Stanley.",13,"Your next question is from the line of Andy Schenker with Morgan Stanley."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Brian's comments in the prepared remarks on PCP. You've been trending down for some time. Maybe if you could just give me a little bit more understanding about the moving parts behind the trend over that time, including maybe specifically how changing mix",75,"Brian's comments in the prepared remarks on PCP. You've been trending down for some time. Maybe if you could just give me a little bit more understanding about the moving parts behind the trend over that time, including maybe specifically how changing mix has impacted that number? So you've mentioned the long-term Support Services, but how to growing exchange, MA growth impact and how we should we be thinking about that metric going forward?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, the major driver really is decapitation. As we continue to increase our petitions and our capitation arrangements, patiently we have a better expense you don't have a reserve. And so that really is a major driver. if you look at the roll forward you",198,"Well, the major driver really is decapitation. As we continue to increase our petitions and our capitation arrangements, patiently we have a better expense you don't have a reserve. And so that really is a major driver. if you look at the roll forward you could see the days move really driven by that. The LTSS business us a similar dynamic in the sense that we pay the nursing homes on a monthly basis. And so again have this expense without having better serve. And so that'll naturally take it down. And then, as I mentioned in my prepared remarks, this quarter, we had an outlier in the sense of H1 and that the members came on a little bit later. There were a bunch of that the claims that we're working through, and we really did that over the fourth quarter. And so that really, I think -- those are the 3 major buckets what's driving the days claims. I'd also pacing had that our cash flow are still very strong. And so as we think about our quality of earnings metrics, we are very focused to make sire our cash flows are good and they are."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So therefore, just a follow-up going forward because you're expecting more growth and capitation. You expect that number to get going down, and does the growth in changes or MA somewhat offset that to the other side or...",38,"So therefore, just a follow-up going forward because you're expecting more growth and capitation. You expect that number to get going down, and does the growth in changes or MA somewhat offset that to the other side or..."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I think, all else being equal, I think that's right.",10,"I think, all else being equal, I think that's right."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Ralph Giacobbe with Credit Suisse.",13,"Your next question comes from the line of Ralph Giacobbe with Credit Suisse."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Back to the Puerto Rico book. Can you give us a sense of size and order magnitude of the loss? And then I know you exited Medicaid there. Can you maybe talk about your commitment to that region within Medicaid, Medicare and/or how you're going to be able",54,"Back to the Puerto Rico book. Can you give us a sense of size and order magnitude of the loss? And then I know you exited Medicaid there. Can you maybe talk about your commitment to that region within Medicaid, Medicare and/or how you're going to be able to sort of fix the issues?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, I'd rather not go into specifics on our P&L in that market. I would say they're real losses. They move the needle. They affected our tax rate. We are working hard to fix the problems in the market. The Medicaid -- losing a Medicaid contract,",141,"Well, again, I'd rather not go into specifics on our P&L in that market. I would say they're real losses. They move the needle. They affected our tax rate. We are working hard to fix the problems in the market. The Medicaid -- losing a Medicaid contract, I think, is indicative of where we are in deciding not to re up there. And so are you guys are working hard on that fixing the problems and getting our members to engage and improve the medical management and the like. Again, we have some one-timers here in 2014 as it related to uncompensated care and that the time in that came into effect with respect to the bids. But as I said, all of our business that are earning their cost of capital need to be evaluated, and we're certainly doing that."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Okay. Maybe I know you don't want to talk about the size of the losses. Can you give us a sense of even just the premium?",26,"Okay. Maybe I know you don't want to talk about the size of the losses. Can you give us a sense of even just the premium?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","There are about -- this is Jim. There are about 50,000 Medicare Advantage members in Puerto Rico as we ended the year. We purposely tried to downsize as respect our activities relative to the AEPs so that we could shrink that membership. The premium that",156,"There are about -- this is Jim. There are about 50,000 Medicare Advantage members in Puerto Rico as we ended the year. We purposely tried to downsize as respect our activities relative to the AEPs so that we could shrink that membership. The premium that we get from the federal government for Medicare is solid. As Brian alluded to earlier, the government made some change in the way that they pay hospitals after our bids where finalized for 2014. That was a big drag on our results. And the other thing that Brian mentioned, the loss of focus because we did lose the Medicaid contract and the clinical model that was commensurate to that negatively impacted our Medicare results. So we expect the smaller portfolio of business in 2015. And as Brian said, we're actively working on things that would improve that -- our prospects in Puerto Rico, and that's probably where we should end it."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Peter Costa with Wells Fargo Securities.",14,"Your next question is from the line of Peter Costa with Wells Fargo Securities."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Again, it's close to that of the year when we hear about what the 2016 Medicare Advantage rates are going to be. We know from December that 2.45% let's sort of what they were talking about for the growth rate at that point. But what are the factors should",69,"Again, it's close to that of the year when we hear about what the 2016 Medicare Advantage rates are going to be. We know from December that 2.45% let's sort of what they were talking about for the growth rate at that point. But what are the factors should we be considering that might be impacting the payments of you get from the government for Medicare rates in 2016?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, Peter, this is pure speculation, so it's always difficult. I think we look at the discussions that have historically been in the rate notice around in-home assessments as being an area of discussion. I also think the MRA adjustments are another area",87,"Yes, Peter, this is pure speculation, so it's always difficult. I think we look at the discussions that have historically been in the rate notice around in-home assessments as being an area of discussion. I also think the MRA adjustments are another area that possibly could be included in the right notice. But that's really based on the dialogue that has happened over the past few years with them, and I don't have any inside information more than anybody else does on what's going to come out."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And in terms of the range of possibilities, how would you think it would impact your ability to price business for next year and obtain growth for next year?",29,"And in terms of the range of possibilities, how would you think it would impact your ability to price business for next year and obtain growth for next year?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","This is Jim. We have always, over the last number of years, expected the worst. And as we focus on what our necessary actions relative to trend vendors, we plan for that and we'll see what happens in April, and then we evaluate our bid processes and strat",91,"This is Jim. We have always, over the last number of years, expected the worst. And as we focus on what our necessary actions relative to trend vendors, we plan for that and we'll see what happens in April, and then we evaluate our bid processes and strategies accordingly. But we're in the process, as we speak, of trying to identify trend vending activity that would address the worst case scenarios in some of the things that Bruce talked about, and we're putting those in place for 2016 as we speak."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","The next question comes from the line of Matthew Borsch with Goldman Sachs.",13,"The next question comes from the line of Matthew Borsch with Goldman Sachs."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Question on your guidance in the Medicaid duals. So I think as I understood, you're looking at a $0.25 approximate tailwind on that business from reduced investment. But am I correct that, that business is still losing money, if you will, when you count i",62,"Question on your guidance in the Medicaid duals. So I think as I understood, you're looking at a $0.25 approximate tailwind on that business from reduced investment. But am I correct that, that business is still losing money, if you will, when you count in the investment or expected to for 2015? Or is that wrong? And can you quantify any magnitude?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, if I wasn't clear, I think we expect around $0.25 of loss in 2015 for the state-based businesses, if that helps. And that is reduced from 2014 pretty meaningfully.",30,"Yes, if I wasn't clear, I think we expect around $0.25 of loss in 2015 for the state-based businesses, if that helps. And that is reduced from 2014 pretty meaningfully."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Okay. And can you give us a range of magnitude on 2014?",12,"Okay. And can you give us a range of magnitude on 2014?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","No, I would say, if you combine, which one and the duals, it was, call it, around $0.70, plus or minus.",21,"No, I would say, if you combine, which one and the duals, it was, call it, around $0.70, plus or minus."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Sarah James of Wedbush Securities.",13,"Your next question is from the line of Sarah James of Wedbush Securities."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Have Humana and other insurers have been working on providing new data to CMS that follows up on actions and results from home health risk assessments? And I'm wondering if there's been any consensus reached among the insurers or with CMS on how to effect",56,"Have Humana and other insurers have been working on providing new data to CMS that follows up on actions and results from home health risk assessments? And I'm wondering if there's been any consensus reached among the insurers or with CMS on how to effectively evaluate the results of that or the sufficiency of solid actions?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","No, there has been discussion on the effectiveness of in-home assessments and the work that's been done there on a number of different locations. I don't think there has been one proposal that has been agreed upon both by the industry and by CMS. And I do",73,"No, there has been discussion on the effectiveness of in-home assessments and the work that's been done there on a number of different locations. I don't think there has been one proposal that has been agreed upon both by the industry and by CMS. And I don't -- we don't want to get into commenting on what we think CMS would come out with based on our discussions about industry-wide and company specific."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Tom Carroll with Stifel.",12,"Your next question is from the line of Tom Carroll with Stifel."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So just a question on the 3Rs. How do you want investors to think about the change in the 3R accruals that you're making for 2015? I mean, is this just you have more color as you put it, which provides more visibility in operations? Or is Humana perhaps g",66,"So just a question on the 3Rs. How do you want investors to think about the change in the 3R accruals that you're making for 2015? I mean, is this just you have more color as you put it, which provides more visibility in operations? Or is Humana perhaps getting a little more aggressive on assumptions? I wonder if you can balance that all for us."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, I guess, I'd say we view it as a good thing that we're able to reduce the reliance on the 3Rs by over half. That's a delivered strategy we made by taking up pricing. we are very, very disciplined their industry part of our strategy that to breakeven",114,"Well, I guess, I'd say we view it as a good thing that we're able to reduce the reliance on the 3Rs by over half. That's a delivered strategy we made by taking up pricing. we are very, very disciplined their industry part of our strategy that to breakeven or better for 2015. So I think when we saw the new sales come in and breakdown by medal tier and age and geography, et cetera, we're able to take it down slightly from where we were on the third quarter, but we view that as a good thing. And again, feel positive about where we are in that business and how we price it."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","When we entered the exchanges in 2014, I think we communicated to the investors that we were going to grow in 2014, while in 2015, transition to, I'm sure that they were sustainability in that business long term. And what you see happening is that's what'",101,"When we entered the exchanges in 2014, I think we communicated to the investors that we were going to grow in 2014, while in 2015, transition to, I'm sure that they were sustainability in that business long term. And what you see happening is that's what's happening, that we grew in 2014. We would define success this year as maintaining our membership that we had in 2014 and 2015 and having maintain that level, while at the same time, reducing our reliance on the 3Rs specifically, 2Rs, to allow us to make that transition when the 2Rs go away next year."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Christine Arnold with Cowen.",12,"Your next question is from the line of Christine Arnold with Cowen."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Could you speak to your expectations for medical trends? Got a better economy, consumer confidence seems to be rising, fuel prices are down. Kind of like increasing big discretionary income for folks. Do think it might impact medical costs? And how do you",70,"Could you speak to your expectations for medical trends? Got a better economy, consumer confidence seems to be rising, fuel prices are down. Kind of like increasing big discretionary income for folks. Do think it might impact medical costs? And how do you build that into your Medicare Advantage assumptions with respect to trend vendors you're going to need and the medical trend expected in '15 versus '14 for MA?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Sure. Well, as you know, we did increase the expected trend for our commercial group business to 5.5% to 6.5% from 4.5%. So that was a significant increase and it's reflecting all the things that you just discussed. On the Medicare side, it's not as direc",103,"Sure. Well, as you know, we did increase the expected trend for our commercial group business to 5.5% to 6.5% from 4.5%. So that was a significant increase and it's reflecting all the things that you just discussed. On the Medicare side, it's not as directly tied to economic growth. There's probably some impact. We focus pretty intently on whether trend benders need to be relative to where the rates coming out from a CMS perspective. And I would say there's probably less marginal unlike the commercial side based on economic growth and other factors, employment, et cetera, that you would typically see."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","What about the fact that fuel prices were lower. Old people are spending less fuel to their vehicles and also what -- can you tell us what kind of trend vendor you assumed in '15 versus '14?",37,"What about the fact that fuel prices were lower. Old people are spending less fuel to their vehicles and also what -- can you tell us what kind of trend vendor you assumed in '15 versus '14?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","We're not going to get to that level of detail. I -- we haven't really evaluated or I don't know the answer to this specific, how fuel impacts it. But our -- we take a holistic view of where trend may be and a number of factors go into that.",51,"We're not going to get to that level of detail. I -- we haven't really evaluated or I don't know the answer to this specific, how fuel impacts it. But our -- we take a holistic view of where trend may be and a number of factors go into that."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I'm actually happy that the seniors have fuel for their cars because of their making...",16,"I'm actually happy that the seniors have fuel for their cars because of their making..."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","To the clinic.",3,"To the clinic."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","They can take care of things that they can take care of rather than wait for an acute event. So I'm happy about that.",24,"They can take care of things that they can take care of rather than wait for an acute event. So I'm happy about that."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Ana Gupte with Leerink Partners.",13,"Your next question is from the line of Ana Gupte with Leerink Partners."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I was just trying to see some of the less focused areas of business as they might be potential drivers for upside. So one of them is individual of exchange. I know there's so much smaller piece of your book. But 2 of your peers have stated that they lost",107,"I was just trying to see some of the less focused areas of business as they might be potential drivers for upside. So one of them is individual of exchange. I know there's so much smaller piece of your book. But 2 of your peers have stated that they lost money in '14 and taking some pretty serious pricing actions and removing see compliance plans. So there anything here that you might have been doing? And I get it that the MLR floor probably too care of the piece of this, but just '14 would guarantee that you community waiting for some of the off exchange books."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, so as we said, and I don't really want to distinguish between off exchange and on exchange in terms of our pricing's. As we said we've been very disciplined on pricing with our entire ACA compliant book. Off exchange is part of our strategy. It's an",82,"Yes, so as we said, and I don't really want to distinguish between off exchange and on exchange in terms of our pricing's. As we said we've been very disciplined on pricing with our entire ACA compliant book. Off exchange is part of our strategy. It's an important part of our strategy. And we're looking to mitigate the losses in both the off exchange and on exchange. And again, all in, as we said, we do expect to do that this year."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And then, secondly, as Brian, secondly on the small-group and maybe just your employer was book, you're employer loss ratio looks pretty good for this quarter. In the third quarter, it deteriorated, if I remember, right, somehow I didn't have a chance to",74,"And then, secondly, as Brian, secondly on the small-group and maybe just your employer was book, you're employer loss ratio looks pretty good for this quarter. In the third quarter, it deteriorated, if I remember, right, somehow I didn't have a chance to follow up on that. Our pricing show you jack up your pricing quite a bit for '15. So any improvement in margin there? And what are you baking into your guidance?"
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, back in the third quarter, we did suffer the impact of some of the transitional relief that we discussed. Now we got some of that back in the fourth quarter through, I would say, both during period and prior period development that were bette",102,"Well, again, back in the third quarter, we did suffer the impact of some of the transitional relief that we discussed. Now we got some of that back in the fourth quarter through, I would say, both during period and prior period development that were better than expectations. That was really the driver of the outperformance, along with the continued focus on admin costs. I would say, as we move into next year, we price for Hep C and the like, hopefully, we'll continue to see improvements there. And really, where we need to focus is on the admin side as well."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","There's one other dynamic in the small-group space of that you're all are aware of I'm sure that there's a movement basin the methodology, and that's kind of an interesting dynamic that we're watching play out with some of our competition whether price th",117,"There's one other dynamic in the small-group space of that you're all are aware of I'm sure that there's a movement basin the methodology, and that's kind of an interesting dynamic that we're watching play out with some of our competition whether price the committee rated business rights versus where we're at. As we sit here right now, we feel pretty good but how we're positioned and are monitoring not only the community rights, but the migration from our existing block of business into those with the transitional relief opportunity that we have. So again, feel pretty good about that, and I'm glad that you'd notice of that in some of the stuff that we provided."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Chris Rigg with Susquehanna Financial Group.",14,"Your next question is from the line of Chris Rigg with Susquehanna Financial Group."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I just wanted to follow up on the flu comments from earlier. I know you talked about $45 million headwind in the quarter. I guess, I'm just try to get a sense for -- I just want to confirm that was relative to budget and just for how much the flu cost inc",57,"I just wanted to follow up on the flu comments from earlier. I know you talked about $45 million headwind in the quarter. I guess, I'm just try to get a sense for -- I just want to confirm that was relative to budget and just for how much the flu cost increased on a year-to-year basis."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","That was relative to our forecast for the fourth quarter. We had a very difficult December with regard to flue. As I've said, it's abated towards the end of the month and early January. And so we feel good about where we are for 2015. The 2014 results wer",71,"That was relative to our forecast for the fourth quarter. We had a very difficult December with regard to flue. As I've said, it's abated towards the end of the month and early January. And so we feel good about where we are for 2015. The 2014 results were worse than the 2013 results, but I wouldn't want to go into specifics there. But they were certainly worse, particularly in December."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your final question comes from the line of Dave Windley with Jefferies.",12,"Your final question comes from the line of Dave Windley with Jefferies."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","On some maybe difficult to answer questions, but curious if your broader thoughts, first of all, on the Supreme Court decision and how you are contingency planning around that. And secondly, your thoughts on President Obama's budget and proposed cuts to M",46,"On some maybe difficult to answer questions, but curious if your broader thoughts, first of all, on the Supreme Court decision and how you are contingency planning around that. And secondly, your thoughts on President Obama's budget and proposed cuts to Medicare and specifically, Medicare Advantage."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, we really don't get into the habit of commenting on those broad aspects until they're finalized. I don't want to get into that because it's just speculation. And I'll leave it at that.I think that was the last question. So that being said, we reall",97,"Yes, we really don't get into the habit of commenting on those broad aspects until they're finalized. I don't want to get into that because it's just speculation. And I'll leave it at that.
I think that was the last question. So that being said, we really appreciate the support by our investors and the confidence in the company, and most importantly, we thank our 55,000 associates for their dedication in helping our members with their health and all the necessary actions that are required with that. So thank you very much, and have a great day."
29618,278392365,754217,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","This concludes the Fourth Quarter 2014 Earnings Conference Call. Thank you for joining. You may now disconnect your lines.",19,"This concludes the Fourth Quarter 2014 Earnings Conference Call. Thank you for joining. You may now disconnect your lines."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Good morning, and welcome to the Fourth Quarter 2014 Earnings Conference Call. [Operator Instructions] I will now hand today's call over to Regina Nethery. Please go ahead.",27,"Good morning, and welcome to the Fourth Quarter 2014 Earnings Conference Call. [Operator Instructions] I will now hand today's call over to Regina Nethery. Please go ahead."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Humana's senior management team will discuss our fourth quarter and full year 2014 results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be: Bruce Broussard, Humana's Pr",344,"Thank you, and good morning. In a moment, Humana's senior management team will discuss our fourth quarter and full year 2014 results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be: Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Senior Vice President and Chief Financial Officer. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts.
Joining Bruce and Brian for the Q&A session will be: Jim Murray, Executive Vice President and Chief Operating Officer; and Christopher Todoroff, Senior Vice President and General Counsel.
We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. This call is also being simulcast via the Internet along with a virtual slide presentation. An Adobe version of today's slide deck has been posted to the Investor Relations section of Humana's website.
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in this morning's earnings press release as well as in our filings with the Securities and Exchange Commission. Today's press release, our historical financial news releases and our filings with the SEC are all available on Humana's Investor Relations website.
Call participants should also note that today's discussion and slide presentation include financial measures that are not in accordance with generally accepted accounting principles. Management's explanation for the use of these non-GAAP measures is included in today's slide presentation, including a reconciliation of GAAP to non-GAAP financial measures. Finally, any references to earnings per share, or EPS, made during this morning's call refer to diluted earnings per common share.
With that, I'll turn the call over to Bruce Broussard."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Good morning, everyone, and thank you for joining us. This morning, Humana reported full year adjusted earnings per share for 2014 of $7.51, in line with our 2014 guidance. This past year was particularly dynamic across the sector and presented a number o",1365,"Good morning, everyone, and thank you for joining us. This morning, Humana reported full year adjusted earnings per share for 2014 of $7.51, in line with our 2014 guidance. This past year was particularly dynamic across the sector and presented a number of challenges as well as some new opportunities. Humana continues to rise to these challenges through our consumer-focused strategy and integrated care delivery model, while simultaneously investing in new growth areas. As a result, we are reiterating our guidance for 2015 earnings of $8.50 to $9 per share, a growth rate of approximately 17% at the midpoint. 
As we outlined in our Investor Day this past December, Humana's investment thesis is driven by our customer-focused integrated care delivery model and the related results. This thesis includes 4 key elements: continued robust organic membership and revenue growth; proven superior clinical operating performance; disciplined capital allocation, which all lead to a sustainable competitive advantage.
I'll begin our discussion this morning with a focus on our membership and revenue growth. We recently raised our net Medicare Advantage membership growth expectations for 2015 to 300,000 to 350,000, primarily as a result of a strong sales during -- or results of strong sales during the recently completed annual election period or AEP.
And looking at the January enrollment data from CMS, Humana continues to lead the industry in membership growth for individual Medicare Advantage plans. The CMS data indicates that Humana accounted for nearly 70% of the individual MA net enrollment growth across the sector. In fact, approximately 52% of our individual gross sales during the AEP came from competitor Medicare Advantage offerings.
From a geographic perspective, we did not see strong specific concentration with this growth, but did experience our highest membership gains in North Carolina. We are pleased with this individual MA growth as it complements the group MA membership increase we experienced in that state in 2014, making this a very important Humana market.
With a large base of Medicare members, we are now able to bring other Humana offerings, like HumanaOne, to the state. As you'll see from Slide 8, approximately 73% of our individual MA net growth was in HMO offerings, including current Humana members who chose to move to an -- into an HMO in 2015. This compares to 64% in 2014. 
Our HMO offerings continue to provide the highest level of engagement from both a member and provider perspective and also have the highest retention rate of our Medicare products. Over the past few years, we've discussed our integrated care delivery model and its 3 core elements: improve the consumer experience by simplifying the interaction, resulting in a trusting relationship; based on the trusting relationship, engage members and clinical programs; and offering assistance to providers and transitioning from fee-for-service to value-based reimbursement. 
This strategy has provided superior clinical operating performance, resulting in a sustainable competitive advantage. Over the past few years, membership growth in Star scores provide evidence of the success of this strategy. We believe there are 5 key points of influence that drive our superior clinical operating performance. Although I will not go through all the detail on the slide today, I did want to highlight how we are already been working with our new 2015 members, allowing us to begin to get to know them and allow for timely enrollment in the proper clinical programs.
I'll begin with wellness and prevention. Staying in tune with the health of our members is a major focus of our wellness and prevention efforts. This all begins with our new member welcome calls. These calls begin shortly after the onset of the AEP this past October. These outreach efforts have already resulted in the completion of over 160,000 health risk assessments. Data from the welcome calls, health risk assessments and our sophisticated predictive modeling have already come together to identify more than 46,000 of our members for referrals to our Humana At Home.
Our wellness efforts have a strong focus on gaps in care. In 2014, we closed approximately 4.3 million gaps in care for our members, driven by improvement in preventative screenings. Better still, we are very pleased that approximately 1.3 million of our members across all lines of business received preventative treatment on schedule.
Turning to the primary care point of influence. We are pleased to report that approximately 55% of our net membership growth during the AEP is for members associated with providers in value-based arrangements. Remember that we offer providers a continuum of opportunities to increase the integration of care. This includes performance bonuses, shared savings and shared risk relationships.
We see HHS announcement last week on its move to paying providers based on value as further validation that our integrated care delivery strategy is on track. We look forward to working with HHS in developing new payment models and continuing to assist providers in the transition to value-based payment.
Health care at home will also be an important element of the care for many of our new members. As we've shared with you in the past, our Humana At Home programs do a terrific job of providing members with clinical support and care that often results in a significantly higher number of days they spend at their homes instead of in an acute care facility. 
Importantly, as we evaluate each of the points of influence I've just described, as well as our pharmacy interactions with our members, we utilize advanced analytics, including sophisticated predictive models, to provide insights that are both actionable and drive value for our members. All these metrics are indicative of the solid value proposition we continue to offer Medicare beneficiaries in the face of rate reductions. Successfully engaging our members in clinical programs is proving we can assist our members with their health needs. This is allowing us to offer stability in their premiums and benefits and reduce the complexity of navigating the health care system and helps produce the robust organic growth we are sharing with you today.
Looking at our other offerings. Humana's stand-alone PDP membership continues to experience strong growth with the bulk of the growth in our low-priced Walmart offering. This, together with growth in our Medicare Advantage membership, drives higher use of the services in our Healthcare Services segment, benefiting the enterprise overall.
Turning to our HumanaOne membership. As we evaluate recent health care exchange enrollment data, we believe it comports well with the pricing assumptions we made for 2015. As we've indicated on prior calls, our 2015 pricing appropriately assume the ultimate elimination of 2 of the 3Rs. We continue to be pleased with the mix of our membership, both across the metal tiers and by age distribution. We also believe that the 55 to 64 age ranges are opportunity to develop relationships with these members before they age into Medicare Advantage.
I also would want to highlight for you today something innovative we are doing in the Employer Group business. In the latter part of 2013, we introduced to our employer customers a product we call Total Health, which turns any standard medical plan of the employers choosing into an integrated health and well-being solution that encourages participation in HumanaVitality, health coaching and clinical programs. Employee participation results in employer discounts, which is then resulting in the shift of our single-year contract to a multiyear relationship that is creating employer solutions to not only cost, but also productivity.
Employer receptivity to the Total Health product is high with membership now at approximately 100,000 versus less than 400,000 at the end of 2013. We anticipate in the future these wellness programs and services will be complementary to employers choosing private and public exchange models. 
In conclusion, we continue to be pleased with our prospects for 2015 and beyond. The engagement of our associates and focus on the consumer through our integrated care delivery model has never been stronger. We believe that will result in the continuation of our superior clinical operating performance and a sustainable competitive advantage for quite some time to come.
With that, I'll turn the call over to Brian for a more detailed discussion of our financials and our commitment to disciplined capital allocation."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. As Bruce said in his remarks, 2014 was an unusually dynamic year full of opportunities and challenges. The growth in our Medicare business was substantial and was supplemented by the power of our Healthcare Se",1301,"Thank you, Bruce, and good morning, everyone. As Bruce said in his remarks, 2014 was an unusually dynamic year full of opportunities and challenges. The growth in our Medicare business was substantial and was supplemented by the power of our Healthcare Services segment, which has prospered, while making a truly positive difference in our members' lives. Our Employer Group business capitalized on the late 2013 rollout of an exciting new offering in the form of Total Health, while also ending the year on a high note in terms of financial performance. All this transpired while we invested heavily in new growth opportunities, both HumanaOne and our state-based businesses, which we believe will generate significant returns for our shareholders down the road.
We are pleased that our full year adjusted EPS came in just above the midpoint of our guidance at $7.51 per share. As we close out the year, there were a few items that adversely affected our 2014 results, but we do not see any of these significantly impacting our 2015 guidance. 
Our Retail segment pretax earnings finished the year below our guidance range. This was primarily attributable to the severity of the flu season, slightly higher investment spending for our duals and state-based contracts and deterioration in the results for our Puerto Rico Medicare business, which continues to be a difficult market for us.
With regard to the flu, hospital inpatient admissions peaked in late December, early January, but have since abated and have returned to more normalized levels. I should hasten to add that utilization more broadly remains benign and within expectations.
With regard to the duals, we continue to build out our infrastructure and are well positioned heading into 2015 to significantly reduce our investments, which we have committed to do.
Turning to the Employer Group segment. Our 2014 earnings results ended meaningfully above the upper end of our guidance range. While the flu did have some adverse impact on the Employer Group results, these were more than offset by lower medical claims utilization that we saw in both our commercial and group Medicare businesses. It is also important to note the effort that our Employer Group team has made to reduce administrative costs, which was also a significant driver of the segment's full year results.
Finally, our effective tax rate came in above the range of our previous guidance. There were several factors driving this, including the associated tax ramifications of higher losses in our Puerto Rico Medicare operations, which are nondeductible for U.S. income tax purposes, as well as lower tax-exempt investment income. We've evaluated each of these factors closely and have confidence that the 2015 guidance points we shared with you this morning encompass any continuing impact of each of these items.
Turning now to 2015. The majority of the guidance points we shared with you last quarter are unchanged. This slide summarizes the more significant changes since our last earnings call.
As we disclosed in a Form 8-K filing last month, we revised our Medicare Advantage and stand-alone PDP enrollment guidance to reflect the results of the 2015 AEP. Our higher projection for Medicare Advantage enrollment resulted in an increase to our revenue guidance that more than offset the revenue impact of the lower expectations for stand-alone PDP membership. As we have discussed in the past, the higher membership in our MA plans from the annual enrollment process will have a nominal impact on our Retail insurance segment performance this year. While there will be a favorable impact on the Healthcare Services segment's home-based business from the higher Medicare Advantage membership, this will be offset by the impact of the revised stand-alone PDP membership we'll have on Humana Pharmacy as PDP members in our low price point offering tend to use our wholly owned mail order and specialty pharmacies at rates slightly higher than our MA members.
One other element of our 2015 guidance points that we updated today is our projected accruals for the premium stabilization programs, commonly called the 3Rs. As Bruce shared in his remarks, we now have more color around the mix of our membership distribution among the metal tiers and by age range. Having evaluated that data, we are comfortable lowering our projection for full year accruals for the 3Rs by approximately $50 million at the midpoint. We now expect the net receivables for 2015 to be less than half of the level they were compared to the balances we accrued at the end of 2014.
As we've noted in prior calls, our pricing strategy for 2015 included significantly lowering reliance on the 3Rs, and we are still on track for 2015 to achieve at a minimum breakeven results.
With regard to the risk corridors, we believe that the 2014 $51 million net receivable that we disclosed this morning is indeed collectible based on statutory and administrative actions. Further, any 2014 amounts must first be satisfied before subsequent years are paid. Finally, for 2015, the risk corridor receivable that we are currently forecasting is insignificant.
Turning to our operating cash flows. We have been around 1.5x net income for some time now, and we anticipate maintaining that quality of earnings metric again in 2015. This morning, we raised our guidance for operating cash flows by approximately $200 million, driven primarily by the timing of certain working capital items. While our days claims payable declined sequentially by 2.8 days to 44.7, this was primarily due to the increase in capitation payments as we continue to grow the number of providers under risk-based contracts as well as the growth in our long-term support services business, whose providers get paid monthly. 
Additionally, our normal December decline in claims inventories, driven by the holiday season and higher staffing associated with preparing for new members coming on January 1, was magnified by the relatively late HumanaOne enrollment and the associated pended claims, which we paid down in the fourth quarter.
I'll now turn to our view of the quarterly breakdown of earnings for 2015. Though we do not provide specific quarterly guidance, we did want to give you a sense for the key drivers of performance among the quarters, as we have done in prior years. Given our expectations that our health care exchange business will at least breakeven and our investments in state-based contracts will begin to mitigate, we've layered in the impact of those newer businesses across the quarters. The result is that we again project the third and fourth quarters to experience the most pressure in light of the quarterly progression of health benefit ratios and the timing of marketing and open enrollment across our lines of business.
I'll conclude my discussion this morning with a few words around capital allocation. As Bruce said in his remarks, disciplined capital allocation is a key component of Humana's investment thesis. At the time of our third quarter release, we announced a significant increase in our share repurchase authorization and a commitment to accelerate our buyback activity. We've held true to that commitment and maintained our expectation to buy back $1 billion in stock by June of this year with approximately $630 million of that already completed. We would also expect to continue share repurchases in the back half of the year.
Aside from share repurchase activity, we are continuing to evaluate all of our businesses to ensure that they fit strategically within our portfolio and our earning their cost of capital will have a convincing plan to do so. To the extent a business does not meet these criteria, that business will be restructured or divested. We expect to continue to update you on the progress of this review over the coming months.
With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] Your first question comes from the line of Justin Lake with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Justin Lake with JPMorgan."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Question around the Retail results. You laid out a few headwinds to the quarter. Can you put some numbers around them and also give us some color on your positioning in Puerto Rico Medicare and how much money you're losing there right now?",43,"Question around the Retail results. You laid out a few headwinds to the quarter. Can you put some numbers around them and also give us some color on your positioning in Puerto Rico Medicare and how much money you're losing there right now?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Sure. So the flu is a major driver. It was around $45 million all-in for the company. About 3/4 of that was driven in the Retail segment. With regard to Puerto Rico, I'd rather not go into the details of the numbers there, but we are losing money in that",164,"Sure. So the flu is a major driver. It was around $45 million all-in for the company. About 3/4 of that was driven in the Retail segment. With regard to Puerto Rico, I'd rather not go into the details of the numbers there, but we are losing money in that market. We lost more this quarter than we expected. And really, that's driven by the fact that the dynamics in that market are different. The medical management of those members is different. We got hit by uncompensated care adjustments that we had to take into our results that weren't in the bids because they came after the bids. And so 2014 was a very difficult year for that market. On the duals side, we're continuing to build out that infrastructure. As we think about investments for 2014, I would say the duals came in slightly higher, individual came in slightly lower. So that's sort of how I'd calibrate those results on the Retail segment."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Kevin Fischbeck with Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck with Bank of America."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Just wanted to follow up on, I guess, that last comment before the Q&A about evaluating certain businesses, making sure that they are appropriately turned out. I don't really remember you guys talking a lot about this before. Is there -- are there signifi",88,"Just wanted to follow up on, I guess, that last comment before the Q&A about evaluating certain businesses, making sure that they are appropriately turned out. I don't really remember you guys talking a lot about this before. Is there -- are there significant business lines that are currently being evaluated? And I think you mentioned either divesting them or fixing them. Is there anything in the guidance that would contemplate some potential cost of fixing a business line that's not in a return that you are targeting?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, our guidance really incorporates all of our current businesses as they stand today. We are very focused on continuing to drive down admin costs. And as you saw that in the Employer Group segment this year, we'll continue to work on that. But we're e",104,"Well, our guidance really incorporates all of our current businesses as they stand today. We are very focused on continuing to drive down admin costs. And as you saw that in the Employer Group segment this year, we'll continue to work on that. But we're evaluating all of our lines of business. I think we've been very clear that all of our businesses over time need to earn their cost of capital, and we're going to make sure that occurs and we're being very disciplined about it. And so I don't want to comment on any specific businesses, but we're evaluating our entire portfolio."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","But I guess maybe is there a way to frame it? Are we talking about things around the edges? Or are there decent-sized parts of the business that are being evaluated?",31,"But I guess maybe is there a way to frame it? Are we talking about things around the edges? Or are there decent-sized parts of the business that are being evaluated?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, I would say all of our businesses are being evaluated. I think we feel very good about our core businesses. So I wouldn't see any major change in that regard. But there are a number of businesses that need to hit their returns, and we'll focu",50,"Well, again, I would say all of our businesses are being evaluated. I think we feel very good about our core businesses. So I wouldn't see any major change in that regard. But there are a number of businesses that need to hit their returns, and we'll focus on that."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Josh Raskin with Barclays.",12,"Your next question is from the line of Josh Raskin with Barclays."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","The question is around that Medicare Advantage growth and the source, the drivers. I think I heard you say 52% had come from competitors. I guess I was a little surprised to hear that, that I know last year was a little bit of an anomaly. But I'm just cur",96,"The question is around that Medicare Advantage growth and the source, the drivers. I think I heard you say 52% had come from competitors. I guess I was a little surprised to hear that, that I know last year was a little bit of an anomaly. But I'm just curious where that's trended in the past. And then as you think about the overall MA growth, how much of that is coming from previously fee-for-service Medicare lives, how many are agent, how many are PDP conversions, and maybe any other buckets, just overall that MA growth?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, this is Jim Murray. As we look across the various markets that we grew, and there were probably 10 or 12 markets that we would point to, we're seeing the beneficial impact of our higher Stars rating, we believe, having a favorable impact in the way t",209,"Yes, this is Jim Murray. As we look across the various markets that we grew, and there were probably 10 or 12 markets that we would point to, we're seeing the beneficial impact of our higher Stars rating, we believe, having a favorable impact in the way that we're able to position ourselves relative to the competition. Bruce earlier talked about North Carolina, and that's the market where we have 4.5 stars, and some of the competitors that were there before didn't have as high a Star score. And we think that, that, in terms of the premium and benefits that we're able to put on The Street, helps to position us better. So I would say that that's one aspect that we're seeing play itself out. We're obviously very pleased about that. As respects the number of members that we get from competitors versus fee-for-service, I would tell you that, that number, as we've looked at it, is about 50-50. Agents generally -- a significant part of the agent growth occurs during the ROI as opposed to during the AEP itself. A lot of favorable dynamics. And again, as Brian and Bruce both pointed out, we're pretty pleased with the way that this AEP played out for us."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Josh, one thing I would add to that is as you -- as we've discussed, we had great growth in our HMO area and our strategy has always been is create a relationship through the PPO product and then evolve them over. And we just see that strategy continuing",68,"Josh, one thing I would add to that is as you -- as we've discussed, we had great growth in our HMO area and our strategy has always been is create a relationship through the PPO product and then evolve them over. And we just see that strategy continuing to be strong, which both helps us on retention, but also the engagement and helping them with their health."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And just a follow-up on that. So one, are you seeing any material impact from PDP conversions in the AEP? And then, I guess, I'm just looking at that sort of competitor impact. Are you seeing -- is that different than what you've seen in previous years? I",74,"And just a follow-up on that. So one, are you seeing any material impact from PDP conversions in the AEP? And then, I guess, I'm just looking at that sort of competitor impact. Are you seeing -- is that different than what you've seen in previous years? Is the impact of Stars more important now? Were you doing better vis-Ã -vis the competition in a different way than you've seen in the previous years?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I think last year, we had the same circumstance. I just -- we sound like a broken record, but our clinical platform has allowed us to offer stable benefits in the marketplace. And the clinical platform is not only helping us with Star scores, but it's als",136,"I think last year, we had the same circumstance. I just -- we sound like a broken record, but our clinical platform has allowed us to offer stable benefits in the marketplace. And the clinical platform is not only helping us with Star scores, but it's also helping engage individuals and getting them in the right clinical programs, which is ultimately lowering the cost of the medical side, which is then turn around and allowing us to offer the proper benefits. So I think it all sort of fits together. It's just not Stars. I would say that that's a contributor in the individual marketplaces, but I wouldn't walk away from the call and say that's our competitive advantage. Our competitive advantage is really the clinical programs that drives both lower medical costs and better quality."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of A.J. Rice with UBS.",13,"Your next question is from the line of A.J. Rice with UBS."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I might just ask you about 2 items that were in your walk forward to guidance last quarter. I think you had in there about a $0.35 tailwind from lower investments in exchange- and state-based contracts. And Brian, you mentioned that a little bit in your p",120,"I might just ask you about 2 items that were in your walk forward to guidance last quarter. I think you had in there about a $0.35 tailwind from lower investments in exchange- and state-based contracts. And Brian, you mentioned that a little bit in your prepared remarks. I wondered if there's an update on what you're thinking in terms of investments and the timing. And then the other one I was going to ask you about was Hep C. You had a $0.45 tailwind in your guidance there. And since then, I know you provide -- you've done your preferred vendor contract with Gilead, and I wondered, did that $0.45 contemplate that contract? Or is there now potential upside?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","So with regard to the first question on the investments, I would say it's similar to what we discussed last call in terms of what we're expecting. Again, H1, we expect to breakeven, or hopefully, do better than that. On the Medicaid duals side, we are exp",142,"So with regard to the first question on the investments, I would say it's similar to what we discussed last call in terms of what we're expecting. Again, H1, we expect to breakeven, or hopefully, do better than that. On the Medicaid duals side, we are expecting to reduce our investments, let's say, pretty significantly. I would think about it sort of as a $0.25 investment, plus or minus, on the Medicaid duals side for 2015. For Hep C, it really is -- it's early to tell. Let's see what happens for 2015. Clearly, the unit price discount helps. But we still need to see where utilization ultimately plays out and we're watching that very closely, and we'll see over the next few months where we stand. I would say, as it looks today, we feel pretty good, but it's still early."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Scott Fidel with Deutsche Bank.",13,"Your next question comes from the line of Scott Fidel with Deutsche Bank."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Just interested if you can give your thoughts on the CMS value-based contracting initiative for fee-for-service and whether we would view that as more of a positive or a risk for MA. And just thinking about from a reimbursement perspective, if you think t",91,"Just interested if you can give your thoughts on the CMS value-based contracting initiative for fee-for-service and whether we would view that as more of a positive or a risk for MA. And just thinking about from a reimbursement perspective, if you think there's any risk that MA rates could be pressured in the intermediate to long term if CMS does assume lower unit costs and lower cost trends in fee-for-service and whether that gets translated into the per capita growth rate assumption that they make for the MA business."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, I think, overall, our view is this transition to value-based reimbursement and getting more providers in those reimbursement models is the best for, I think, the industry as a whole. I think we look at that as an opportunity for us both in helping p",180,"Well, I think, overall, our view is this transition to value-based reimbursement and getting more providers in those reimbursement models is the best for, I think, the industry as a whole. I think we look at that as an opportunity for us both in helping providers and, at the same time, continuing to advance the Medicare Advantage positioning. In regards to does it affect the benchmark, I think, is where you're getting to. Over time, it will affect the benchmark, I think, in any kind of plan that's there. It's lowering the cost of Medicare and you get affected. But I do think long term the Medicare Advantage offers a significantly better advantage as you look at the comprehensive nature of it. It's just not about the price. And also what we found is about the integration of the services and the systems that's provided there. But at the same time, we realized that we have to be better than the competition at our clinical programs, and that competition is both within Medicare Advantage and also Medicare as a whole."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Andy Schenker with Morgan Stanley.",13,"Your next question is from the line of Andy Schenker with Morgan Stanley."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So I appreciate Brian's comments in the prepared remarks on PCP. You've been trending down for some time. So maybe if you could just give me a little bit more understanding about the moving parts behind the trend over that time, including maybe specifical",80,"So I appreciate Brian's comments in the prepared remarks on PCP. You've been trending down for some time. So maybe if you could just give me a little bit more understanding about the moving parts behind the trend over that time, including maybe specifically how changing mix has impacted that number. So you've mentioned the long-term support services, but how do growing exchange and MA growth impact then how should we really be thinking about that metric going forward?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, the major driver really is the capitation. As we continue to increase our physicians and our capitation arrangements, basically, you have a benefit expense and you don't have a reserve. And so that really is the major driver. If you look at the roll",201,"Well, the major driver really is the capitation. As we continue to increase our physicians and our capitation arrangements, basically, you have a benefit expense and you don't have a reserve. And so that really is the major driver. If you look at the roll forward, you could see the days move really driven by that. The LTSS business has a similar dynamic in the sense that we pay the nursing homes on a monthly basis. And so again, you have this expense without having that reserve and so that'll naturally take it down. And then, as I mentioned in my prepared remarks, this quarter, we had an outlier in the sense of H1 and that the members came on a little bit late. There were a bunch of pended claims that we were working through, and we really did that over the fourth quarter. And so that really, I think -- those are the 3 major buckets what's driving the days claims. I'd also hasten to add that our cash flows are still very strong. And so as we think about our quality of earnings metrics, we're very focused to make sure our cash flows are good and they are."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So therefore, just to follow up going forward because you're expecting more growth in capitation, you'd expect that number to keep going down. And does the growth in exchanges or MA somewhat offset that to the other side or...",39,"So therefore, just to follow up going forward because you're expecting more growth in capitation, you'd expect that number to keep going down. And does the growth in exchanges or MA somewhat offset that to the other side or..."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I'd say all else being equal, I think that's right.",11,"I'd say all else being equal, I think that's right."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Ralph Giacobbe with CrÃ©dit Suisse.",13,"Your next question comes from the line of Ralph Giacobbe with CrÃ©dit Suisse."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Back to the Puerto Rico book, can you give us a sense of size and/or magnitude of the loss? And then I know you exited Medicaid there. Can you maybe talk about your commitment to that region within Medicare and/or how you're going to be able to sort of fi",52,"Back to the Puerto Rico book, can you give us a sense of size and/or magnitude of the loss? And then I know you exited Medicaid there. Can you maybe talk about your commitment to that region within Medicare and/or how you're going to be able to sort of fix the issues?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, I'd rather not go into specifics on our P&L of that market. I would say they're real losses. They move the needle. They affected our tax rate. We are working hard to fix the problems in the market. The Medicaid -- losing the Medicaid contract",140,"Well, again, I'd rather not go into specifics on our P&L of that market. I would say they're real losses. They move the needle. They affected our tax rate. We are working hard to fix the problems in the market. The Medicaid -- losing the Medicaid contract, I think, is indicative of where we are and deciding not to re-up there. And so our guys are working hard on that, on fixing the problems, and getting our members to engage and improve the medical management and the like. Again, we had some one-timers here in 2014 as they're related to uncompensated care and the time when that came into effect with respect to the bids. But as I said, all of our businesses that aren't earning their cost of capital need to be evaluated, and we are certainly doing that."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Okay. And maybe -- I know you don't want to talk about the size of the losses. Can you give us a sense of even just the premium?",28,"Okay. And maybe -- I know you don't want to talk about the size of the losses. Can you give us a sense of even just the premium?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","There are about -- this is Jim. There are about 50,000 Medicare Advantage members in Puerto Rico as we ended the year. We purposely tried to downsize as respect to our activities relative to the AEPs so that we could shrink that membership. The premium th",157,"There are about -- this is Jim. There are about 50,000 Medicare Advantage members in Puerto Rico as we ended the year. We purposely tried to downsize as respect to our activities relative to the AEPs so that we could shrink that membership. The premium that we get from the federal government for Medicare is solid. As Brian alluded to earlier, the government made some change in the way that they pay hospitals after our bids were finalized for 2014. That was a big drag on our results. And the other thing that Brian mentioned, the loss of focus, because we did lose the Medicaid contract and the clinical model that was commensurate with that, negatively impacted our Medicare results. So we expect a smaller portfolio of business in 2015. And as Brian said, we're actively working on things that would improve that -- our prospects in Puerto Rico, and that's probably where we should end it."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Peter Costa with Wells Fargo Securities.",14,"Your next question is from the line of Peter Costa with Wells Fargo Securities."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Again, it's close to that of the year when we hear about what the 2016 Medicare Advantage rates are going to be. We know from December that 2.45% was sort of what they were talking about for the growth rate at that point. But what are the factors should w",69,"Again, it's close to that of the year when we hear about what the 2016 Medicare Advantage rates are going to be. We know from December that 2.45% was sort of what they were talking about for the growth rate at that point. But what are the factors should we be considering that might be impacting the payments that you get from the government for Medicare rates in 2016?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, Peter, this is pure speculation, so it's always difficult. I think we look at the discussions that have historically been in the rate notice around in-home assessments as being an area of discussion. I also think the MRA adjustments are another area",87,"Yes, Peter, this is pure speculation, so it's always difficult. I think we look at the discussions that have historically been in the rate notice around in-home assessments as being an area of discussion. I also think the MRA adjustments are another area that possibly could be included in the rate notice. But that's really based on the dialogue that has happened over the past few years with them, and I don't have any inside information more than anybody else has on what's going to come out."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And in terms of the range of possibilities, how do you think it will impact your ability to price business for next year and obtain growth for next year?",29,"And in terms of the range of possibilities, how do you think it will impact your ability to price business for next year and obtain growth for next year?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","This is Jim. We have always, over the last number of years, expected the worst. And as we focus on what are necessary actions relative to trend vendors, we plan for that and we'll see what happens in April, and then we evaluate our bid processes and strat",90,"This is Jim. We have always, over the last number of years, expected the worst. And as we focus on what are necessary actions relative to trend vendors, we plan for that and we'll see what happens in April, and then we evaluate our bid processes and strategies accordingly. But we're in the process, as we speak, of trying to identify trend vending activities that would address the worst-case scenario in some of the things that Bruce talked about, and we're putting those in place for 2016 as we speak."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Matthew Borsch with Goldman Sachs.",13,"Your next question comes from the line of Matthew Borsch with Goldman Sachs."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","A question on your guidance in the Medicaid duals. So I think as I understood, you're looking at a $0.25 approximate tailwind on that business from reduced investment. But am I correct that, that business is still losing money, if you will, when you count",63,"A question on your guidance in the Medicaid duals. So I think as I understood, you're looking at a $0.25 approximate tailwind on that business from reduced investment. But am I correct that, that business is still losing money, if you will, when you count in the investment or expected to for 2015? Or is that wrong? And can you quantify any magnitude?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, and if I wasn't clear, I think we expect around $0.25 of loss in 2015 for the state-based businesses, if that helps. And that is reduced from 2014 pretty meaningfully.",31,"Yes, and if I wasn't clear, I think we expect around $0.25 of loss in 2015 for the state-based businesses, if that helps. And that is reduced from 2014 pretty meaningfully."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Okay. And can you give us a range of magnitude on 2014?",12,"Okay. And can you give us a range of magnitude on 2014?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","No, I would say, if you combine H1 and the duals, it was, call it, around $0.70 plus or minus.",20,"No, I would say, if you combine H1 and the duals, it was, call it, around $0.70 plus or minus."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Sarah James with Wedbush Securities.",13,"Your next question is from the line of Sarah James with Wedbush Securities."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Humana and the other insurers have been working on providing new data to CMS that follows up on actions and results from home health risk assessments, and I'm wondering if there's been any consensus reached among the insurers or with CMS on how to effecti",56,"Humana and the other insurers have been working on providing new data to CMS that follows up on actions and results from home health risk assessments, and I'm wondering if there's been any consensus reached among the insurers or with CMS on how to effectively evaluate the results of that or the sufficiency of solid actions."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","No, there has been discussion on the effectiveness of in-home assessments and the work that's been done there on a number of different occasions. I don't think there has been one proposal that has been agreed upon both by the industry and by CMS. And I do",73,"No, there has been discussion on the effectiveness of in-home assessments and the work that's been done there on a number of different occasions. I don't think there has been one proposal that has been agreed upon both by the industry and by CMS. And I don't -- we don't want to get into commenting on what we think CMS would come out with based on our discussions about industry-wide and company specific."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Tom Carroll with Stifel.",12,"Your next question is from the line of Tom Carroll with Stifel."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So just a question on the 3Rs. How do you want investors to think about the change in the 3R accruals that you're making for 2015? I mean, is this just you have more color, as you put it, which provides more visibility in operations? Or is Humana perhaps",65,"So just a question on the 3Rs. How do you want investors to think about the change in the 3R accruals that you're making for 2015? I mean, is this just you have more color, as you put it, which provides more visibility in operations? Or is Humana perhaps getting a little more aggressive on assumptions? Wonder if you could balance that out for us."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, I guess, I'd say we view it as a good thing that we're able to reduce the reliance on the 3Rs by over half. That's a delivered strategy we made by ticking up pricing. We're being very disciplined there and that's really part of our strategy to get t",118,"Well, I guess, I'd say we view it as a good thing that we're able to reduce the reliance on the 3Rs by over half. That's a delivered strategy we made by ticking up pricing. We're being very disciplined there and that's really part of our strategy to get to breakeven or better for 2015. So I think when we saw the new sales come in and break down by metal tier and age and geography, et cetera, we were able to take it down slightly from where we were on the third quarter, but we view that as a good thing, and again, feel positive about where we are with that business and how we priced it."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","When we entered the exchanges in 2014, I think we communicated to the investors that we were going to grow in 2014, while in 2015, transition to ensure that there was sustainability in that business long term. And what you see happening is that's what's h",100,"When we entered the exchanges in 2014, I think we communicated to the investors that we were going to grow in 2014, while in 2015, transition to ensure that there was sustainability in that business long term. And what you see happening is that's what's happening, that we grew in 2014. We would define success this year as maintaining our membership that we had in 2014 and 2015 and having maintain that level, while at the same time, reducing our reliance on the 3Rs, specifically 2Rs, to allow us to make that transition when the 2Rs go away next year."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Christine Arnold with Cowen.",12,"Your next question is from the line of Christine Arnold with Cowen."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Could you speak to your expectations for medical trends? Better economy. Consumer confidence seems to be rising. Fuel prices are down. Kind of like increasing discretionary income for folks. How do you think that might impact medical costs? And how do you",70,"Could you speak to your expectations for medical trends? Better economy. Consumer confidence seems to be rising. Fuel prices are down. Kind of like increasing discretionary income for folks. How do you think that might impact medical costs? And how do you build that into your Medicare Advantage assumptions with respect to trend vendors that you're going to need and the medical trend expected in '15 versus '14 for MA?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Sure. Well, as you know, we did increase the expected trend for our commercial group business to 5.5% to 6.5% from 4% to 4.5%. So that was a significant increase, I think, reflecting all the things that you just discussed. On the Medicare side, it's not a",108,"Sure. Well, as you know, we did increase the expected trend for our commercial group business to 5.5% to 6.5% from 4% to 4.5%. So that was a significant increase, I think, reflecting all the things that you just discussed. On the Medicare side, it's not as directly tied to economic growth but there's probably some impact. We focus pretty intently on where the trend vendors need to be relative to where the rate's coming at from a CMS perspective. And I would say there's probably less marginal move, unlike the commercial side, based on economic growth and other factors, employment, et cetera, that you would typically see."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","What about the fact that fuel prices were lower? Old people are spending less to fuel up their vehicles. And also, what -- can you tell us what kind of trend vendor you assumed in '15 versus '14?",38,"What about the fact that fuel prices were lower? Old people are spending less to fuel up their vehicles. And also, what -- can you tell us what kind of trend vendor you assumed in '15 versus '14?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","We're not going to get to that level of detail. I -- we haven't really evaluated or I don't know the answer to this specific, how fuel impacts it. But our -- we take a holistic view of where trend may be and a number of factors go into that.",51,"We're not going to get to that level of detail. I -- we haven't really evaluated or I don't know the answer to this specific, how fuel impacts it. But our -- we take a holistic view of where trend may be and a number of factors go into that."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I'm actually happy that the seniors have fuel for their cars because they're making them go and see their doctors...",21,"I'm actually happy that the seniors have fuel for their cars because they're making them go and see their doctors..."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","To the clinic.",3,"To the clinic."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","So that they can take care of all the things that they need to take care of rather than waiting for an acute event. So I'm happy about that.",29,"So that they can take care of all the things that they need to take care of rather than waiting for an acute event. So I'm happy about that."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Ana Gupte with Leerink Partners.",13,"Your next question is from the line of Ana Gupte with Leerink Partners."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I was just trying to see some of the less focused areas of business as they might be potential drivers for upside. So one of them is individual off-exchange and I know that's a much smaller piece of your book. But 2 of your peers have stated that they los",109,"I was just trying to see some of the less focused areas of business as they might be potential drivers for upside. So one of them is individual off-exchange and I know that's a much smaller piece of your book. But 2 of your peers have stated that they lost money in '14 and taking some pretty serious pricing actions and removing ACA compliance plans. Is there anything here that you might have been doing? And I get it that the MLR floors probably took care of a piece of this, but just '14 would guarantee the shoe [ph] and community rating did hurt some of the off-exchange books."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes. So as we said, and I don't really want to distinguish between off-exchange and on-exchange in terms of our pricing, as we've said, we've been very disciplined on pricing with our entire ACA-compliant book. Off-exchange is part of our strategy. It's a",75,"Yes. So as we said, and I don't really want to distinguish between off-exchange and on-exchange in terms of our pricing, as we've said, we've been very disciplined on pricing with our entire ACA-compliant book. Off-exchange is part of our strategy. It's an important part of our strategy. And we're looking to mitigate the losses in both the off-exchange and on-exchange. And again, all-in, as we said, we do expect to do that this year."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And then, secondly, Brian, secondly on the small group and maybe just the broader commercial fully insured book, your employer loss ratio looks pretty good for this quarter. In the third quarter, it deteriorated, if I remember right, and somehow I didn't",78,"And then, secondly, Brian, secondly on the small group and maybe just the broader commercial fully insured book, your employer loss ratio looks pretty good for this quarter. In the third quarter, it deteriorated, if I remember right, and somehow I didn't have a chance to follow up on that. Our pricing survey show you've jacked up your pricing quite a bit for '15. So any improvement in margin there? And what are you baking into your guidance?"
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, back in the third quarter, we did suffer the impact of some of the transitional relief that we discussed. Now we got some of that back in the fourth quarter through, I would say, both current period and prior period development that were bett",103,"Well, again, back in the third quarter, we did suffer the impact of some of the transitional relief that we discussed. Now we got some of that back in the fourth quarter through, I would say, both current period and prior period development that were better than expectations. And that really was the driver of the outperformance, along with the continued focus on admin costs. I would say, as we move into next year, we price for Hep C and the like, hopefully, we'll continue to see improvements there. And really, where we need to focus is on the admin side as well."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes. There's one other dynamic in the small group space that you're all aware of, I'm sure, is that there's a movement into the community-based rating methodology and that's kind of an interesting dynamic that we're watching play out with some of our comp",119,"Yes. There's one other dynamic in the small group space that you're all aware of, I'm sure, is that there's a movement into the community-based rating methodology and that's kind of an interesting dynamic that we're watching play out with some of our competition and where they price their community-rated business rights versus where we're at. As we sit here right now, we feel pretty good about how we're positioned and are monitoring not only the community rights, but the migration from our existing block of business into those with the transitional relief opportunity that we have. So again, feel pretty good about that, and I'm glad that you notice that in some of the stuff that we provided."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Chris Rigg with Susquehanna Financial Group.",14,"Your next question is from the line of Chris Rigg with Susquehanna Financial Group."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I just wanted to follow up on the flu comments from earlier. I know you talked about a $45 million headwind in the quarter. I guess, I'm just try to get a sense for -- I just want to confirm if that was relative to budget and just for how much the flu cos",59,"I just wanted to follow up on the flu comments from earlier. I know you talked about a $45 million headwind in the quarter. I guess, I'm just try to get a sense for -- I just want to confirm if that was relative to budget and just for how much the flu cost increased on a year-to-year basis."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","That was relative to our forecast for the fourth quarter. We had a very difficult December with regard to flu. As I've said, it's abated towards the end of the month and early January, and so we feel good about where we are for 2015. The 2014 results were",71,"That was relative to our forecast for the fourth quarter. We had a very difficult December with regard to flu. As I've said, it's abated towards the end of the month and early January, and so we feel good about where we are for 2015. The 2014 results were worse than the 2013 results, but I wouldn't want to go into specifics there, but they were certainly worse, particularly in December."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your final question comes from the line of Dave Windley with Jefferies.",12,"Your final question comes from the line of Dave Windley with Jefferies."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","On some maybe difficult-to-answer questions, but curious of your broader thoughts, first of all, on the Supreme Court decision and how you are contingency planning around that. And secondly, your thoughts on President Obama's budget and proposed cuts to M",45,"On some maybe difficult-to-answer questions, but curious of your broader thoughts, first of all, on the Supreme Court decision and how you are contingency planning around that. And secondly, your thoughts on President Obama's budget and proposed cuts to Medicare, and specifically, Medicare Advantage."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, we really don't get into the habit of commenting on those broad aspects until they're finalized. So I don't want to get into that because it's just speculation and I'll leave it at that.I think that was the last question. So with that being said, w",99,"Yes, we really don't get into the habit of commenting on those broad aspects until they're finalized. So I don't want to get into that because it's just speculation and I'll leave it at that.
I think that was the last question. So with that being said, we really appreciate the support by our investors and the confidence in the company. And most importantly, we thank our 55,000 associates for their dedication in helping our members with their health and all the necessary actions that are required with that. So thank you very much, and have a great day."
29618,278392365,754494,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","This concludes the Fourth Quarter 2014 Earnings Conference Call. Thank you for joining. You may now disconnect your lines.",19,"This concludes the Fourth Quarter 2014 Earnings Conference Call. Thank you for joining. You may now disconnect your lines."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Good morning, and welcome to the Fourth Quarter 2014 Earnings Conference Call. [Operator Instructions] I will now hand today's call over to Regina Nethery. Please go ahead.",27,"Good morning, and welcome to the Fourth Quarter 2014 Earnings Conference Call. [Operator Instructions] I will now hand today's call over to Regina Nethery. Please go ahead."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Humana's senior management team will discuss our fourth quarter and full year 2014 results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be: Bruce Broussard, Humana's Pr",344,"Thank you, and good morning. In a moment, Humana's senior management team will discuss our fourth quarter and full year 2014 results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be: Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Senior Vice President and Chief Financial Officer. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts.
Joining Bruce and Brian for the Q&A session will be: Jim Murray, Executive Vice President and Chief Operating Officer; and Christopher Todoroff, Senior Vice President and General Counsel.
We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. This call is also being simulcast via the Internet along with a virtual slide presentation. An Adobe version of today's slide deck has been posted to the Investor Relations section of Humana's website.
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in this morning's earnings press release as well as in our filings with the Securities and Exchange Commission. Today's press release, our historical financial news releases and our filings with the SEC are all available on Humana's Investor Relations website.
Call participants should also note that today's discussion and slide presentation include financial measures that are not in accordance with generally accepted accounting principles. Management's explanation for the use of these non-GAAP measures is included in today's slide presentation, including a reconciliation of GAAP to non-GAAP financial measures. Finally, any references to earnings per share, or EPS, made during this morning's call refer to diluted earnings per common share.
With that, I'll turn the call over to Bruce Broussard."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Good morning, everyone, and thank you for joining us. This morning, Humana reported full year adjusted earnings per share for 2014 of $7.51, in line with our 2014 guidance. This past year was particularly dynamic across the sector and presented a number o",1365,"Good morning, everyone, and thank you for joining us. This morning, Humana reported full year adjusted earnings per share for 2014 of $7.51, in line with our 2014 guidance. This past year was particularly dynamic across the sector and presented a number of challenges as well as some new opportunities. Humana continues to rise to these challenges through our consumer-focused strategy and integrated care delivery model, while simultaneously investing in new growth areas. As a result, we are reiterating our guidance for 2015 earnings of $8.50 to $9 per share, a growth rate of approximately 17% at the midpoint. 
As we outlined in our Investor Day this past December, Humana's investment thesis is driven by our customer-focused integrated care delivery model and the related results. This thesis includes 4 key elements: continued robust organic membership and revenue growth; proven superior clinical operating performance; disciplined capital allocation, which all lead to a sustainable competitive advantage.
I'll begin our discussion this morning with a focus on our membership and revenue growth. We recently raised our net Medicare Advantage membership growth expectations for 2015 to 300,000 to 350,000, primarily as a result of a strong sales during -- or results of strong sales during the recently completed annual election period or AEP.
And looking at the January enrollment data from CMS, Humana continues to lead the industry in membership growth for individual Medicare Advantage plans. The CMS data indicates that Humana accounted for nearly 70% of the individual MA net enrollment growth across the sector. In fact, approximately 52% of our individual gross sales during the AEP came from competitor Medicare Advantage offerings.
From a geographic perspective, we did not see strong specific concentration with this growth, but did experience our highest membership gains in North Carolina. We are pleased with this individual MA growth as it complements the group MA membership increase we experienced in that state in 2014, making this a very important Humana market.
With a large base of Medicare members, we are now able to bring other Humana offerings, like HumanaOne, to the state. As you'll see from Slide 8, approximately 73% of our individual MA net growth was in HMO offerings, including current Humana members who chose to move to an -- into an HMO in 2015. This compares to 64% in 2014. 
Our HMO offerings continue to provide the highest level of engagement from both a member and provider perspective and also have the highest retention rate of our Medicare products. Over the past few years, we've discussed our integrated care delivery model and its 3 core elements: improve the consumer experience by simplifying the interaction, resulting in a trusting relationship; based on the trusting relationship, engage members and clinical programs; and offering assistance to providers and transitioning from fee-for-service to value-based reimbursement. 
This strategy has provided superior clinical operating performance, resulting in a sustainable competitive advantage. Over the past few years, membership growth in Star scores provide evidence of the success of this strategy. We believe there are 5 key points of influence that drive our superior clinical operating performance. Although I will not go through all the detail on the slide today, I did want to highlight how we are already been working with our new 2015 members, allowing us to begin to get to know them and allow for timely enrollment in the proper clinical programs.
I'll begin with wellness and prevention. Staying in tune with the health of our members is a major focus of our wellness and prevention efforts. This all begins with our new member welcome calls. These calls begin shortly after the onset of the AEP this past October. These outreach efforts have already resulted in the completion of over 160,000 health risk assessments. Data from the welcome calls, health risk assessments and our sophisticated predictive modeling have already come together to identify more than 46,000 of our members for referrals to our Humana At Home.
Our wellness efforts have a strong focus on gaps in care. In 2014, we closed approximately 4.3 million gaps in care for our members, driven by improvement in preventative screenings. Better still, we are very pleased that approximately 1.3 million of our members across all lines of business received preventative treatment on schedule.
Turning to the primary care point of influence. We are pleased to report that approximately 55% of our net membership growth during the AEP is for members associated with providers in value-based arrangements. Remember that we offer providers a continuum of opportunities to increase the integration of care. This includes performance bonuses, shared savings and shared risk relationships.
We see HHS announcement last week on its move to paying providers based on value as further validation that our integrated care delivery strategy is on track. We look forward to working with HHS in developing new payment models and continuing to assist providers in the transition to value-based payment.
Health care at home will also be an important element of the care for many of our new members. As we've shared with you in the past, our Humana At Home programs do a terrific job of providing members with clinical support and care that often results in a significantly higher number of days they spend at their homes instead of in an acute care facility. 
Importantly, as we evaluate each of the points of influence I've just described, as well as our pharmacy interactions with our members, we utilize advanced analytics, including sophisticated predictive models, to provide insights that are both actionable and drive value for our members. All these metrics are indicative of the solid value proposition we continue to offer Medicare beneficiaries in the face of rate reductions. Successfully engaging our members in clinical programs is proving we can assist our members with their health needs. This is allowing us to offer stability in their premiums and benefits and reduce the complexity of navigating the health care system and helps produce the robust organic growth we are sharing with you today.
Looking at our other offerings. Humana's stand-alone PDP membership continues to experience strong growth with the bulk of the growth in our low-priced Walmart offering. This, together with growth in our Medicare Advantage membership, drives higher use of the services in our Healthcare Services segment, benefiting the enterprise overall.
Turning to our HumanaOne membership. As we evaluate recent health care exchange enrollment data, we believe it comports well with the pricing assumptions we made for 2015. As we've indicated on prior calls, our 2015 pricing appropriately assume the ultimate elimination of 2 of the 3Rs. We continue to be pleased with the mix of our membership, both across the metal tiers and by age distribution. We also believe that the 55 to 64 age ranges are opportunity to develop relationships with these members before they age into Medicare Advantage.
I also would want to highlight for you today something innovative we are doing in the Employer Group business. In the latter part of 2013, we introduced to our employer customers a product we call Total Health, which turns any standard medical plan of the employers choosing into an integrated health and well-being solution that encourages participation in HumanaVitality, health coaching and clinical programs. Employee participation results in employer discounts, which is then resulting in the shift of our single-year contract to a multiyear relationship that is creating employer solutions to not only cost, but also productivity.
Employer receptivity to the Total Health product is high with membership now at approximately 100,000 versus less than 400,000 at the end of 2013. We anticipate in the future these wellness programs and services will be complementary to employers choosing private and public exchange models. 
In conclusion, we continue to be pleased with our prospects for 2015 and beyond. The engagement of our associates and focus on the consumer through our integrated care delivery model has never been stronger. We believe that will result in the continuation of our superior clinical operating performance and a sustainable competitive advantage for quite some time to come.
With that, I'll turn the call over to Brian for a more detailed discussion of our financials and our commitment to disciplined capital allocation."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. As Bruce said in his remarks, 2014 was an unusually dynamic year full of opportunities and challenges. The growth in our Medicare business was substantial and was supplemented by the power of our Healthcare Se",1301,"Thank you, Bruce, and good morning, everyone. As Bruce said in his remarks, 2014 was an unusually dynamic year full of opportunities and challenges. The growth in our Medicare business was substantial and was supplemented by the power of our Healthcare Services segment, which has prospered, while making a truly positive difference in our members' lives. Our Employer Group business capitalized on the late 2013 rollout of an exciting new offering in the form of Total Health, while also ending the year on a high note in terms of financial performance. All this transpired while we invested heavily in new growth opportunities, both HumanaOne and our state-based businesses, which we believe will generate significant returns for our shareholders down the road.
We are pleased that our full year adjusted EPS came in just above the midpoint of our guidance at $7.51 per share. As we close out the year, there were a few items that adversely affected our 2014 results, but we do not see any of these significantly impacting our 2015 guidance. 
Our Retail segment pretax earnings finished the year below our guidance range. This was primarily attributable to the severity of the flu season, slightly higher investment spending for our duals and state-based contracts and deterioration in the results for our Puerto Rico Medicare business, which continues to be a difficult market for us.
With regard to the flu, hospital inpatient admissions peaked in late December, early January, but have since abated and have returned to more normalized levels. I should hasten to add that utilization more broadly remains benign and within expectations.
With regard to the duals, we continue to build out our infrastructure and are well positioned heading into 2015 to significantly reduce our investments, which we have committed to do.
Turning to the Employer Group segment. Our 2014 earnings results ended meaningfully above the upper end of our guidance range. While the flu did have some adverse impact on the Employer Group results, these were more than offset by lower medical claims utilization that we saw in both our commercial and group Medicare businesses. It is also important to note the effort that our Employer Group team has made to reduce administrative costs, which was also a significant driver of the segment's full year results.
Finally, our effective tax rate came in above the range of our previous guidance. There were several factors driving this, including the associated tax ramifications of higher losses in our Puerto Rico Medicare operations, which are nondeductible for U.S. income tax purposes, as well as lower tax-exempt investment income. We've evaluated each of these factors closely and have confidence that the 2015 guidance points we shared with you this morning encompass any continuing impact of each of these items.
Turning now to 2015. The majority of the guidance points we shared with you last quarter are unchanged. This slide summarizes the more significant changes since our last earnings call.
As we disclosed in a Form 8-K filing last month, we revised our Medicare Advantage and stand-alone PDP enrollment guidance to reflect the results of the 2015 AEP. Our higher projection for Medicare Advantage enrollment resulted in an increase to our revenue guidance that more than offset the revenue impact of the lower expectations for stand-alone PDP membership. As we have discussed in the past, the higher membership in our MA plans from the annual enrollment process will have a nominal impact on our Retail insurance segment performance this year. While there will be a favorable impact on the Healthcare Services segment's home-based business from the higher Medicare Advantage membership, this will be offset by the impact of the revised stand-alone PDP membership we'll have on Humana Pharmacy as PDP members in our low price point offering tend to use our wholly owned mail order and specialty pharmacies at rates slightly higher than our MA members.
One other element of our 2015 guidance points that we updated today is our projected accruals for the premium stabilization programs, commonly called the 3Rs. As Bruce shared in his remarks, we now have more color around the mix of our membership distribution among the metal tiers and by age range. Having evaluated that data, we are comfortable lowering our projection for full year accruals for the 3Rs by approximately $50 million at the midpoint. We now expect the net receivables for 2015 to be less than half of the level they were compared to the balances we accrued at the end of 2014.
As we've noted in prior calls, our pricing strategy for 2015 included significantly lowering reliance on the 3Rs, and we are still on track for 2015 to achieve at a minimum breakeven results.
With regard to the risk corridors, we believe that the 2014 $51 million net receivable that we disclosed this morning is indeed collectible based on statutory and administrative actions. Further, any 2014 amounts must first be satisfied before subsequent years are paid. Finally, for 2015, the risk corridor receivable that we are currently forecasting is insignificant.
Turning to our operating cash flows. We have been around 1.5x net income for some time now, and we anticipate maintaining that quality of earnings metric again in 2015. This morning, we raised our guidance for operating cash flows by approximately $200 million, driven primarily by the timing of certain working capital items. While our days claims payable declined sequentially by 2.8 days to 44.7, this was primarily due to the increase in capitation payments as we continue to grow the number of providers under risk-based contracts as well as the growth in our long-term support services business, whose providers get paid monthly. 
Additionally, our normal December decline in claims inventories, driven by the holiday season and higher staffing associated with preparing for new members coming on January 1, was magnified by the relatively late HumanaOne enrollment and the associated pended claims, which we paid down in the fourth quarter.
I'll now turn to our view of the quarterly breakdown of earnings for 2015. Though we do not provide specific quarterly guidance, we did want to give you a sense for the key drivers of performance among the quarters, as we have done in prior years. Given our expectations that our health care exchange business will at least breakeven and our investments in state-based contracts will begin to mitigate, we've layered in the impact of those newer businesses across the quarters. The result is that we again project the third and fourth quarters to experience the most pressure in light of the quarterly progression of health benefit ratios and the timing of marketing and open enrollment across our lines of business.
I'll conclude my discussion this morning with a few words around capital allocation. As Bruce said in his remarks, disciplined capital allocation is a key component of Humana's investment thesis. At the time of our third quarter release, we announced a significant increase in our share repurchase authorization and a commitment to accelerate our buyback activity. We've held true to that commitment and maintained our expectation to buy back $1 billion in stock by June of this year with approximately $630 million of that already completed. We would also expect to continue share repurchases in the back half of the year.
Aside from share repurchase activity, we are continuing to evaluate all of our businesses to ensure that they fit strategically within our portfolio and our earning their cost of capital will have a convincing plan to do so. To the extent a business does not meet these criteria, that business will be restructured or divested. We expect to continue to update you on the progress of this review over the coming months.
With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] Your first question comes from the line of Justin Lake with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Justin Lake with JPMorgan."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Question around the Retail results. You laid out a few headwinds to the quarter. Can you put some numbers around them and also give us some color on your positioning in Puerto Rico Medicare and how much money you're losing there right now?",43,"Question around the Retail results. You laid out a few headwinds to the quarter. Can you put some numbers around them and also give us some color on your positioning in Puerto Rico Medicare and how much money you're losing there right now?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Sure. So the flu is a major driver. It was around $45 million all-in for the company. About 3/4 of that was driven in the Retail segment. With regard to Puerto Rico, I'd rather not go into the details of the numbers there, but we are losing money in that",164,"Sure. So the flu is a major driver. It was around $45 million all-in for the company. About 3/4 of that was driven in the Retail segment. With regard to Puerto Rico, I'd rather not go into the details of the numbers there, but we are losing money in that market. We lost more this quarter than we expected. And really, that's driven by the fact that the dynamics in that market are different. The medical management of those members is different. We got hit by uncompensated care adjustments that we had to take into our results that weren't in the bids because they came after the bids. And so 2014 was a very difficult year for that market. On the duals side, we're continuing to build out that infrastructure. As we think about investments for 2014, I would say the duals came in slightly higher, individual came in slightly lower. So that's sort of how I'd calibrate those results on the Retail segment."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Kevin Fischbeck with Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck with Bank of America."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Just wanted to follow up on, I guess, that last comment before the Q&A about evaluating certain businesses, making sure that they are appropriately turned out. I don't really remember you guys talking a lot about this before. Is there -- are there signifi",88,"Just wanted to follow up on, I guess, that last comment before the Q&A about evaluating certain businesses, making sure that they are appropriately turned out. I don't really remember you guys talking a lot about this before. Is there -- are there significant business lines that are currently being evaluated? And I think you mentioned either divesting them or fixing them. Is there anything in the guidance that would contemplate some potential cost of fixing a business line that's not in a return that you are targeting?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, our guidance really incorporates all of our current businesses as they stand today. We are very focused on continuing to drive down admin costs. And as you saw that in the Employer Group segment this year, we'll continue to work on that. But we're e",104,"Well, our guidance really incorporates all of our current businesses as they stand today. We are very focused on continuing to drive down admin costs. And as you saw that in the Employer Group segment this year, we'll continue to work on that. But we're evaluating all of our lines of business. I think we've been very clear that all of our businesses over time need to earn their cost of capital, and we're going to make sure that occurs and we're being very disciplined about it. And so I don't want to comment on any specific businesses, but we're evaluating our entire portfolio."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","But I guess maybe is there a way to frame it? Are we talking about things around the edges? Or are there decent-sized parts of the business that are being evaluated?",31,"But I guess maybe is there a way to frame it? Are we talking about things around the edges? Or are there decent-sized parts of the business that are being evaluated?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, I would say all of our businesses are being evaluated. I think we feel very good about our core businesses. So I wouldn't see any major change in that regard. But there are a number of businesses that need to hit their returns, and we'll focu",50,"Well, again, I would say all of our businesses are being evaluated. I think we feel very good about our core businesses. So I wouldn't see any major change in that regard. But there are a number of businesses that need to hit their returns, and we'll focus on that."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Josh Raskin with Barclays.",12,"Your next question is from the line of Josh Raskin with Barclays."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","The question is around that Medicare Advantage growth and the source, the drivers. I think I heard you say 52% had come from competitors. I guess I was a little surprised to hear that, that I know last year was a little bit of an anomaly. But I'm just cur",96,"The question is around that Medicare Advantage growth and the source, the drivers. I think I heard you say 52% had come from competitors. I guess I was a little surprised to hear that, that I know last year was a little bit of an anomaly. But I'm just curious where that's trended in the past. And then as you think about the overall MA growth, how much of that is coming from previously fee-for-service Medicare lives, how many are agent, how many are PDP conversions, and maybe any other buckets, just overall that MA growth?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, this is Jim Murray. As we look across the various markets that we grew, and there were probably 10 or 12 markets that we would point to, we're seeing the beneficial impact of our higher Stars rating, we believe, having a favorable impact in the way t",209,"Yes, this is Jim Murray. As we look across the various markets that we grew, and there were probably 10 or 12 markets that we would point to, we're seeing the beneficial impact of our higher Stars rating, we believe, having a favorable impact in the way that we're able to position ourselves relative to the competition. Bruce earlier talked about North Carolina, and that's the market where we have 4.5 stars, and some of the competitors that were there before didn't have as high a Star score. And we think that, that, in terms of the premium and benefits that we're able to put on The Street, helps to position us better. So I would say that that's one aspect that we're seeing play itself out. We're obviously very pleased about that. As respects the number of members that we get from competitors versus fee-for-service, I would tell you that, that number, as we've looked at it, is about 50-50. Agents generally -- a significant part of the agent growth occurs during the ROI as opposed to during the AEP itself. A lot of favorable dynamics. And again, as Brian and Bruce both pointed out, we're pretty pleased with the way that this AEP played out for us."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Josh, one thing I would add to that is as you -- as we've discussed, we had great growth in our HMO area and our strategy has always been is create a relationship through the PPO product and then evolve them over. And we just see that strategy continuing",68,"Josh, one thing I would add to that is as you -- as we've discussed, we had great growth in our HMO area and our strategy has always been is create a relationship through the PPO product and then evolve them over. And we just see that strategy continuing to be strong, which both helps us on retention, but also the engagement and helping them with their health."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And just a follow-up on that. So one, are you seeing any material impact from PDP conversions in the AEP? And then, I guess, I'm just looking at that sort of competitor impact. Are you seeing -- is that different than what you've seen in previous years? I",74,"And just a follow-up on that. So one, are you seeing any material impact from PDP conversions in the AEP? And then, I guess, I'm just looking at that sort of competitor impact. Are you seeing -- is that different than what you've seen in previous years? Is the impact of Stars more important now? Were you doing better vis-Ã -vis the competition in a different way than you've seen in the previous years?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I think last year, we had the same circumstance. I just -- we sound like a broken record, but our clinical platform has allowed us to offer stable benefits in the marketplace. And the clinical platform is not only helping us with Star scores, but it's als",136,"I think last year, we had the same circumstance. I just -- we sound like a broken record, but our clinical platform has allowed us to offer stable benefits in the marketplace. And the clinical platform is not only helping us with Star scores, but it's also helping engage individuals and getting them in the right clinical programs, which is ultimately lowering the cost of the medical side, which is then turn around and allowing us to offer the proper benefits. So I think it all sort of fits together. It's just not Stars. I would say that that's a contributor in the individual marketplaces, but I wouldn't walk away from the call and say that's our competitive advantage. Our competitive advantage is really the clinical programs that drives both lower medical costs and better quality."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of A.J. Rice with UBS.",13,"Your next question is from the line of A.J. Rice with UBS."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I might just ask you about 2 items that were in your walk forward to guidance last quarter. I think you had in there about a $0.35 tailwind from lower investments in exchange- and state-based contracts. And Brian, you mentioned that a little bit in your p",120,"I might just ask you about 2 items that were in your walk forward to guidance last quarter. I think you had in there about a $0.35 tailwind from lower investments in exchange- and state-based contracts. And Brian, you mentioned that a little bit in your prepared remarks. I wondered if there's an update on what you're thinking in terms of investments and the timing. And then the other one I was going to ask you about was Hep C. You had a $0.45 tailwind in your guidance there. And since then, I know you provide -- you've done your preferred vendor contract with Gilead, and I wondered, did that $0.45 contemplate that contract? Or is there now potential upside?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","So with regard to the first question on the investments, I would say it's similar to what we discussed last call in terms of what we're expecting. Again, H1, we expect to breakeven, or hopefully, do better than that. On the Medicaid duals side, we are exp",142,"So with regard to the first question on the investments, I would say it's similar to what we discussed last call in terms of what we're expecting. Again, H1, we expect to breakeven, or hopefully, do better than that. On the Medicaid duals side, we are expecting to reduce our investments, let's say, pretty significantly. I would think about it sort of as a $0.25 investment, plus or minus, on the Medicaid duals side for 2015. For Hep C, it really is -- it's early to tell. Let's see what happens for 2015. Clearly, the unit price discount helps. But we still need to see where utilization ultimately plays out and we're watching that very closely, and we'll see over the next few months where we stand. I would say, as it looks today, we feel pretty good, but it's still early."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Scott Fidel with Deutsche Bank.",13,"Your next question comes from the line of Scott Fidel with Deutsche Bank."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Just interested if you can give your thoughts on the CMS value-based contracting initiative for fee-for-service and whether we would view that as more of a positive or a risk for MA. And just thinking about from a reimbursement perspective, if you think t",91,"Just interested if you can give your thoughts on the CMS value-based contracting initiative for fee-for-service and whether we would view that as more of a positive or a risk for MA. And just thinking about from a reimbursement perspective, if you think there's any risk that MA rates could be pressured in the intermediate to long term if CMS does assume lower unit costs and lower cost trends in fee-for-service and whether that gets translated into the per capita growth rate assumption that they make for the MA business."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, I think, overall, our view is this transition to value-based reimbursement and getting more providers in those reimbursement models is the best for, I think, the industry as a whole. I think we look at that as an opportunity for us both in helping p",180,"Well, I think, overall, our view is this transition to value-based reimbursement and getting more providers in those reimbursement models is the best for, I think, the industry as a whole. I think we look at that as an opportunity for us both in helping providers and, at the same time, continuing to advance the Medicare Advantage positioning. In regards to does it affect the benchmark, I think, is where you're getting to. Over time, it will affect the benchmark, I think, in any kind of plan that's there. It's lowering the cost of Medicare and you get affected. But I do think long term the Medicare Advantage offers a significantly better advantage as you look at the comprehensive nature of it. It's just not about the price. And also what we found is about the integration of the services and the systems that's provided there. But at the same time, we realized that we have to be better than the competition at our clinical programs, and that competition is both within Medicare Advantage and also Medicare as a whole."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Andy Schenker with Morgan Stanley.",13,"Your next question is from the line of Andy Schenker with Morgan Stanley."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So I appreciate Brian's comments in the prepared remarks on PCP. You've been trending down for some time. So maybe if you could just give me a little bit more understanding about the moving parts behind the trend over that time, including maybe specifical",80,"So I appreciate Brian's comments in the prepared remarks on PCP. You've been trending down for some time. So maybe if you could just give me a little bit more understanding about the moving parts behind the trend over that time, including maybe specifically how changing mix has impacted that number. So you've mentioned the long-term support services, but how do growing exchange and MA growth impact then how should we really be thinking about that metric going forward?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, the major driver really is the capitation. As we continue to increase our physicians and our capitation arrangements, basically, you have a benefit expense and you don't have a reserve. And so that really is the major driver. If you look at the roll",201,"Well, the major driver really is the capitation. As we continue to increase our physicians and our capitation arrangements, basically, you have a benefit expense and you don't have a reserve. And so that really is the major driver. If you look at the roll forward, you could see the days move really driven by that. The LTSS business has a similar dynamic in the sense that we pay the nursing homes on a monthly basis. And so again, you have this expense without having that reserve and so that'll naturally take it down. And then, as I mentioned in my prepared remarks, this quarter, we had an outlier in the sense of H1 and that the members came on a little bit late. There were a bunch of pended claims that we were working through, and we really did that over the fourth quarter. And so that really, I think -- those are the 3 major buckets what's driving the days claims. I'd also hasten to add that our cash flows are still very strong. And so as we think about our quality of earnings metrics, we're very focused to make sure our cash flows are good and they are."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So therefore, just to follow up going forward because you're expecting more growth in capitation, you'd expect that number to keep going down. And does the growth in exchanges or MA somewhat offset that to the other side or...",39,"So therefore, just to follow up going forward because you're expecting more growth in capitation, you'd expect that number to keep going down. And does the growth in exchanges or MA somewhat offset that to the other side or..."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I'd say all else being equal, I think that's right.",11,"I'd say all else being equal, I think that's right."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Ralph Giacobbe with CrÃ©dit Suisse.",13,"Your next question comes from the line of Ralph Giacobbe with CrÃ©dit Suisse."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Back to the Puerto Rico book, can you give us a sense of size and/or magnitude of the loss? And then I know you exited Medicaid there. Can you maybe talk about your commitment to that region within Medicare and/or how you're going to be able to sort of fi",52,"Back to the Puerto Rico book, can you give us a sense of size and/or magnitude of the loss? And then I know you exited Medicaid there. Can you maybe talk about your commitment to that region within Medicare and/or how you're going to be able to sort of fix the issues?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, I'd rather not go into specifics on our P&L of that market. I would say they're real losses. They move the needle. They affected our tax rate. We are working hard to fix the problems in the market. The Medicaid -- losing the Medicaid contract",140,"Well, again, I'd rather not go into specifics on our P&L of that market. I would say they're real losses. They move the needle. They affected our tax rate. We are working hard to fix the problems in the market. The Medicaid -- losing the Medicaid contract, I think, is indicative of where we are and deciding not to re-up there. And so our guys are working hard on that, on fixing the problems, and getting our members to engage and improve the medical management and the like. Again, we had some one-timers here in 2014 as they're related to uncompensated care and the time when that came into effect with respect to the bids. But as I said, all of our businesses that aren't earning their cost of capital need to be evaluated, and we are certainly doing that."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Okay. And maybe -- I know you don't want to talk about the size of the losses. Can you give us a sense of even just the premium?",28,"Okay. And maybe -- I know you don't want to talk about the size of the losses. Can you give us a sense of even just the premium?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","There are about -- this is Jim. There are about 50,000 Medicare Advantage members in Puerto Rico as we ended the year. We purposely tried to downsize as respect to our activities relative to the AEPs so that we could shrink that membership. The premium th",157,"There are about -- this is Jim. There are about 50,000 Medicare Advantage members in Puerto Rico as we ended the year. We purposely tried to downsize as respect to our activities relative to the AEPs so that we could shrink that membership. The premium that we get from the federal government for Medicare is solid. As Brian alluded to earlier, the government made some change in the way that they pay hospitals after our bids were finalized for 2014. That was a big drag on our results. And the other thing that Brian mentioned, the loss of focus, because we did lose the Medicaid contract and the clinical model that was commensurate with that, negatively impacted our Medicare results. So we expect a smaller portfolio of business in 2015. And as Brian said, we're actively working on things that would improve that -- our prospects in Puerto Rico, and that's probably where we should end it."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Peter Costa with Wells Fargo Securities.",14,"Your next question is from the line of Peter Costa with Wells Fargo Securities."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Again, it's close to that of the year when we hear about what the 2016 Medicare Advantage rates are going to be. We know from December that 2.45% was sort of what they were talking about for the growth rate at that point. But what are the factors should w",69,"Again, it's close to that of the year when we hear about what the 2016 Medicare Advantage rates are going to be. We know from December that 2.45% was sort of what they were talking about for the growth rate at that point. But what are the factors should we be considering that might be impacting the payments that you get from the government for Medicare rates in 2016?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, Peter, this is pure speculation, so it's always difficult. I think we look at the discussions that have historically been in the rate notice around in-home assessments as being an area of discussion. I also think the MRA adjustments are another area",87,"Yes, Peter, this is pure speculation, so it's always difficult. I think we look at the discussions that have historically been in the rate notice around in-home assessments as being an area of discussion. I also think the MRA adjustments are another area that possibly could be included in the rate notice. But that's really based on the dialogue that has happened over the past few years with them, and I don't have any inside information more than anybody else has on what's going to come out."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And in terms of the range of possibilities, how do you think it will impact your ability to price business for next year and obtain growth for next year?",29,"And in terms of the range of possibilities, how do you think it will impact your ability to price business for next year and obtain growth for next year?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","This is Jim. We have always, over the last number of years, expected the worst. And as we focus on what are necessary actions relative to trend vendors, we plan for that and we'll see what happens in April, and then we evaluate our bid processes and strat",90,"This is Jim. We have always, over the last number of years, expected the worst. And as we focus on what are necessary actions relative to trend vendors, we plan for that and we'll see what happens in April, and then we evaluate our bid processes and strategies accordingly. But we're in the process, as we speak, of trying to identify trend vending activities that would address the worst-case scenario in some of the things that Bruce talked about, and we're putting those in place for 2016 as we speak."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Matthew Borsch with Goldman Sachs.",13,"Your next question comes from the line of Matthew Borsch with Goldman Sachs."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","A question on your guidance in the Medicaid duals. So I think as I understood, you're looking at a $0.25 approximate tailwind on that business from reduced investment. But am I correct that, that business is still losing money, if you will, when you count",63,"A question on your guidance in the Medicaid duals. So I think as I understood, you're looking at a $0.25 approximate tailwind on that business from reduced investment. But am I correct that, that business is still losing money, if you will, when you count in the investment or expected to for 2015? Or is that wrong? And can you quantify any magnitude?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, and if I wasn't clear, I think we expect around $0.25 of loss in 2015 for the state-based businesses, if that helps. And that is reduced from 2014 pretty meaningfully.",31,"Yes, and if I wasn't clear, I think we expect around $0.25 of loss in 2015 for the state-based businesses, if that helps. And that is reduced from 2014 pretty meaningfully."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Okay. And can you give us a range of magnitude on 2014?",12,"Okay. And can you give us a range of magnitude on 2014?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","No, I would say, if you combine H1 and the duals, it was, call it, around $0.70 plus or minus.",20,"No, I would say, if you combine H1 and the duals, it was, call it, around $0.70 plus or minus."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Sarah James with Wedbush Securities.",13,"Your next question is from the line of Sarah James with Wedbush Securities."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Humana and the other insurers have been working on providing new data to CMS that follows up on actions and results from home health risk assessments, and I'm wondering if there's been any consensus reached among the insurers or with CMS on how to effecti",56,"Humana and the other insurers have been working on providing new data to CMS that follows up on actions and results from home health risk assessments, and I'm wondering if there's been any consensus reached among the insurers or with CMS on how to effectively evaluate the results of that or the sufficiency of solid actions."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","No, there has been discussion on the effectiveness of in-home assessments and the work that's been done there on a number of different occasions. I don't think there has been one proposal that has been agreed upon both by the industry and by CMS. And I do",73,"No, there has been discussion on the effectiveness of in-home assessments and the work that's been done there on a number of different occasions. I don't think there has been one proposal that has been agreed upon both by the industry and by CMS. And I don't -- we don't want to get into commenting on what we think CMS would come out with based on our discussions about industry-wide and company specific."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Tom Carroll with Stifel.",12,"Your next question is from the line of Tom Carroll with Stifel."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So just a question on the 3Rs. How do you want investors to think about the change in the 3R accruals that you're making for 2015? I mean, is this just you have more color, as you put it, which provides more visibility in operations? Or is Humana perhaps",65,"So just a question on the 3Rs. How do you want investors to think about the change in the 3R accruals that you're making for 2015? I mean, is this just you have more color, as you put it, which provides more visibility in operations? Or is Humana perhaps getting a little more aggressive on assumptions? Wonder if you could balance that out for us."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, I guess, I'd say we view it as a good thing that we're able to reduce the reliance on the 3Rs by over half. That's a delivered strategy we made by ticking up pricing. We're being very disciplined there and that's really part of our strategy to get t",118,"Well, I guess, I'd say we view it as a good thing that we're able to reduce the reliance on the 3Rs by over half. That's a delivered strategy we made by ticking up pricing. We're being very disciplined there and that's really part of our strategy to get to breakeven or better for 2015. So I think when we saw the new sales come in and break down by metal tier and age and geography, et cetera, we were able to take it down slightly from where we were on the third quarter, but we view that as a good thing, and again, feel positive about where we are with that business and how we priced it."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","When we entered the exchanges in 2014, I think we communicated to the investors that we were going to grow in 2014, while in 2015, transition to ensure that there was sustainability in that business long term. And what you see happening is that's what's h",100,"When we entered the exchanges in 2014, I think we communicated to the investors that we were going to grow in 2014, while in 2015, transition to ensure that there was sustainability in that business long term. And what you see happening is that's what's happening, that we grew in 2014. We would define success this year as maintaining our membership that we had in 2014 and 2015 and having maintain that level, while at the same time, reducing our reliance on the 3Rs, specifically 2Rs, to allow us to make that transition when the 2Rs go away next year."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Christine Arnold with Cowen.",12,"Your next question is from the line of Christine Arnold with Cowen."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Could you speak to your expectations for medical trends? Better economy. Consumer confidence seems to be rising. Fuel prices are down. Kind of like increasing discretionary income for folks. How do you think that might impact medical costs? And how do you",70,"Could you speak to your expectations for medical trends? Better economy. Consumer confidence seems to be rising. Fuel prices are down. Kind of like increasing discretionary income for folks. How do you think that might impact medical costs? And how do you build that into your Medicare Advantage assumptions with respect to trend vendors that you're going to need and the medical trend expected in '15 versus '14 for MA?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Sure. Well, as you know, we did increase the expected trend for our commercial group business to 5.5% to 6.5% from 4% to 4.5%. So that was a significant increase, I think, reflecting all the things that you just discussed. On the Medicare side, it's not a",108,"Sure. Well, as you know, we did increase the expected trend for our commercial group business to 5.5% to 6.5% from 4% to 4.5%. So that was a significant increase, I think, reflecting all the things that you just discussed. On the Medicare side, it's not as directly tied to economic growth but there's probably some impact. We focus pretty intently on where the trend vendors need to be relative to where the rate's coming at from a CMS perspective. And I would say there's probably less marginal move, unlike the commercial side, based on economic growth and other factors, employment, et cetera, that you would typically see."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","What about the fact that fuel prices were lower? Old people are spending less to fuel up their vehicles. And also, what -- can you tell us what kind of trend vendor you assumed in '15 versus '14?",38,"What about the fact that fuel prices were lower? Old people are spending less to fuel up their vehicles. And also, what -- can you tell us what kind of trend vendor you assumed in '15 versus '14?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","We're not going to get to that level of detail. I -- we haven't really evaluated or I don't know the answer to this specific, how fuel impacts it. But our -- we take a holistic view of where trend may be and a number of factors go into that.",51,"We're not going to get to that level of detail. I -- we haven't really evaluated or I don't know the answer to this specific, how fuel impacts it. But our -- we take a holistic view of where trend may be and a number of factors go into that."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I'm actually happy that the seniors have fuel for their cars because they're making them go and see their doctors...",21,"I'm actually happy that the seniors have fuel for their cars because they're making them go and see their doctors..."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","To the clinic.",3,"To the clinic."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","So that they can take care of all the things that they need to take care of rather than waiting for an acute event. So I'm happy about that.",29,"So that they can take care of all the things that they need to take care of rather than waiting for an acute event. So I'm happy about that."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Ana Gupte with Leerink Partners.",13,"Your next question is from the line of Ana Gupte with Leerink Partners."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I was just trying to see some of the less focused areas of business as they might be potential drivers for upside. So one of them is individual off-exchange and I know that's a much smaller piece of your book. But 2 of your peers have stated that they los",109,"I was just trying to see some of the less focused areas of business as they might be potential drivers for upside. So one of them is individual off-exchange and I know that's a much smaller piece of your book. But 2 of your peers have stated that they lost money in '14 and taking some pretty serious pricing actions and removing ACA compliance plans. Is there anything here that you might have been doing? And I get it that the MLR floors probably took care of a piece of this, but just '14 would guarantee the shoe [ph] and community rating did hurt some of the off-exchange books."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes. So as we said, and I don't really want to distinguish between off-exchange and on-exchange in terms of our pricing, as we've said, we've been very disciplined on pricing with our entire ACA-compliant book. Off-exchange is part of our strategy. It's a",75,"Yes. So as we said, and I don't really want to distinguish between off-exchange and on-exchange in terms of our pricing, as we've said, we've been very disciplined on pricing with our entire ACA-compliant book. Off-exchange is part of our strategy. It's an important part of our strategy. And we're looking to mitigate the losses in both the off-exchange and on-exchange. And again, all-in, as we said, we do expect to do that this year."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And then, secondly, Brian, secondly on the small group and maybe just the broader commercial fully insured book, your employer loss ratio looks pretty good for this quarter. In the third quarter, it deteriorated, if I remember right, and somehow I didn't",78,"And then, secondly, Brian, secondly on the small group and maybe just the broader commercial fully insured book, your employer loss ratio looks pretty good for this quarter. In the third quarter, it deteriorated, if I remember right, and somehow I didn't have a chance to follow up on that. Our pricing survey show you've jacked up your pricing quite a bit for '15. So any improvement in margin there? And what are you baking into your guidance?"
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, back in the third quarter, we did suffer the impact of some of the transitional relief that we discussed. Now we got some of that back in the fourth quarter through, I would say, both current period and prior period development that were bett",103,"Well, again, back in the third quarter, we did suffer the impact of some of the transitional relief that we discussed. Now we got some of that back in the fourth quarter through, I would say, both current period and prior period development that were better than expectations. And that really was the driver of the outperformance, along with the continued focus on admin costs. I would say, as we move into next year, we price for Hep C and the like, hopefully, we'll continue to see improvements there. And really, where we need to focus is on the admin side as well."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes. There's one other dynamic in the small group space that you're all aware of, I'm sure, is that there's a movement into the community-based rating methodology and that's kind of an interesting dynamic that we're watching play out with some of our comp",119,"Yes. There's one other dynamic in the small group space that you're all aware of, I'm sure, is that there's a movement into the community-based rating methodology and that's kind of an interesting dynamic that we're watching play out with some of our competition and where they price their community-rated business rights versus where we're at. As we sit here right now, we feel pretty good about how we're positioned and are monitoring not only the community rights, but the migration from our existing block of business into those with the transitional relief opportunity that we have. So again, feel pretty good about that, and I'm glad that you notice that in some of the stuff that we provided."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Chris Rigg with Susquehanna Financial Group.",14,"Your next question is from the line of Chris Rigg with Susquehanna Financial Group."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I just wanted to follow up on the flu comments from earlier. I know you talked about a $45 million headwind in the quarter. I guess, I'm just try to get a sense for -- I just want to confirm if that was relative to budget and just for how much the flu cos",59,"I just wanted to follow up on the flu comments from earlier. I know you talked about a $45 million headwind in the quarter. I guess, I'm just try to get a sense for -- I just want to confirm if that was relative to budget and just for how much the flu cost increased on a year-to-year basis."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","That was relative to our forecast for the fourth quarter. We had a very difficult December with regard to flu. As I've said, it's abated towards the end of the month and early January, and so we feel good about where we are for 2015. The 2014 results were",71,"That was relative to our forecast for the fourth quarter. We had a very difficult December with regard to flu. As I've said, it's abated towards the end of the month and early January, and so we feel good about where we are for 2015. The 2014 results were worse than the 2013 results, but I wouldn't want to go into specifics there, but they were certainly worse, particularly in December."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your final question comes from the line of Dave Windley with Jefferies.",12,"Your final question comes from the line of Dave Windley with Jefferies."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","On some maybe difficult-to-answer questions, but curious of your broader thoughts, first of all, on the Supreme Court decision and how you are contingency planning around that. And secondly, your thoughts on President Obama's budget and proposed cuts to M",45,"On some maybe difficult-to-answer questions, but curious of your broader thoughts, first of all, on the Supreme Court decision and how you are contingency planning around that. And secondly, your thoughts on President Obama's budget and proposed cuts to Medicare, and specifically, Medicare Advantage."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, we really don't get into the habit of commenting on those broad aspects until they're finalized. So I don't want to get into that because it's just speculation and I'll leave it at that.I think that was the last question. So with that being said, w",99,"Yes, we really don't get into the habit of commenting on those broad aspects until they're finalized. So I don't want to get into that because it's just speculation and I'll leave it at that.
I think that was the last question. So with that being said, we really appreciate the support by our investors and the confidence in the company. And most importantly, we thank our 55,000 associates for their dedication in helping our members with their health and all the necessary actions that are required with that. So thank you very much, and have a great day."
29618,278392365,754496,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","This concludes the Fourth Quarter 2014 Earnings Conference Call. Thank you for joining. You may now disconnect your lines.",19,"This concludes the Fourth Quarter 2014 Earnings Conference Call. Thank you for joining. You may now disconnect your lines."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Good morning, and welcome to the Fourth Quarter 2014 Earnings Conference Call. [Operator Instructions] I will now hand today's call over to Regina Nethery. Please go ahead.",27,"Good morning, and welcome to the Fourth Quarter 2014 Earnings Conference Call. [Operator Instructions] I will now hand today's call over to Regina Nethery. Please go ahead."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Humana's senior management team will discuss our fourth quarter and full year 2014 results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be: Bruce Broussard, Humana's Pr",344,"Thank you, and good morning. In a moment, Humana's senior management team will discuss our fourth quarter and full year 2014 results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be: Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Senior Vice President and Chief Financial Officer. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts.
Joining Bruce and Brian for the Q&A session will be: Jim Murray, Executive Vice President and Chief Operating Officer; and Christopher Todoroff, Senior Vice President and General Counsel.
We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. This call is also being simulcast via the Internet along with a virtual slide presentation. An Adobe version of today's slide deck has been posted to the Investor Relations section of Humana's website.
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in this morning's earnings press release as well as in our filings with the Securities and Exchange Commission. Today's press release, our historical financial news releases and our filings with the SEC are all available on Humana's Investor Relations website.
Call participants should also note that today's discussion and slide presentation include financial measures that are not in accordance with generally accepted accounting principles. Management's explanation for the use of these non-GAAP measures is included in today's slide presentation, including a reconciliation of GAAP to non-GAAP financial measures. Finally, any references to earnings per share, or EPS, made during this morning's call refer to diluted earnings per common share.
With that, I'll turn the call over to Bruce Broussard."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Good morning, everyone, and thank you for joining us. This morning, Humana reported full year adjusted earnings per share for 2014 of $7.51, in line with our 2014 guidance. This past year was particularly dynamic across the sector and presented a number o",1364,"Good morning, everyone, and thank you for joining us. This morning, Humana reported full year adjusted earnings per share for 2014 of $7.51, in line with our 2014 guidance. This past year was particularly dynamic across the sector and presented a number of challenges as well as some new opportunities. Humana continues to rise to these challenges through our consumer-focused strategy and integrated care delivery model, while simultaneously investing in new growth areas. As a result, we are reiterating our guidance for 2015 earnings of $8.50 to $9 per share, a growth rate of approximately 17% at the midpoint. 
As we outlined at our Investor Day this past December, Humana's investment thesis is driven by our customer-focused integrated care delivery model and the related results. This thesis includes 4 key elements: continued robust organic membership and revenue growth; proven superior clinical operating performance; disciplined capital allocation, which all lead to a sustainable competitive advantage.
I'll begin our discussion this morning with a focus on our membership and revenue growth. We recently raised our net Medicare Advantage membership growth expectations for 2015 to 300,000 to 350,000, primarily as a result of a strong sales during -- or results of strong sales during the recently completed annual election period or AEP.
And looking at the January enrollment data from CMS, Humana continues to lead the industry in membership growth for individual Medicare Advantage plans. The CMS data indicates that Humana accounted for nearly 70% of the individual MA net enrollment growth across the sector. In fact, approximately 52% of our individual gross sales during the AEP came from competitor Medicare Advantage offerings.
From a geographic perspective, we did not see strong specific concentration with this growth, but did experience our highest membership gains in North Carolina. We are pleased with this individual MA growth as it complements the group MA membership increase we experienced in that state in 2014, making this a very important Humana market.
With a large base of Medicare members, we are now able to bring other Humana offerings, like HumanaOne, to the state. As you'll see from Slide 8, approximately 73% of our individual MA net growth was in HMO offerings, including current Humana members who chose to move to an -- into an HMO in 2015. This compares to 64% in 2014. 
Our HMO offerings continue to provide the highest level of engagement from both a member and provider perspective and also have the highest retention rate of our Medicare products. Over the past few years, we've discussed our integrated care delivery model and its 3 core elements: improve the consumer experience by simplifying the interaction, resulting in a trusting relationship; based on the trusting relationship, engage members in clinical programs; and offering assistance to providers and transitioning from fee-for-service to value-based reimbursement. 
This strategy has provided superior clinical operating performance, resulting in a sustainable competitive advantage. Over the past few years, membership growth in Star scores provide evidence of the success of this strategy. We believe there are 5 key points of influence that drive our superior clinical operating performance. Although I will not go through all the detail on the slide today, I did want to highlight how we are already been working with our new 2015 members, allowing us to begin to get to know them and allow for timely enrollment in the proper clinical programs.
I'll begin with wellness and prevention. Staying in tune with the health of our members is a major focus of our wellness and prevention efforts. This all begins with our new member welcome calls. These calls begin shortly after the onset of the AEP this past October. These outreach efforts have already resulted in the completion of over 160,000 health risk assessments. Data from the welcome calls, health risk assessments and our sophisticated predictive modeling have already come together to identify more than 46,000 of our members for referrals to our Humana At Home.
Our wellness efforts have a strong focus on gaps in care. In 2014, we closed approximately 4.3 million gaps in care for our members, driven by improvement in preventative screenings. Better still, we are very pleased that approximately 1.3 million of our members across all lines of business received preventative treatment on schedule.
Turning to the primary care point of influence. We are pleased to report that approximately 55% of our net membership growth during the AEP is for members associated with providers in value-based arrangements. Remember that we offer providers a continuum of opportunities to increase the integration of care. This includes performance bonuses, shared savings and shared risk relationships.
We see HHS announcement last week on its move to paying providers based on value as further validation that our integrated care delivery strategy is on track. We look forward to working with HHS in developing new payment models and continuing to assist providers in the transition to value-based payment.
Health care at home will also be an important element of the care for many of our new members. As we've shared with you in the past, our Humana At Home programs do a terrific job of providing members with clinical support and care that often results in a significantly higher number of days they spend at their homes instead of in an acute care facility. 
Importantly, as we evaluate each of the points of influence I've just described, as well as our pharmacy interactions with our members, we utilize advanced analytics, including sophisticated predictive models, to provide insights that are both actionable and drive value for our members. All these metrics are indicative of the solid value proposition we continue to offer Medicare beneficiaries in the face of rate reductions. Successfully engaging our members in clinical programs is proving we can assist our members with their health needs. This is allowing us to offer stability in their premiums and benefits, and reduce the complexity of navigating the health care system and helps produce the robust organic growth we are sharing with you today.
Looking at our other offerings. Humana's stand-alone PDP membership continues to experience strong growth with the bulk of the growth in our low-priced Walmart offering. This, together with growth in our Medicare Advantage membership, drives higher use of the services in our Healthcare Services segment, benefiting the enterprise overall.
Turning to our HumanaOne membership. As we evaluate recent health care exchange enrollment data, we believe it comports well with the pricing assumptions we made for 2015. As we've indicated on prior calls, our 2015 pricing appropriately assume the ultimate elimination of 2 of the 3Rs. We continue to be pleased with the mix of our membership, both across the metal tiers and by age distribution. We also believe that the 55 to 64 age ranges are opportunity to develop relationships with these members before they age into Medicare Advantage.
I also would want to highlight for you today something innovative we are doing in the Employer Group business. In the latter part of 2013, we introduced to our employer customers a product we call Total Health, which turns any standard medical plan of the employers choosing into an integrated health and well-being solution that encourages participation in HumanaVitality, health coaching and clinical programs. Employee participation results in employer discounts, which is resulting in the shift of our single-year contract to a multiyear relationship that is creating employer solutions to not only cost, but also productivity.
Employer receptivity to the Total Health product is high with membership now at approximately 100,000 versus less than 400,000 at the end of 2013. We anticipate in the future these wellness programs and services will be complementary to employers choosing private and public exchange models. 
In conclusion, we continue to be pleased with our prospects for 2015 and beyond. The engagement of our associates and focus on the consumer through our integrated care delivery model has never been stronger. We believe that will result in the continuation of our superior clinical operating performance and a sustainable competitive advantage for quite some time to come.
With that, I'll turn the call over to Brian for a more detailed discussion of our financials and our commitment to disciplined capital allocation."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. As Bruce said in his remarks, 2014 was an unusually dynamic year full of opportunities and challenges. The growth in our Medicare business was substantial and was supplemented by the power of our Healthcare Se",1302,"Thank you, Bruce, and good morning, everyone. As Bruce said in his remarks, 2014 was an unusually dynamic year full of opportunities and challenges. The growth in our Medicare business was substantial and was supplemented by the power of our Healthcare Services segment, which has prospered, while making a truly positive difference in our members' lives. Our Employer Group business capitalized on the late 2013 rollout of an exciting new offering in the form of Total Health, while also ending the year on a high note in terms of financial performance. All this transpired while we invested heavily in new growth opportunities, both HumanaOne and our state-based businesses, which we believe will generate significant returns for our shareholders down the road.
We are pleased that our full year adjusted EPS came in just above the midpoint of our guidance at $7.51 per share. As we closed out the year, there were a few items that adversely affected our 2014 results, but we do not see any of these significantly impacting our 2015 guidance. 
Our Retail segment pretax earnings finished the year below our guidance range. This was primarily attributable to the severity of the flu season, slightly higher investment spending for our duals and state-based contracts and deterioration in the results for our Puerto Rico Medicare business, which continues to be a difficult market for us.
With regard to the flu, hospital inpatient admissions peaked in late December, early January, but have since abated and have returned to more normalized levels. I should hasten to add that utilization more broadly remains benign and within expectations.
With regard to the duals, we continue to build out our infrastructure and are well positioned heading into 2015 to significantly reduce our investments, which we have committed to do.
Turning to the Employer Group segment. Our 2014 earnings results ended meaningfully above the upper end of our guidance range. While the flu did have some adverse impact on the Employer Group results, these were more than offset by lower medical claims utilization that we saw in both our commercial and group Medicare businesses. It is also important to note the effort that our Employer Group team has made to reduce administrative costs, which was also a significant driver of the segment's full year results.
Finally, our effective tax rate came in above the range of our previous guidance. There were several factors driving this, including the associated tax ramifications of higher losses in our Puerto Rico Medicare operations, which are nondeductible for U.S. income tax purposes, as well as lower tax-exempt investment income. We've evaluated each of these factors closely and have confidence that the 2015 guidance points we shared with you this morning encompass any continuing impact of each of these items.
Turning now to 2015. The majority of the guidance points we shared with you last quarter are unchanged. This slide summarizes the more significant changes since our last earnings call.
As we disclosed in a Form 8-K filing last month, we revised our Medicare Advantage and stand-alone PDP enrollment guidance to reflect the results of the 2015 AEP. Our higher projection for Medicare Advantage enrollment resulted in an increase to our revenue guidance that more than offset the revenue impact of the lower expectations for stand-alone PDP membership. As we have discussed in the past, the higher membership in our MA plans from the annual enrollment process will have a nominal impact on our Retail insurance segment performance this year. While there will be a favorable impact on the Healthcare Services segment's home-based business from the higher Medicare Advantage membership, this will be offset by the impact of the revised stand-alone PDP membership will have on Humana Pharmacy, as PDP members in our low price point offering tend to use our wholly owned mail order and specialty pharmacies at rates slightly higher than our MA members.
One other element of our 2015 guidance points that we updated today is our projected accruals for the premium stabilization programs, commonly called the 3Rs. As Bruce shared in his remarks, we now have more color around the mix of our membership distribution among the metal tiers and by age range. Having evaluated that data, we are comfortable lowering our projection for full year accruals for the 3Rs by approximately $50 million at the midpoint. We now expect the net receivables for 2015 to be less than half of the level they were compared to the balances we accrued at the end of 2014.
As we've noted in prior calls, our pricing strategy for 2015 included significantly lowering reliance on the 3Rs, and we are still on track for 2015 to achieve at a minimum breakeven results.
With regard to the risk corridors, we believe that the 2014 $51 million net receivable that we disclosed this morning is indeed collectible based on statutory and administrative actions. Further, any 2014 amounts must first be satisfied before subsequent years are paid. Finally, for 2015, the risk corridor receivable that we are currently forecasting is insignificant.
Turning to our operating cash flows. We have been around 1.5x net income for some time now, and we anticipate maintaining that quality of earnings metric again in 2015. This morning, we raised our guidance for operating cash flows by approximately $200 million, driven primarily by the timing of certain working capital items. While our days claims payable declined sequentially by 2.8 days to 44.7, this was primarily due to the increase in capitation payments as we continue to grow the number of providers under risk-based contracts as well as the growth in our long-term support services business, whose providers get paid monthly. 
Additionally, our normal December decline in claims inventories, driven by the holiday season and higher staffing associated with preparing for new members coming on January 1, was magnified by the relatively late HumanaOne enrollment and the associated pended claims, which we paid down in the fourth quarter.
I'll now turn to our view of the quarterly breakdown of earnings for 2015. Though we do not provide specific quarterly guidance, we did want to give you a sense for the key drivers of performance among the quarters, as we have done in prior years. Given our expectations that our health care exchange business will at least break even and our investments in state-based contracts will begin to mitigate, we've layered in the impact of those newer businesses across the quarters. The result is that we again project the third and fourth quarters to experience the most pressure in light of the quarterly progression of health benefit ratios and the timing of marketing and open enrollment across our lines of business.
I'll conclude my discussion this morning with a few words around capital allocation. As Bruce said in his remarks, disciplined capital allocation is a key component of Humana's investment thesis. At the time of our third quarter release, we announced a significant increase in our share repurchase authorization and a commitment to accelerate our buyback activity. We've held true to that commitment and maintain our expectation to buy back $1 billion in stock by June of this year with approximately $630 million of that already completed. We would also expect to continue share repurchases in the back half of the year.
Aside from share repurchase activity, we are continuing to evaluate all of our businesses to ensure that they fit strategically within our portfolio and are earning their cost of capital or have a convincing plan to do so. To the extent a business does not meet these criteria, that business will be restructured or divested. We expect to continue to update you on the progress of this review over the coming months.
With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] Your first question comes from the line of Justin Lake with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Justin Lake with JPMorgan."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Question around the Retail results. You laid out a few headwinds to the quarter. Can you put some numbers around them and also give us some color on your positioning in Puerto Rico Medicare and how much money you're losing there right now?",43,"Question around the Retail results. You laid out a few headwinds to the quarter. Can you put some numbers around them and also give us some color on your positioning in Puerto Rico Medicare and how much money you're losing there right now?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Sure. So the flu was a major driver. It was around $45 million all-in for the company. About 3/4 of that was driven in the Retail segment. With regard to Puerto Rico, I'd rather not go into the details of the numbers there, but we are losing money in that",164,"Sure. So the flu was a major driver. It was around $45 million all-in for the company. About 3/4 of that was driven in the Retail segment. With regard to Puerto Rico, I'd rather not go into the details of the numbers there, but we are losing money in that market. We lost more this quarter than we expected. And really, that's driven by the fact that the dynamics in that market are different. The medical management of those members is different. We got hit by uncompensated care adjustments that we had to take into our results that weren't in the bids because they came after the bids. And so 2014 was a very difficult year for that market. On the duals side, we're continuing to build out that infrastructure. As we think about investments for 2014, I would say the duals came in slightly higher, individual came in slightly lower. So that's sort of how I'd calibrate those results on the Retail segment."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Kevin Fischbeck with Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck with Bank of America."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Just wanted to follow up on, I guess, that last comment before the Q&A about evaluating certain businesses, making sure that they are appropriately turned out. I don't really remember you guys talking a lot about this before. Is there -- are there signifi",88,"Just wanted to follow up on, I guess, that last comment before the Q&A about evaluating certain businesses, making sure that they are appropriately turned out. I don't really remember you guys talking a lot about this before. Is there -- are there significant business lines that are currently being evaluated? And I think you mentioned either divesting them or fixing them. Is there anything in the guidance that would contemplate some potential cost of fixing a business line that's not earning a return that you are targeting?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, our guidance really incorporates all of our current businesses as they stand today. We are very focused on continuing to drive down admin costs. And as you saw that in the Employer Group segment this year, we'll continue to work on that. But we're e",104,"Well, our guidance really incorporates all of our current businesses as they stand today. We are very focused on continuing to drive down admin costs. And as you saw that in the Employer Group segment this year, we'll continue to work on that. But we're evaluating all of our lines of business. I think we've been very clear that all of our businesses over time need to earn their cost of capital, and we're going to make sure that occurs and we're being very disciplined about it. And so I don't want to comment on any specific businesses, but we're evaluating our entire portfolio."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","But I guess maybe is there a way to frame it? Are we talking about things around the edges? Or are there decent-sized parts of the business that are being evaluated?",31,"But I guess maybe is there a way to frame it? Are we talking about things around the edges? Or are there decent-sized parts of the business that are being evaluated?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, I would say all of our businesses are being evaluated. I think we feel very good about our core businesses. So I wouldn't see any major change in that regard. But there are a number of businesses that need to hit their returns, and we're focu",50,"Well, again, I would say all of our businesses are being evaluated. I think we feel very good about our core businesses. So I wouldn't see any major change in that regard. But there are a number of businesses that need to hit their returns, and we're focused on that."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Josh Raskin with Barclays.",12,"Your next question is from the line of Josh Raskin with Barclays."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","The question is around that Medicare Advantage growth and the source, the drivers. I think I heard you say 52% had come from competitors. I guess I was a little surprised to hear that, that I know last year was a little bit of an anomaly. But I'm just cur",96,"The question is around that Medicare Advantage growth and the source, the drivers. I think I heard you say 52% had come from competitors. I guess I was a little surprised to hear that, that I know last year was a little bit of an anomaly. But I'm just curious where that's trended in the past. And then as you think about the overall MA growth, how much of that is coming from previously fee-for-service Medicare lives, how many are agents, how many are PDP conversions, and maybe any other buckets, just overall that MA growth?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, this is Jim Murray. As we look across the various markets that we grew, and there were probably 10 or 12 markets that we would point to, we're seeing the beneficial impact of our higher Stars rating, we believe, having a favorable impact in the way t",210,"Yes, this is Jim Murray. As we look across the various markets that we grew, and there were probably 10 or 12 markets that we would point to, we're seeing the beneficial impact of our higher Stars rating, we believe, having a favorable impact in the way that we're able to position ourselves relative to the competition. Bruce earlier talked about North Carolina, and that's the market where we have 4.5 stars, and some of the competitors that were there before didn't have as high a Star score. And we think that, that, in terms of the premium and benefits that we're able to put on The Street, helps to position us better. So I would say that that's one aspect that we're seeing play itself out. We're obviously very pleased about that. As respects the number of members that we get from competitors versus fee-for-service, I would tell you that, that number, as we've looked at it, is about 50-50. Agents generally -- a significant part of the agent growth occurs during the ROI [ph] as opposed to during the AEP itself. A lot of favorable dynamics. And again, as Brian and Bruce both pointed out, we're pretty pleased with the way that this AEP played out for us."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Josh, one thing I would add to that is as you -- as we've discussed, we had great growth in our HMO area and our strategy has always been is create a relationship through the PPO product and then evolve them over. And we just see that strategy continuing",68,"Josh, one thing I would add to that is as you -- as we've discussed, we had great growth in our HMO area and our strategy has always been is create a relationship through the PPO product and then evolve them over. And we just see that strategy continuing to be strong, which both helps us on retention, but also the engagement and helping them with their health."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And just a follow-up on that. So one, are you seeing any material impact from PDP conversions in the AEP? And then, I guess, I'm just looking at that sort of competitor impact. Are you seeing -- is that different than what you've seen in previous years? I",74,"And just a follow-up on that. So one, are you seeing any material impact from PDP conversions in the AEP? And then, I guess, I'm just looking at that sort of competitor impact. Are you seeing -- is that different than what you've seen in previous years? Is the impact of Stars more important now? Were you doing better vis-Ã -vis the competition in a different way than you've seen in the previous years?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I think last year, we had the same circumstance. I just -- we sound like a broken record, but our clinical platform has allowed us to offer stable benefits in the marketplace. And that clinical platform is not only helping us with Star scores, but it's al",136,"I think last year, we had the same circumstance. I just -- we sound like a broken record, but our clinical platform has allowed us to offer stable benefits in the marketplace. And that clinical platform is not only helping us with Star scores, but it's also helping engage individuals and getting them in the right clinical programs, which is ultimately lowering the cost of the medical side, which is then turn around and allowing us to offer the proper benefits. So I think it all sort of fits together. It's just not Stars. I would say that that's a contributor in the individual marketplaces, but I wouldn't walk away from the call and say that's our competitive advantage. Our competitive advantage is really the clinical programs that drives both lower medical costs and better quality."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of A.J. Rice with UBS.",13,"Your next question is from the line of A.J. Rice with UBS."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I might just ask you about 2 items that were in your walk forward to guidance last quarter. I think you had in there about a $0.35 tailwind from lower investments in exchange- and state-based contracts. And Brian, you mentioned that a little bit in your p",120,"I might just ask you about 2 items that were in your walk forward to guidance last quarter. I think you had in there about a $0.35 tailwind from lower investments in exchange- and state-based contracts. And Brian, you mentioned that a little bit in your prepared remarks. I wondered if there's an update on what you're thinking in terms of investments and the timing. And then the other one I was going to ask you about was Hep C. You had a $0.45 tailwind in your guidance there. And since then, I know you provide -- you've done your preferred vendor contract with Gilead, and I wondered, did that $0.45 contemplate that contract? Or is there now potential upside?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","So with regard to the first question on the investments, I would say it's similar to what we discussed last call in terms of what we're expecting. Again, H1, we expect to break even, or hopefully, do better than that. On the Medicaid duals side, we are ex",143,"So with regard to the first question on the investments, I would say it's similar to what we discussed last call in terms of what we're expecting. Again, H1, we expect to break even, or hopefully, do better than that. On the Medicaid duals side, we are expecting to reduce our investments, let's say, pretty significantly. I would think about it sort of as a $0.25 investment, plus or minus, on the Medicaid duals side for 2015. For Hep C, it really is -- it's early to tell. Let's see what happens for 2015. Clearly, the unit price discount helps. But we still need to see where utilization ultimately plays out and we're watching that very closely, and we'll see over the next few months where we stand. I would say, as it looks today, we feel pretty good, but it's still early."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Scott Fidel with Deutsche Bank.",13,"Your next question comes from the line of Scott Fidel with Deutsche Bank."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Just interested if you can give your thoughts on the CMS value-based contracting initiative for fee-for-service and whether we would view that as more of a positive or a risk for MA. And just thinking about from a reimbursement perspective, if you think t",91,"Just interested if you can give your thoughts on the CMS value-based contracting initiative for fee-for-service and whether we would view that as more of a positive or a risk for MA. And just thinking about from a reimbursement perspective, if you think there's any risk that MA rates could be pressured in the intermediate to long term if CMS does assume lower unit costs and lower cost trends in fee-for-service and whether that can translate into the per capita growth rate assumption that they make for the MA business."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, I think, overall, our view is this transition to value-based reimbursement and getting more providers in those reimbursement models is the best for, I think, the industry as a whole. I think we look at that as an opportunity for us both in helping p",180,"Well, I think, overall, our view is this transition to value-based reimbursement and getting more providers in those reimbursement models is the best for, I think, the industry as a whole. I think we look at that as an opportunity for us both in helping providers and, at the same time, continuing to advance the Medicare Advantage positioning. In regards to does it affect the benchmark, I think, is where you're getting to. Over time, it will affect the benchmark, I think, in any kind of plan that's there. It's lowering the cost of Medicare and you get affected. But I do think long term the Medicare Advantage offers a significantly better advantage as you look at the comprehensive nature of it. It's just not about the price. And also what we found is about the integration of the services and the assistance that's provided there. But at the same time, we realize that we have to be better than the competition at our clinical programs, and that competition is both within Medicare Advantage and also Medicare as a whole."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Andy Schenker with Morgan Stanley.",13,"Your next question is from the line of Andy Schenker with Morgan Stanley."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So I appreciate Brian's comments in the prepared remarks on PCP. You've been trending down for some time. So maybe if you could just give me a little bit more understanding about the moving parts behind the trend over that time, including maybe specifical",80,"So I appreciate Brian's comments in the prepared remarks on PCP. You've been trending down for some time. So maybe if you could just give me a little bit more understanding about the moving parts behind the trend over that time, including maybe specifically how changing mix has impacted that number. So you've mentioned the long-term support services, but how do growing exchange and MA growth impact and how should we really be thinking about that metric going forward?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, the major driver really is the capitation. As we continue to increase our physicians and our capitation arrangements, basically, you have a benefit expense and you don't have a reserve. And so that really is the major driver. If you look at the roll",203,"Well, the major driver really is the capitation. As we continue to increase our physicians and our capitation arrangements, basically, you have a benefit expense and you don't have a reserve. And so that really is the major driver. If you look at the roll forward, you could see the days move really driven by that. The LTSS business has a similar dynamic in the sense that we pay the nursing homes on a monthly basis. And so again, you have this expense without having that reserve and so that'll naturally take it down. And then, as I mentioned in my prepared remarks, this quarter, we had an outlier in the sense of H1 and that the members came on a little bit late. There were a bunch of pended claims that we were working through, and we really did that over the fourth quarter. And so that really, I think -- I'd put those as the 3 major buckets what's driving the days claims. I'd also hasten to add that our cash flows are still very strong. And so as we think about our quality of earnings metrics, we're very focused to make sure our cash flows are good and they are."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So therefore, just to follow up going forward because you're expecting more growth in capitation, you'd expect that number to keep going down. And does the growth in exchanges or MA somewhat offset that to the other side or...",39,"So therefore, just to follow up going forward because you're expecting more growth in capitation, you'd expect that number to keep going down. And does the growth in exchanges or MA somewhat offset that to the other side or..."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I'd say all else being equal, I think that's right.",11,"I'd say all else being equal, I think that's right."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Ralph Giacobbe with CrÃ©dit Suisse.",13,"Your next question comes from the line of Ralph Giacobbe with CrÃ©dit Suisse."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Back to the Puerto Rico book, can you give us a sense of size and/or magnitude of the loss? And then I know you exited Medicaid there. Can you maybe talk about your commitment to that region within Medicare and/or how you're going to be able to sort of fi",52,"Back to the Puerto Rico book, can you give us a sense of size and/or magnitude of the loss? And then I know you exited Medicaid there. Can you maybe talk about your commitment to that region within Medicare and/or how you're going to be able to sort of fix the issues?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, I'd rather not go into specifics on our P&L of that market. I would say they're real losses. They move the needle. They affected our tax rate. We are working hard to fix the problems in the market. The Medicaid -- losing the Medicaid contract",140,"Well, again, I'd rather not go into specifics on our P&L of that market. I would say they're real losses. They move the needle. They affected our tax rate. We are working hard to fix the problems in the market. The Medicaid -- losing the Medicaid contract, I think, is indicative of where we are and deciding not to re-up there. And so our guys are working hard on that, on fixing the problems, and getting our members to engage and improve the medical management and the like. Again, we had some one-timers here in 2014 as it related to uncompensated care and the time when that came into effect with respect to the bids. But as I said, all of our businesses that aren't earning their cost of capital need to be evaluated, and we are certainly doing that."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Okay. And maybe -- I know you don't want to talk about the size of the losses. Can you give us a sense of even just the premium?",28,"Okay. And maybe -- I know you don't want to talk about the size of the losses. Can you give us a sense of even just the premium?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","There are about -- this is Jim. There are about 50,000 Medicare Advantage members in Puerto Rico as we ended the year. We purposely tried to downsize as respect to our activities relative to the AEPs so that we could shrink that membership. The premium th",157,"There are about -- this is Jim. There are about 50,000 Medicare Advantage members in Puerto Rico as we ended the year. We purposely tried to downsize as respect to our activities relative to the AEPs so that we could shrink that membership. The premium that we get from the federal government for Medicare is solid. As Brian alluded to earlier, the government made some change in the way that they pay hospitals after our bids were finalized for 2014. That was a big drag on our results. And the other thing that Brian mentioned, the loss of focus, because we did lose the Medicaid contract and the clinical model that was commensurate with that, negatively impacted our Medicare results. So we expect a smaller portfolio of business in 2015. And as Brian said, we're actively working on things that would improve that -- our prospects in Puerto Rico, and that's probably where we should end it."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Peter Costa with Wells Fargo Securities.",14,"Your next question is from the line of Peter Costa with Wells Fargo Securities."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","It's getting close to that time of year when we hear about what the 2016 Medicare Advantage rates are going to be. We know from December that 2.45% was sort of what they were talking about for the growth rate at that point. But what other factors should w",69,"It's getting close to that time of year when we hear about what the 2016 Medicare Advantage rates are going to be. We know from December that 2.45% was sort of what they were talking about for the growth rate at that point. But what other factors should we be considering that might be impacting the payments that you get from the government for Medicare rates in 2016?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, Peter, this is pure speculation, so it's always difficult. I think we look at the discussions that have historically been in the rate notice around in-home assessments as being an area of discussion. I also think the MRA adjustments are another area",87,"Yes, Peter, this is pure speculation, so it's always difficult. I think we look at the discussions that have historically been in the rate notice around in-home assessments as being an area of discussion. I also think the MRA adjustments are another area that possibly could be included in the rate notice. But that's really based on the dialogue that has happened over the past few years with them, and I don't have any inside information more than anybody else has on what's going to come out."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And in terms of the range of possibilities, how do you think it will impact your ability to price business for next year and obtain growth for next year?",29,"And in terms of the range of possibilities, how do you think it will impact your ability to price business for next year and obtain growth for next year?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","This is Jim. We have always, over the last number of years, expected the worst. And as we focus on what are necessary actions relative to trend vendors, we plan for that and we see what happens in April, and then we evaluate our bid processes and strategi",90,"This is Jim. We have always, over the last number of years, expected the worst. And as we focus on what are necessary actions relative to trend vendors, we plan for that and we see what happens in April, and then we evaluate our bid processes and strategies accordingly. But we're in the process, as we speak, of trying to identify trend vending activities that would address the worst-case scenario in some of the things that Bruce talked about, and we're putting those in place for 2016 as we speak."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Matthew Borsch with Goldman Sachs.",13,"Your next question comes from the line of Matthew Borsch with Goldman Sachs."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","A question on your guidance in the Medicaid duals. So I think as I understood, you're looking at a $0.25 approximate tailwind on that business from reduced investment. But am I correct that, that business is still losing money, if you will, when you count",63,"A question on your guidance in the Medicaid duals. So I think as I understood, you're looking at a $0.25 approximate tailwind on that business from reduced investment. But am I correct that, that business is still losing money, if you will, when you count in the investment or expected to for 2015? Or is that wrong? And can you quantify any magnitude?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, and if I wasn't clear, I think we expect around $0.25 of loss in 2015 for the state-based businesses, if that helps. And that is reduced from 2014 pretty meaningfully.",31,"Yes, and if I wasn't clear, I think we expect around $0.25 of loss in 2015 for the state-based businesses, if that helps. And that is reduced from 2014 pretty meaningfully."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Okay. And can you give us a range of magnitude on 2014?",12,"Okay. And can you give us a range of magnitude on 2014?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I would say, if you combine H1 and the duals, it was, call it, around $0.70 plus or minus.",19,"I would say, if you combine H1 and the duals, it was, call it, around $0.70 plus or minus."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Sarah James with Wedbush Securities.",13,"Your next question is from the line of Sarah James with Wedbush Securities."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Humana and the other insurers have been working on providing new data to CMS that follows up on actions and results from home health risk assessments, and I'm wondering if there's been any consensus reached among the insurers or with CMS on how to effecti",56,"Humana and the other insurers have been working on providing new data to CMS that follows up on actions and results from home health risk assessments, and I'm wondering if there's been any consensus reached among the insurers or with CMS on how to effectively evaluate the results of that or the sufficiency of solid actions."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","No, there has been discussion on the effectiveness of in-home assessments and the work that's been done there on a number of different occasions. I don't think there has been one proposal that has been agreed upon both by the industry and by CMS. And I do",73,"No, there has been discussion on the effectiveness of in-home assessments and the work that's been done there on a number of different occasions. I don't think there has been one proposal that has been agreed upon both by the industry and by CMS. And I don't -- we don't want to get into commenting on what we think CMS would come out with based on our discussions about industry-wide and company specific."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Tom Carroll with Stifel.",12,"Your next question is from the line of Tom Carroll with Stifel."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","So just a question on the 3Rs. How do you want investors to think about the change in the 3R accruals that you're making for 2015? I mean, is this just you have more color, as you put it, which provides more visibility in operations? Or is Humana perhaps",65,"So just a question on the 3Rs. How do you want investors to think about the change in the 3R accruals that you're making for 2015? I mean, is this just you have more color, as you put it, which provides more visibility in operations? Or is Humana perhaps getting a little more aggressive on assumptions? Wonder if you could balance that out for us."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, I guess, I'd say we view it as a good thing that we're able to reduce the reliance on the 3Rs by over half. That's a deliberate strategy we made by ticking up pricing. We're being very disciplined there and that's really part of our strategy to get",118,"Well, I guess, I'd say we view it as a good thing that we're able to reduce the reliance on the 3Rs by over half. That's a deliberate strategy we made by ticking up pricing. We're being very disciplined there and that's really part of our strategy to get to breakeven or better for 2015. So I think when we saw the new sales come in and break down by metal tier and age and geography, et cetera, we were able to take it down slightly from where we were on the third quarter, but we view that as a good thing, and again, feel positive about where we are with that business and how we priced it."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","When we entered the exchanges in 2014, I think we communicated to the investors that we were going to grow in 2014, while in 2015, transition to ensure that there was sustainability in that business long term. And what you see happening is that's what's h",100,"When we entered the exchanges in 2014, I think we communicated to the investors that we were going to grow in 2014, while in 2015, transition to ensure that there was sustainability in that business long term. And what you see happening is that's what's happening, that we grew in 2014. We would define success this year as maintaining our membership that we had in 2014 and 2015 and having maintained that level, while at the same time, reducing our reliance on the 3Rs, specifically 2Rs, to allow us to make that transition when the 2Rs go away next year."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Christine Arnold with Cowen.",12,"Your next question is from the line of Christine Arnold with Cowen."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","Could you speak to your expectations for medical trends? You got a better economy. Consumer confidence seems to be rising. Fuel prices are down. Kind of like increasing discretionary income for folks. How do you think that might impact medical costs? And",73,"Could you speak to your expectations for medical trends? You got a better economy. Consumer confidence seems to be rising. Fuel prices are down. Kind of like increasing discretionary income for folks. How do you think that might impact medical costs? And how do you build that into your Medicare Advantage assumptions with respect to trend vendors that you're going to need and the medical trend expected in '15 versus '14 for MA?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Sure. Well, as you know, we did increase the expected trend for our commercial group business to 5.5% to 6.5% from 4% to 4.5%. So that was a significant increase, I think, reflecting all the things that you just discussed. On the Medicare side, it's not a",108,"Sure. Well, as you know, we did increase the expected trend for our commercial group business to 5.5% to 6.5% from 4% to 4.5%. So that was a significant increase, I think, reflecting all the things that you just discussed. On the Medicare side, it's not as directly tied to economic growth there was probably some impact. We focus pretty intently on where the trend vendors need to be relative to where the rate's coming at from a CMS perspective. And I would say there's probably less marginal move, unlike the commercial side, based on economic growth and other factors, employment, et cetera, that you would typically see."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","What about the fact that fuel prices are lower? Old people are spending less to fuel up their vehicles. And also, what -- can you tell us what kind of trend vendor you assumed in '15 versus '14?",38,"What about the fact that fuel prices are lower? Old people are spending less to fuel up their vehicles. And also, what -- can you tell us what kind of trend vendor you assumed in '15 versus '14?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","We're not going to get to that level of detail. I -- we haven't really evaluated or I don't know the answer to this specific, how fuel impacts it. But our -- we take a holistic view of where trend may be and a number of factors go into that.",51,"We're not going to get to that level of detail. I -- we haven't really evaluated or I don't know the answer to this specific, how fuel impacts it. But our -- we take a holistic view of where trend may be and a number of factors go into that."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","I'm actually happy that the seniors have fuel for their cars because then they can go and see their doctors...",21,"I'm actually happy that the seniors have fuel for their cars because then they can go and see their doctors..."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","To the clinic.",3,"To the clinic."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","So that they can take care of all the things that they need to take care of rather than waiting for an acute event. So I'm happy about that.",29,"So that they can take care of all the things that they need to take care of rather than waiting for an acute event. So I'm happy about that."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Ana Gupte with Leerink Partners.",13,"Your next question is from the line of Ana Gupte with Leerink Partners."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I was just trying to see some of the less focused areas of business as they might be potential drivers for upside. So one of them is individual off-exchange and I know that's a much smaller piece of your book. But 2 of your peers have stated that they los",109,"I was just trying to see some of the less focused areas of business as they might be potential drivers for upside. So one of them is individual off-exchange and I know that's a much smaller piece of your book. But 2 of your peers have stated that they lost money in '14 and taking some pretty serious pricing actions and removing ACA compliance plans. Is there anything here that you might have been doing? And I get it that the MLR floors probably took care of a piece of this, but just '14 would guarantee the shoe [ph] and community rating did hurt some of the off-exchange books."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes. So as we said, and I don't really want to distinguish between off-exchange and on-exchange in terms of our pricing, as we've said, we've been very disciplined on pricing with our entire ACA-compliant book. Off-exchange is part of our strategy. It's a",75,"Yes. So as we said, and I don't really want to distinguish between off-exchange and on-exchange in terms of our pricing, as we've said, we've been very disciplined on pricing with our entire ACA-compliant book. Off-exchange is part of our strategy. It's an important part of our strategy. And we're looking to mitigate the losses in both the off-exchange and on-exchange. And again, all-in, as we said, we do expect to do that this year."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","And then, secondly, Brian, secondly on the small group and maybe just the broader commercial fully insured book, your employer loss ratio looks pretty good for this quarter. In the third quarter, it deteriorated, if I remember right, and somehow I didn't",78,"And then, secondly, Brian, secondly on the small group and maybe just the broader commercial fully insured book, your employer loss ratio looks pretty good for this quarter. In the third quarter, it deteriorated, if I remember right, and somehow I didn't have a chance to follow up on that. Our pricing survey show you've jacked up your pricing quite a bit for '15. So any improvement in margin there? And what are you baking into your guidance?"
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Well, again, back in the third quarter, we did suffer the impact of some of the transitional relief that we discussed. Now we got some of that back in the fourth quarter through, I would say, both current period and prior period development that were bett",103,"Well, again, back in the third quarter, we did suffer the impact of some of the transitional relief that we discussed. Now we got some of that back in the fourth quarter through, I would say, both current period and prior period development that were better than expectations. And that really was the driver of the outperformance, along with the continued focus on admin costs. I would say, as we move into next year, we price for Hep C and the like, hopefully, we'll continue to see improvements there. And really, where we need to focus is on the admin side as well."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes. There's one other dynamic in the small group space that you're all aware of, I'm sure, is that there's a movement into the community-based rating methodology and that's kind of an interesting dynamic that we're watching play out with some of our comp",119,"Yes. There's one other dynamic in the small group space that you're all aware of, I'm sure, is that there's a movement into the community-based rating methodology and that's kind of an interesting dynamic that we're watching play out with some of our competition and where they price their community-rated business rights versus where we're at. As we sit here right now, we feel pretty good about how we're positioned and are monitoring not only the community rights, but the migration from our existing block of business into those with the transitional relief opportunity that we have. So again, feel pretty good about that, and I'm glad that you noticed that in some of the stuff that we provided."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Chris Rigg with Susquehanna Financial Group.",14,"Your next question is from the line of Chris Rigg with Susquehanna Financial Group."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","I just wanted to follow up on the flu comments from earlier. I know you talked about a $45 million headwind in the quarter. I guess, I'm just trying to get a sense for -- I just want to confirm and that was relative to budget and just for how much the flu",59,"I just wanted to follow up on the flu comments from earlier. I know you talked about a $45 million headwind in the quarter. I guess, I'm just trying to get a sense for -- I just want to confirm and that was relative to budget and just for how much the flu cost increased on a year-to-year basis."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","That was relative to our forecast for the fourth quarter. We had a very difficult December with regard to flu. As I've said, it's abated towards the end of the month and early January, and so we feel good about where we are for 2015. The 2014 results were",71,"That was relative to our forecast for the fourth quarter. We had a very difficult December with regard to flu. As I've said, it's abated towards the end of the month and early January, and so we feel good about where we are for 2015. The 2014 results were worse than the 2013 results, but I wouldn't want to go into specifics there, but they were certainly worse, particularly in December."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","Your final question comes from the line of Dave Windley with Jefferies.",12,"Your final question comes from the line of Dave Windley with Jefferies."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Analysts","On some maybe difficult-to-answer questions, but curious of your broader thoughts, first of all, on the Supreme Court decision and how you are contingency planning around that. And secondly, your thoughts on President Obama's budget and proposed cuts to M",45,"On some maybe difficult-to-answer questions, but curious of your broader thoughts, first of all, on the Supreme Court decision and how you are contingency planning around that. And secondly, your thoughts on President Obama's budget and proposed cuts to Medicare, and specifically, Medicare Advantage."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Executives","Yes, we really don't get into the habit of commenting on those broad aspects until they're finalized. So I don't want to get into that because it's just speculation and I'll leave it at that.I think that was the last question. So with that being said, w",99,"Yes, we really don't get into the habit of commenting on those broad aspects until they're finalized. So I don't want to get into that because it's just speculation and I'll leave it at that.
I think that was the last question. So with that being said, we really appreciate the support by our investors and the confidence in the company. And most importantly, we thank our 55,000 associates for their dedication in helping our members with their health and all the necessary actions that are required with that. So thank you very much, and have a great day."
29618,278392365,754605,"Humana Inc., Q4 2014 Earnings Call, Feb 04, 2015",2015-02-04,"Earnings Calls","Humana Inc.","Operator","This concludes the Fourth Quarter 2014 Earnings Conference Call. Thank you for joining. You may now disconnect your lines.",19,"This concludes the Fourth Quarter 2014 Earnings Conference Call. Thank you for joining. You may now disconnect your lines."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Good morning. My name is Melissa, and I will be your conference operator for today. At this time, I would like to welcome, everyone to the Humana First Quarter 2015 Earnings Conference Call. [Operator Instructions] Thank you. I will now turn the call ov",53,"Good morning. My name is Melissa, and I will be your conference operator for today. At this time, I would like to welcome, everyone to the Humana First Quarter 2015 Earnings Conference Call. [Operator Instructions] 
Thank you. I will now turn the call over to Ms. Regina Nethery. You may begin your conference."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Humana's senior management team will discuss our first quarter results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be Bruce Broussard, Humana's President and Chief Exe",341,"Thank you, and good morning. In a moment, Humana's senior management team will discuss our first quarter results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Senior Vice President and Chief Financial Officer. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts.
Joining Bruce and Brian for the Q&A session will be Jim Murray, Executive Vice President and Chief Operating Officer; and Christopher Todoroff, Senior Vice President and General Counsel.
We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. This call is also being simulcast via the Internet along with the virtual slide presentation. An Adobe version of today's slide deck has been posted to the Investor Relations section of Humana's website.
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain other matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in this morning's earnings press release, as well as in our filings with the Securities and Exchange Commission. Today's press release, our historical financial news releases and our filings with the SEC are all available on Humana's Investor Relations website.
Call participants should also note that today's discussion and slide presentation include financial measures that are not in accordance with Generally Accepted Accounting Principles. Management's explanation for the use of these non-GAAP measures is included in today's slide presentation, as well as a reconciliation of GAAP to non-GAAP financial measures.
Finally, any references to earnings per share, or EPS, made during this morning's call refer to diluted earnings per common share.
With that, I'll turn the call over to Bruce Broussard."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Good morning, everyone, and thank you for joining us. This morning, Humana announced first quarter 2015 adjusted earnings per share of $2.47, up 5% from the first quarter of last year. Our pretax earnings of $744 million were a record high and we believe",1370,"Good morning, everyone, and thank you for joining us. This morning, Humana announced first quarter 2015 adjusted earnings per share of $2.47, up 5% from the first quarter of last year. Our pretax earnings of $744 million were a record high and we believe are a clear demonstration on the progress we continue to make as a company. Further, we continue to have confidence in our full year guidance for adjusted earnings of $8.50 to $9 per share.
Our more significant achievements during the quarter included substantial membership growth in our Medicare Advantage stand-alone PDP and HumanaOne products; the recent launch of our population health technology business, Transcend Insights; announcement of the pending sale of our Concentra business; and completion of our $500 million accelerated share repurchase program. I'll begin with our Medicare Advantage growth.
As we shared with you last quarter, we experienced another successful Medicare enrollment season for 2015. Individual Medicare Advantage membership at March 31, 2015, was up 11% versus the end of the fourth quarter 2014, up 14% year-over-year. We continue to see the positive impact for our members of stability in our value proposition, as well as high Star quality ratings.
A recent McKinsey study on the 2015 Star ratings concludes that HMO plans performed best on an enrollment weighted basis. Approximately 56% of our individual members are in HMO plans compared to 4 -- 53% a year ago. Further, the McKinsey study indicates that plans built around integrated delivery networks achieve higher average Star ratings.
CMS recently eliminated certain fixed thresholds for 4 Star ratings for 2017 bonus year. These changes may result in some pressure on our overall Star ratings, but we believe we will sustain our solid competitive advantage. We expect we will maintain our high-quality ratings due to our successful integrated care delivery model. Our model includes use of data analytics to engage members in preventative measures and wellness programs that close clinical gaps-in-care.
In some, we believe the combination of a solid value proposition and a high-quality ratings are critical to attracting new membership and retaining our existing membership base. Our projected 2015 net new membership gains of approximately 12%, including a voluntary retention rate of approximately 90%, are all helping to validate this belief.
CMS has also recently released its final Medicare rates for 2016. While we were encouraged by the average rate increase for the first time in 7 years, this average still lags fee-for-service medical cost trends. Additionally, CMS' transition to the new risk adjustment model will negatively impact certain of our markets, better leading in our country in value-based reimbursement methods and holistically assisting members with multiple complex chronic conditions, both which are key goals for CMS.
As we prepare our Medicare bids for 2016, we will seek to minimize any disruption that rate changes may cause to Medicare beneficiaries while holding firm on our 4.5% to 5% pretax margin target. The continuing investment in our clinical model are expected to provide some offsets to rate pressures that will vary, of course, from market to market. Those investments were highlighted this month by Humana's @Home acquisition of Your Home Advantage, a leading provider of nurse practitioner in home visits. 
Additionally, we believe our focus on the consumer experience and our proprietary market point distribution channel will be important elements in solidifying our relationship with our members as we face these rate challenges at the market level.
Turning to our stand-alone PDP offerings. We also experienced significant growth for these products with membership up 10% since the end of 2014 and 14% to the first quarter of last year, primarily in our low price point offerings.
And now we'll spend some time in our investments in health care exchanges and state-based contracts. We're pleased that HumanaOne membership has continued to grow nicely. While we'll continue to project at least breakeven results for our HumanaOne business, our projected increased reliance on the 3 Rs is driven primarily by the results for the State of Georgia and our outer network provider usage. We believe both are isolated and addressable. Brian will discuss each of these factors in his remarks.
Entering a new customer segment is never an easy task. However, we believe that health care exchanges are a leading example of the ongoing movement to the retail model where we have been so effective in Medicare. We continue to be highly targeted in terms of where we will participate in health care exchanges with a strong emphasis on current Medicare Advantage markets to enable customer migration as member's life situations change.
Our expansions into health care exchanges and our state-based contracts are deepening our partnership with local providers -- local market providers as we develop local market scale through multiple product offerings. 
State-based Medicaid membership was now includes those members associated with dual demonstration programs is up significantly both on a sequential basis and year-over-year. We continue to monitor the RFP pipeline and plan to pursue other state-based opportunities later in 2015. These opportunities would not be as a viable if it weren't for our integrated care delivery model. 
Importantly, we continue to show progress in key integrated care delivery model metrics. Some examples include the number of individual Medicare Advantage members covered by value-based arrangements is now more than 54%. This is particularly encouraging, given the substantial increase in membership this quarter. Membership in our Humana Chronic Care Program is up 10% since the end of the year and 56% versus the prior year.
Adoption of mail order pharmacy among our members continues to grow as we highlight this benefit more fully during the sales process and welcome calls. Individual Medicare Advantage mail-order penetration is now, on an average, approaching 35%.
We continue to focus on reaching out to members with gaps-in-care and have sent over 4 million proactive messages to 2.5 million members to prevent gaps-in-care. These actions have resulted in a gap closure rate of more than 30%. As a leader in both the development and execution of value-based payment models and technology driven population health management analytics, we support trends that encourage care coordination across all payers.
In that context, this quarter, we launched Transcend Insights, which leverages the population health capabilities we have developed in our Medicare Advantage business. Our goal is to provide payer agnostic tools to our provider partners, allowing more of our members to be in value-based reimbursement models. As we've shared with you in the past, value-based arrangements have proven to lead to higher heat scores, lower medical costs and higher membership satisfaction.
Before closing, I'd like to spend a moment on our recently announced sale of Concentra. As we've said in previous calls, we review our various businesses on an ongoing basis to ensure each earns its cost of capital and is aligned with our integrated care delivery strategy. The Concentra acquisition was part of a multipronged approach to increase our capabilities of managing risk through primary care physicians. Our subsequent MSO acquisitions and joint venture investments provided a more integrated primary care platform than Concentra. Although it did not ultimately fit strategically, we are able to achieve an attractive price that will result in a gain versus our initial investment.
Brian will speak more to the details of this transaction in his remarks. We expect the transaction will close in the next few weeks. I want to thank all of our Concentra associates for their dedication to the consumer and to our company. Several of you have asked for an update on our PBM evaluation. That work continues, and we expect to provide a full debriefing on our analysis during the third quarter earnings call in November.
In summary, we believe our robust organic membership and revenue growth, together with our proven superior clinical operating performance and disciplined capital allocation, all come together to provide our sustainable competitive advantage. Excluding the one-time gains that we expect from the Concentra sale, we continue to expect our full year adjusted earnings per share to be in the range of $8.50 to $9 and look forward to providing you updates as the year progresses.
With that, I'll turn the call over to Brian for a more detailed discussion of our financials."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. As Bruce mentioned, the first quarter of 2015 produced strong results and continues to demonstrate the successful implementation of our integrated care delivery model. The attractiveness of our product offerin",2234,"Thank you, Bruce, and good morning, everyone. As Bruce mentioned, the first quarter of 2015 produced strong results and continues to demonstrate the successful implementation of our integrated care delivery model. The attractiveness of our product offerings is resonating with our customers, as demonstrated by the continuing increases in our Medicare Advantage, stand-alone PDP and exchange membership.
Consequently, we have raised full year membership expectations for both stand-alone PDP and HumanaOne. Stand-alone PDP is being driven by higher retention that we are seeing post the open enrollment period, which is largely the results of fewer auto enrollees being reassigned. I'll speak more to the HumanaOne business shortly.
With regard to our Medicare Advantage growth, early indications for our new members are positive as we evaluate individual market growth and performance. Additionally, the growth in our PBM and Humana At Home businesses remains unabated with not only more volume driven by membership growth, but also deeper penetration in terms of increased engagement, as well as benefits from scale that are driving results.
First quarter revenues for the Healthcare Services segment rose 26% versus the prior year and pretax earnings are up 24% year-over-year. The quarter had several developments that will be the focus of my remarks today. These include the following: The increase in our projected 3R receivables for the year; medical utilization and prior period development; days in claims payable and cash flows from operations; the earnings implications of the Concentra transaction; and capital allocation.
Let's begin with our exchange business and the premium stabilization programs commonly called the 3Rs. Our conviction in our health care exchange strategy remained strong. We continue to focus on our key growth markets by offering high-value networks to drive affordability and access for our customers. We believe that this strategy has been effective in successfully establishing a new growth business while providing a compelling products that our members value. 
Over time, we believe that HumanaOne will not only contribute meaningfully to our results, but it will also, as Bruce emphasized, advance our objectives of local market presence and scale with providers while allowing us to offer a range of products that are relevant to our customers no matter of their age or income circumstances.
As with any startup business, we have had our successes, as well as our challenges. In terms of successes, our ACA-compliant membership for HumanaOne is up 38% from the end of 2014, well ahead of our previous expectations. This was driven by better-than-forecast sales and lower-than-anticipated attrition. Consequently, we have adjusted our aggregate HumanaOne guidance to reflect higher projected membership in the ACA-compliant business, which we also believe results in us approaching the scale we need for long-term success.
We continue to forecast that we will have at least breakeven results in 2015 and earn a reasonable return on capital in 2016, albeit, that achievement of breakeven results this year now includes higher reliance on the 3Rs than previously anticipated coming into 2015. 
As you've seen from our release, we have increased our net 2015 3R guidance range to $450 million to $550 million, with reinsurance accounting for approximately 75% and risk adjustment and risk corridors accounting for approximately 25% of the total.
As we have discussed in the past, there is an interplay between risk adjustment and risk corridors. And that if we don't get the risk adjustment exactly right, a meaningful part of the balance, either positive or negative, is captured to the risk corridors.
As we evaluate our financial performance to date, including runoff claims from 2014, the drivers of the increase in full year receivables related to the 3Rs are quantifiable and addressable. The first 2 Bruce mentioned in his remarks are higher-than-anticipated out of network utilization and poor results in our Georgia market. The last driver of the higher receivables is simply a function of having more members than we had previously expected.
I'll start with out of network utilization. As the exchanges were rolling out across the nation, we believe there would be time period during which our members will be getting accustomed to our efficient network products. Consequently, we permitted out of network utilization for the small proportion of our members who did not stay in network to avoid disruption, notwithstanding the products design, which underpin the affordability that our members seek.
Our provider network team has thoroughly evaluated our networks in light of our membership levels by market, and we are very satisfied in our level of network adequacy. As a consequence, we are in the process of implementing stricter enforcement of network utilization by working closely with nonnetwork providers, as well as educating our members on the product.
Higher levels of in network utilization are anticipated to ensure the continued affordability of our health care exchange offerings, as well as aligned with our pricing assumptions for the remainder of the year and for 2016.
After adjusting for the out of network usage, our markets across the country, including our largest HumanaOne market in Florida, are performing within expectations with the notable exception of Georgia. One of the challenges we faced in both 2013 and 2014 was the immaturity of the claims data we had available at the time we set our health care exchange pricing for the following year versus what we would have preferred, specifically, more detail regarding statewide market conditions and health status based on significant exchange claims data.
To help address this, we juxtaposed the limited Georgia claims data we had against claims data nationally for states that we believe had similar utilization patterns and mix of likely enrollees to derive assumptions around the population health of each estate, and in turn, set our pricing.
Recent actuarial claims data for the State of Georgia now indicate that enrollees in the state as a whole are skewing more towards being a less healthy state population than we had believed and have priced for. Consequently, we are accruing both a risk adjustment and risk corridor receivable.
It's important to recall that this was the original intent behind the premium stabilization programs, namely earlier protection in this circumstance. We are, of course, incorporating our emerging experience into our actuarial assumptions and are taking the appropriate targeted actions through pricing and product design when we file our 2016 rates in the next few weeks to ensure that Georgia's results will be back on track for 2016 without reliance on the risk corridors.
As I mentioned, the remaining driver of the higher 3R balance relates to higher-than-projected growth of our ACA-compliant business. This will result in higher 2015 receivable so than we had expected primarily associated with reinsurance.
Finally, a quick word on our 2014 3R accruals. As you will see, we have decreased reinsurance by approximately $50 million and have increased our risk corridors by around $40 million as an offset. As we have evaluated the runoff of our 2014 claims, fewer of our members that anticipated will hit the reinsurance attachment point, which is the reason we have made this change. 
Turning to medical utilization. We are watching very closely the hospital inpatient admissions per thousand data for our Medicare Advantage business. We have seen some of the hospital published data, which suggest higher Medicare usage of inpatient services and have also witnessed in the last number of weeks an uptick in inpatient authorizations. For Medicare Advantage, we have projected a decline year-over-year in hospital admissions. And for the first quarter, we have seen that decline bear out. In other words, our trend benders continue to result in lower admissions.
However, during the last weeks of the quarter and into April, we are seeing an elevated level of authorizations for hospitals admissions, which although still declining, are slightly higher than we had anticipated. Importantly, we have also seen data throughout the quarter that would suggest our cost per admit is lower than forecast, implying lower severity conditions are driving the admissions.
While it is too early to draw any conclusions from what I just described, especially as admissions tend to fluctuate, it is something that bears close watching as the actual claims experience develops over the coming months.
As was highlighted in this morning's press release, we did see a lower level of favorable prior period development than in last year's first quarter. A meaningful portion of the lower prior period development was anticipated due to the PPD for the first quarter of 2014 having been unusually high and as a result of claims processing changes involving the implementation in early 2014 of a front-end review for Medicare claims.
Front-end review enables us to improve the initial accuracy of claim payments, reducing the amount of overpayments recaptured later as part of prior period development. PPD was also adversely impacted by fourth quarter flu claims that came through in the first quarter of 2015 across our lines of business.
I will now turn to the balance sheet and operating cash flow. I'll start with days in claims payable or DCP. You will note that we have revised the DCP table to exclude reinsurance associated with the 3Rs. Given that reinsurance reduces benefits expense but does not impact the related benefits payable, it skews DCP trends over the 3-year period of the program.
Days in claims payable during the first quarter of 2015 declined by less than a day, driven primarily by the typical first quarter increase in Part D claims associated with our Medicare Advantage business. That impact is included in the all other category of the DCP roll forward table in our press release. Recall that our stand-alone PDP business is excluded from our days and claims payable calculation. 
Much like our stand-alone PDP offerings, our Medicare Advantage Part D benefit designs generally have the plan picking up substantially all the initial pharmacy claims, but covering less of the benefit as the year progresses. While the pharmacy expense associated with these members is in our DCP calculation, the related payable is relatively small due to the speed of processing pharmacy claims.
Higher capitation and provider settlements also resulted in a slight decrease to DCP during the quarter. But importantly, this was more than offset by an increase in unprocessed and processed claims inventories.
Cash flow from operations is down versus the first quarter of 2014, as higher net income was more than offset by working capital items. Specifically, the increase in benefits payable, which accompanies growing membership, was smaller year-over-year due to the lower level of overall growth in average membership given the outsized growth we experienced in 2014. This pressured the cash flow from operations on a comparative basis by approximately $250 million in the quarter. Working capital needs for our growing Pharmacy business primarily accounted for the remainder of the delta in the first quarter cash flows.
For the year, our operating cash flow guidance is largely unchanged, other than reducing operating cash flow by guidance -- cash flow guidance by approximately $200 million at the midpoint, primarily reflecting the increase in the 3R receivable that I just discussed previously, as well as the pending sale of Concentra.
Before closing, I'll spend just a few minutes on capital allocation and earnings guidance. As Bruce said in his remarks, we announced this quarter the sale of our Concentra business. The timing of the signing of the definitive agreement triggered the need to recognize the gain on the establishment of a deferred tax asset. And thus, the $0.35 per share gain was included in our first quarter GAAP results.
We expect this transaction to close in the next few weeks, so we have included the full impact of the transaction in our earnings guidance, both from a GAAP and an adjusted perspective. 
For GAAP, we are including a total projected gain from the sale in the range of $1.35 to $1.45 per share, including the $0.35 tax gain. On an adjusted basis, excluding this one-time gain, we continue to forecast earnings per share in the range of $8.50 to $9 per share.
The sale of Concentra is expected to generate net of taxes and deal expenses approximately $1 billion in net proceeds. Before any anticipated use of these proceeds, the sale will results in $0.11 of 2015 EPS dilution. We continue to look for value-enhancing acquisitions, such as the Your Home Advantage deal we recently announced that will advance our in home capabilities, as well as pursue additional share repurchase opportunistically.
However, given where we are in the year, it is likely that a good portion of this dilution will persist. 
With respect to share repurchase, this quarter, we completed our $500 million accelerated share repurchase program. Additionally, holding true on our commitment to buy back $1 billion of stock by June of this year, we have entered into a 10b5-1 plan that we expect will complete that goal. You will note, however, that we have raised our guidance slightly for the average fully diluted share count due largely to the higher-than-anticipated buyback price, which will have a several [ph] cent negative EPS impact.
Finally, our work around optimizing our portfolio continues to ensure that each of our businesses fit strategically and earns its cost of capital. More generally, we are encouraged by our progress in our prospects, all driven by execution around our integrated care delivery strategy. 
With that, we will open the lines up for your questions. Operator, please introduce the first caller."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] Your first question comes from Joshua Raskin with Barclays.",11,"[Operator Instructions] Your first question comes from Joshua Raskin with Barclays."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Want to talk a little bit about the utilization trends that you guys are monitoring and just better understand what exactly is driving that. I think you mentioned from public data from some of the hospitals. But I have to assume you're going off of more i",82,"Want to talk a little bit about the utilization trends that you guys are monitoring and just better understand what exactly is driving that. I think you mentioned from public data from some of the hospitals. But I have to assume you're going off of more internal data. So is there any specific minds of service? Or is there specific type of lines? Any geographies for these new members? And just kind of any color on where this utilization is coming from."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Josh, certainly, from our own data that we're seeing a slight uptick in admissions over the last few weeks and into April. There's no specific geography that we would point to. It's something that we continue to evaluate. I would note that interestingly,",124,"Josh, certainly, from our own data that we're seeing a slight uptick in admissions over the last few weeks and into April. There's no specific geography that we would point to. It's something that we continue to evaluate. I would note that interestingly, not only are the unit cost of these admits lower, which, as I said in my remarks, suggesting lower severity of claims. But also, our outpatient utilization seems to be down and our pharmacy utilization is in line. And so it's very early really to ascertain exactly what this is telling us. It's just helping that we thought it would be important to communicate because it's something that we're watching very closely and it's something that we always watch very closely."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Josh, just to build on what Brian talked about and the reason that he specifically addressed it in his opening remarks is, as we saw this, we began to dive into a lot of the information relative to new members and what we call concurrent members. And actu",184,"Josh, just to build on what Brian talked about and the reason that he specifically addressed it in his opening remarks is, as we saw this, we began to dive into a lot of the information relative to new members and what we call concurrent members. And actually, the new members that we just joined the plans, which were fairly significant, we're seeing actually better utilization than the concurrent members. So that gives us comfort that there wasn't an issue with any of the markets that we grew in. A lot of the deep dives that we're doing and there's a lot of work that we're trying to pull together, would suggest that there's some respiratory issues that we're facing. So that leaves us somewhat to a conclusion that it's maybe a longer extension of the flu. But a lot of work needs to be done to get our arms around it. But we feel very confident about how it's progressing, and we feel good about a lot of the things that we do from a process perspective. This looks like an isolated incident."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay, that's helpful, Jim. Just maybe help us the magnitude here. If you take holistically this uptick in in-patient utilization, but then lower outpatient and RX in line and maybe just flu. I mean, if this were to persist through April, May, June, is thi",71,"Okay, that's helpful, Jim. Just maybe help us the magnitude here. If you take holistically this uptick in in-patient utilization, but then lower outpatient and RX in line and maybe just flu. I mean, if this were to persist through April, May, June, is this enough to change guidance? Or is this just something that the pressure point and the reason we're so comfortable in the relatively wide range of EPS?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Yes, Josh, I would say if this persist as we see it, it's not something that would impact guidance. But it's something that we watch very closely, obviously, to the extent there was a continued uptick and a greater uptick. That's something that would have",54,"Yes, Josh, I would say if this persist as we see it, it's not something that would impact guidance. But it's something that we watch very closely, obviously, to the extent there was a continued uptick and a greater uptick. That's something that would have an impact. But we're not seeing that right now."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from David Windley from Jefferies.",9,"Your next question is from David Windley from Jefferies."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm going to shift over to HumanaOne. I wanted to understand if you were changed in or lack of change in age distribution in that book of business in the slide that you presented to us the last quarter, yet fairly significant change in mental care distrib",63,"I'm going to shift over to HumanaOne. I wanted to understand if you were changed in or lack of change in age distribution in that book of business in the slide that you presented to us the last quarter, yet fairly significant change in mental care distribution if essentially that adverse selection had anything to do with your additional reliance on 3Rs."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","It's something we continue to evaluate. We certainly evaluate all of our medical tiers and try to understand where utilization is coming from, particularly in Georgia, where we've seen that. I think it's fair to say that we're going to continue to evaluat",101,"It's something we continue to evaluate. We certainly evaluate all of our medical tiers and try to understand where utilization is coming from, particularly in Georgia, where we've seen that. I think it's fair to say that we're going to continue to evaluate as we go into 2016, our participation in the various metal tiers. And certainly, our pricing will reflect the increased morbidity that we're seeing in our block. It's always a that the out-of-network utilization is something that we could think we can address in short order. And so that will not be a recurring issue going forward."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","And on the out of networks, just to follow up on that. Is that something where you were essentially, only lightly enforcing the existing policy or rule? And now you're going to more stringently enforce? Or do you actually have to change the policy? And is",51,"And on the out of networks, just to follow up on that. Is that something where you were essentially, only lightly enforcing the existing policy or rule? And now you're going to more stringently enforce? Or do you actually have to change the policy? And is that possible into a year?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I would say the former. It's something that we likely enforces as we were coming to this program with the new product with new customers. And it's something that they were going to get accustomed to the product design over the next few months, it's someth",138,"I would say the former. It's something that we likely enforces as we were coming to this program with the new product with new customers. And it's something that they were going to get accustomed to the product design over the next few months, it's something that we will enforce, the policy that exist. And that really, as I said in my remarks, goes both to working with providers, should I say, the out-of-network providers, and some of the reimbursement levels that we paid them, as well as educating our customers as to the product that they bought. We believe strongly that the strategy that we pursue is one that allows our customers to have a very affordable and compelling products. And as we educate them, we think we'll be able to get that out-of-network utilization under control."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from A.J. Rice with UBS.",10,"Your next question comes from A.J. Rice with UBS."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm going to go back to the comments that Bruce have made about there being some pressure from threshold eliminations on the Stars program. Can you give us more color on how significant that would be? And are we talking about something that would impact y",70,"I'm going to go back to the comments that Bruce have made about there being some pressure from threshold eliminations on the Stars program. Can you give us more color on how significant that would be? And are we talking about something that would impact your -- potentially in 2017, is that the right way to think about it? Or is there any reason that would impact it earlier?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","This is Jim Murray. It would be 2017. And as many of you know, we're in the process today and for the next several weeks of finalizing a lot of the work related to benefit year 2017. The threshold elimination puts a little bit of pressure, and what that w",172,"This is Jim Murray. It would be 2017. And as many of you know, we're in the process today and for the next several weeks of finalizing a lot of the work related to benefit year 2017. The threshold elimination puts a little bit of pressure, and what that would translate into is the number of members that are enforced our greater plans. A lot of the feedback that we're getting, we have a team of people that comes before us every Friday to talk about the progress that we're making a lot -- around a lot of the tactical steps that are a part of this whole process that goes over this 2-month period. And we feel very good about where we are positioned. Some pressure related to the elimination by CMS, the threshold. But frankly, feel pretty good about how things are playing out this year, and we should be favorably positioned relative to the competition because a lot of the good work that we do around the Stars program."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","And A.J., I think it's just important to keep in mind that it is a relative measurement. And so our performance is highly predicated on everyone else's performance. And I think, as investors have seen over the past few years, our clinical capabilities has",71,"And A.J., I think it's just important to keep in mind that it is a relative measurement. And so our performance is highly predicated on everyone else's performance. And I think, as investors have seen over the past few years, our clinical capabilities has really outperformed the industry as a whole. And we continue to be confident that we'll be able to continue to outperform even as these changes persist."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Andrew Schenker with Morgan Stanley.",10,"Your next question is from Andrew Schenker with Morgan Stanley."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Jim, I was just hoping to follow up on your comments around maybe some of the moving parts in guidance. Since it sounds like Concentra deal, as you kind of point out on the press release, was originally is going to be about $0.11 headwind turning this yea",109,"Jim, I was just hoping to follow up on your comments around maybe some of the moving parts in guidance. Since it sounds like Concentra deal, as you kind of point out on the press release, was originally is going to be about $0.11 headwind turning this year. You also called around the pressure on the impact from share repurchases related to the stock appreciation here. Now looking at guidance, it seems like tax rate may have come down a little bit. Curious what some of the other moving parts where that led you feel confident to maintain your guidance range maybe versus where it was the last quarter."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think you outlined some of the major issues that we're focused on Concentra. We'll pressure earnings by $0.11. The share repurchase and tax rate and the like, it's probably about $0.04. So it's sort of a $0.15 headwind coming into this quarterly call. A",102,"I think you outlined some of the major issues that we're focused on Concentra. We'll pressure earnings by $0.11. The share repurchase and tax rate and the like, it's probably about $0.04. So it's sort of a $0.15 headwind coming into this quarterly call. Again, we feel comfortable about reiterating our guidance of $8.50 to $9. And really, what's going to drive that performance, as we said to the first question, is where does utilization ultimately end up? And right now, we feel good about where we are. But that's something we're focused on that will ultimately drive the year's numbers."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think the important point on the Concentra sale is it is a timing issue for us versus a long-term business problem. And as we think about the sale, we think about it as that we are really allowing the company to redeploy assets that will advance us stra",103,"I think the important point on the Concentra sale is it is a timing issue for us versus a long-term business problem. And as we think about the sale, we think about it as that we are really allowing the company to redeploy assets that will advance us strategically at a price that we feel is -- was a very good value for what we are doing. I know what we can do is take that and we deploy it, whether it's in capital structure, alterations, such as stock buybacks or acquisitions that will be more accretive long-term and strategically much stronger."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Maybe if I can squeeze one more real quick. The Healthcare Services segment specifically here, a lot of moving parts related to Concentra, as well as your health -- Home Health acquisition. If you could just maybe talk about how those kind of offset each",87,"Maybe if I can squeeze one more real quick. The Healthcare Services segment specifically here, a lot of moving parts related to Concentra, as well as your health -- Home Health acquisition. If you could just maybe talk about how those kind of offset each other, as well as maybe membership growth that allowed you to kind of maintain revenue guidance. And seems like the only impact pretax result was related to the pretax gains. So just making sure I understand the moving parts there as well."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Sure. Well, as you see in Healthcare Services segment guidance, we did adjust the revenue numbers and the like to comport with the divestiture of Concentra. I would say more broadly that, as I said in my remarks, that business is performing extremely well",131,"Sure. Well, as you see in Healthcare Services segment guidance, we did adjust the revenue numbers and the like to comport with the divestiture of Concentra. I would say more broadly that, as I said in my remarks, that business is performing extremely well. Memberships growing pretty dramatically based on largely through our Medicare Advantage and PDP growth. But we're also seeing better engagement with our members, both from a mail older perspective on the pharmacy, which is very important, but also with Humana At Home, as our analytical capabilities continue to identify people who would benefit from our Humana At Home capabilities. And so the combination of those is really driving that performance. So we feel very good about the range we have out there for our Healthcare Services pretax."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Matthew Borsch with Goldman Sachs.",10,"Your next question is from Matthew Borsch with Goldman Sachs."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Yes, if I could ask a question about the individual market. Just with 2 parts. Number one, the extent to, which you're seeing inflow of new members coming into the exchanges generally for this year. Your peer company of yours earlier today, talked about s",72,"Yes, if I could ask a question about the individual market. Just with 2 parts. Number one, the extent to, which you're seeing inflow of new members coming into the exchanges generally for this year. Your peer company of yours earlier today, talked about seeing less inflow than they had expected. Secondly, just on Georgia. How are you repriced in that market and avoid getting stuck in-source of an adverse selections viral?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think as far as new members, I think, really, it's consistent with what we expected in terms of coming into the market. And actually, feel reasonably good about the overall pool of what we received. With Georgia, there's no doubt, Matt, that that's some",94,"I think as far as new members, I think, really, it's consistent with what we expected in terms of coming into the market. And actually, feel reasonably good about the overall pool of what we received. With Georgia, there's no doubt, Matt, that that's something we're very focused as you put in higher price increases or you're going to attract the wrong members. Part of that is going to go to product design and the metal tiers that we participate in. And so we're very cognizant about risk and we're going to price appropriately."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Peter Costa with Wells Fargo Securities.",11,"Your next question comes from Peter Costa with Wells Fargo Securities."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Getting back to the individual business again. Why do you think you have a problem in Georgia when your competitors report earnings earlier than has a number of low-priced silver plants in Georgia? It didn't seem to sell the problem that you guys are havi",88,"Getting back to the individual business again. Why do you think you have a problem in Georgia when your competitors report earnings earlier than has a number of low-priced silver plants in Georgia? It didn't seem to sell the problem that you guys are having there. Do you think it's local market related to you? Is it some cost disadvantage that you have in Georgia? And how do we avoid this from happening in another state down the road, when the risk corridors and risk reinsurance goes away?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Peak, this is Jim, I'll take your question. And we wondered how long before you would dial in. With respect to Georgia, as Brian said earlier, one of the things that we did at the very beginning was to take our individual legacy business and do relativiti",290,"Peak, this is Jim, I'll take your question. And we wondered how long before you would dial in. With respect to Georgia, as Brian said earlier, one of the things that we did at the very beginning was to take our individual legacy business and do relativities to our small group block of business because that was a guarantee issue population. We thought that was fairly close to what might ultimately happen on the exchanges. And after that, and that was done local market by local market, we evaluated morbidities across a national basis with the help of an outside consulting actuarial firm. And as a result of that overall evaluation from a national perspective, we've lowered some of our market's expected morbidities. And with respects to Georgia, while other markets turned out just fine relative to that pricing philosophy, Georgia didn't. Another part of the Georgia issue has to do with the Platinum plans, which you asked about in the past. One of the things that we're seeing with the platinum plans is that the philosophy or the strategy that we've enumerated in the past with you and others is that you need to have documentable risk conditions for the members that are heavier utilizers. And as we study the Georgia population, as we're doing some of our risk adjustment work, we're seeing that the Georgia population, although have year utilizers, don't have documentable risk conditions, which doesn't allow us then to get risk adjustment for them. And as a result of that, as Brian said, not only in Georgia, but also in other states, we're evaluating that requirement as it respects our our platinum plan strategies going forward, and you'll see us take some actions relative to that."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","That's helpful. And what is your strategy for avoiding this going forward in other states?",16,"That's helpful. And what is your strategy for avoiding this going forward in other states?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, now, we have had a lot of our actual claims information on which to set pricing. And so, as we've done with all of our other products over the years, we're using actual claims to set our pricing. And so our pricing will be consistent with our desire",116,"Well, now, we have had a lot of our actual claims information on which to set pricing. And so, as we've done with all of our other products over the years, we're using actual claims to set our pricing. And so our pricing will be consistent with our desire that this block of business will produce satisfactory return. A lot of what we've done up to this point has been models and estimates based upon other lines of business. Now that we've gotten some real claims information relative to, not only '14 but '15, that's how we'll set our pricing going forward. And we feel very confident in our ability to properly set the right rates."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Will you offer platinum plans next year?",7,"Will you offer platinum plans next year?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","We're going to evaluate that market-by-market. And to the extent that it doesn't make sense because what I talked about relative to documentable risk conditions, we'll evaluate that and will act accordingly.",33,"We're going to evaluate that market-by-market. And to the extent that it doesn't make sense because what I talked about relative to documentable risk conditions, we'll evaluate that and will act accordingly."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","The next question comes from Kevin Fischbeck with active America.",10,"The next question comes from Kevin Fischbeck with active America."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Just wanted to ask a little bit about the commentary on the Medicaid side of the business. The company seems to be more aggressively pursuing RFPs. I guess, you had in the past. Can you talk a bit about your view kind of what's changed in the last couple",85,"Just wanted to ask a little bit about the commentary on the Medicaid side of the business. The company seems to be more aggressively pursuing RFPs. I guess, you had in the past. Can you talk a bit about your view kind of what's changed in the last couple of years? And you pursuit RFPs in a couple of different ways, outright or through joint ventures and things like that. So how do you think about the form of these types of participation might take?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I don't think our cost has changed relative to what we look at going forward. I think we continue to believe a partnership model in Medicaid makes sense in most states, if not all states, then we'll continue to do that. We do look at states where we have",122,"I don't think our cost has changed relative to what we look at going forward. I think we continue to believe a partnership model in Medicaid makes sense in most states, if not all states, then we'll continue to do that. We do look at states where we have consistent membership. Their RFPs come out, we want to participate in those RFPs. And that's really has been a standard direction a strategy for us. And our existing Medicaid results continue to meet expectations and continues to grow quite nicely. So as we look at it going forward, we continue to believe that the Medicaid platform is a platform that has partnership model in states that we are operating at within today."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Sarah James with Wedbush.",9,"Your next question comes from Sarah James with Wedbush."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I wanted to go back to the out-of-network position over the 3R boost. It sounded like this was mainly something that pertains to new members transitioning onto any change products. And there's been some stricter network enforcement going on lately and I g",97,"I wanted to go back to the out-of-network position over the 3R boost. It sounded like this was mainly something that pertains to new members transitioning onto any change products. And there's been some stricter network enforcement going on lately and I guess, going forward. Should I think about this as really dipping into the 3Rs for just the first quarter and it's just going forward? Or is this something that's going to continue on through the year? And how can you modify your benefit designs in '16 in a way that would improve this scenario?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, I would say it's going to impact the 3Rs for this year, just given where we are with our performance and the like. With people who are out-of-network, those are higher cost than we had anticipated. And that's drives the receivables. As I mentioned i",139,"Well, I would say it's going to impact the 3Rs for this year, just given where we are with our performance and the like. With people who are out-of-network, those are higher cost than we had anticipated. And that's drives the receivables. As I mentioned in my remarks, we are working with these out-of-network providers, both in terms of the reimbursable fees that we paid them and the fee schedules, contracting with them and the like. And it's also a matter of educating our members as to their product -- the product that they have. I would say we believe very deeply in the strategy of having these high-value networks that allows us to drive very affordable and attractive pricing to our members. So those are really the puts and takes. It's a combination of provider and member education."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","So it's more education that was in financial and kind of...",12,"So it's more education that was in financial and kind of..."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, I would say, with the providers, there will be financial impacts and financial incentives to ensure that we pay the appropriate levels of reimbursement for our -- for what we call our non-par or nonparticipating providers. I should know that it's a",140,"Well, I would say, with the providers, there will be financial impacts and financial incentives to ensure that we pay the appropriate levels of reimbursement for our -- for what we call our non-par or nonparticipating providers. I should know that it's a small number of members that are utilizing the benefit out-of-network. And to some extent, there might be some product design in terms of higher out of pocket cost for members who tend to go out of network. And that's something that we would be evaluating for next year. But I think the combination of provider education, provider contracting, as well as member education and some tweaks in the product design, is a problem that we think we can get our head around and solve for next year and frankly, the back half of this year as well."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Scott Fidel with Deutsche Bank.",10,"Your next question is from Scott Fidel with Deutsche Bank."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Just wanted to stick on the individual business and know you're talking about Georgia specifically. But just interested in how much you think you're going to need to be raising premiums on the exchange business more broadly. If we look at your 3Rs accrual",130,"Just wanted to stick on the individual business and know you're talking about Georgia specifically. But just interested in how much you think you're going to need to be raising premiums on the exchange business more broadly. If we look at your 3Rs accruals now for this year, they're right around $0.5 billion for 2015. And I would calculate that on your sort of your ACA-compliant individual business, that equates around 13% of revenues. So given that both of reinsurance and risk corridors really sort of scale we over the next year or 2, just help us think about how much sort of excess premium increases you're going to need to be implementing in order to reflect the -- this -- the expiration of those 2Rs of the 3Rs."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","That's not a specific number for obviously, competitive reasons. We wouldn't want to comment on, right now, I would say that, certainly that we have the 3Rs squarely in mind as we price for next year. We recognize that there's one more year to go here wit",112,"That's not a specific number for obviously, competitive reasons. We wouldn't want to comment on, right now, I would say that, certainly that we have the 3Rs squarely in mind as we price for next year. We recognize that there's one more year to go here with 2 of the 3Rs. And so we're going to price such that. As I said in my remarks, we can earn an attractive return on capital in 2016 and beyond. And so we understand the dynamics of the market in the 3Rs and the pricing required to do that. And we'll take the necessary steps to make sure we get the right financial return."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","To Brian's earlier point, many of the markets are performing well, and we've got some problems in the State of Georgia that we plan to address with our pricing and our product design.",34,"To Brian's earlier point, many of the markets are performing well, and we've got some problems in the State of Georgia that we plan to address with our pricing and our product design."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. And then just quickly just on the Medicare hospital admission. How geographically broad-based are you seeing that? I mean, I'm just trying to tie that the comments from CMS on their final 2016 rates call, where they said that their actuaries have al",79,"Okay. And then just quickly just on the Medicare hospital admission. How geographically broad-based are you seeing that? I mean, I'm just trying to tie that the comments from CMS on their final 2016 rates call, where they said that their actuaries have also seen some flattening out of the the admissions trends. And I would assume that CMS was highlighting that it will be probably more broader base so just interested geographically on how much you're seeing there."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think, as Jim said earlier, we would call it a specific geographies. Where we were very focus was to see where we grew in particular markets and whether that's more outsized growth was the cost of this -- the slightly higher admits, and we haven't seen",66,"I think, as Jim said earlier, we would call it a specific geographies. Where we were very focus was to see where we grew in particular markets and whether that's more outsized growth was the cost of this -- the slightly higher admits, and we haven't seen that. They're actually running pretty favorably. So I would suggest it's a broad-based phenomena that we're watching very closely."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Ralph Giacobbe with CrÃ©dit Suisse.",10,"Your next question comes from Ralph Giacobbe with CrÃ©dit Suisse."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Switching a little bit. You guys reclassified segments. And I guess, within the group book, you've seen enrollment declines. I guess, the question is, how committed are you to this business, I guess going forward? Is there any strep overview been limited",105,"Switching a little bit. You guys reclassified segments. And I guess, within the group book, you've seen enrollment declines. I guess, the question is, how committed are you to this business, I guess going forward? Is there any strep overview been limited for this segment? And I guess usually of the PBM, just wanted to clarify. You talked about sort of a full debrief on the 3Q call in November. Just hoping to get all of our collective that? Is just final decision you expected that point whether you kind of keep it or come up with some sort of outsourcing placement or the like?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","To your question on enrollment declines, we made the strategic decision a year or so ago. I think we talked about that with the large group business, we were going to wind that down over the next several years because we are not a national player and we c",279,"To your question on enrollment declines, we made the strategic decision a year or so ago. I think we talked about that with the large group business, we were going to wind that down over the next several years because we are not a national player and we can't compete in that space. But we are focused on what we call our sweet spot of smaller case sizes. And over the last 6 months, we performed reasonably well with our sweet spot focus. You may recall that in the fourth quarter, we grew very nicely with our small or focused business. This past quarter, we have seen some shrinkage in our fully insured smaller Capesize membership as a lot of our competitors are implementing their new rates relative to community rating. And we're seeing a little bit of an aggressive posture in some of the states that we do business. That will ultimately change over time. And we think that, that will work itself out. We feel very confident with our focus on the smaller case sizes. Over the next several years, we're going to be evaluating our Group business. And again, feel very good about its prospects for continued profitability. And it serves very nicely as a complement to our focus on local market scale. We talked a lot about that with our Medicare business, our individual business, our Medicaid business and our Group business in certain of the bar of what we referred to as bold move markets. So again, we feel very confident in our ability to compete and win in the smaller Capesize, and hopefully, you'll see that play out over the next several quarters."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think even as the results show this quarter, we really have a 3-pronged approach within group. One is around continuing to increase our efficiency within the group sector. And you can see that as you see our cost ratios coming down. Second is to focus o",154,"I think even as the results show this quarter, we really have a 3-pronged approach within group. One is around continuing to increase our efficiency within the group sector. And you can see that as you see our cost ratios coming down. Second is to focus on where we probably have better value proposition on that in the small group, as what Jim just talked about, our sweet spot, and begin to start exiting relationships that are not profitable for us and that traditionally is the larger ASO model. And then the third is to continue to migrate customers to more of a consumer choice model within the markets that we are at, and that would be both the private exchange and public exchanges as we see that being both a long-term trend. And frankly, I think where we can even add more value with our retail capabilities that we've had in the past."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","That's helpful. Just on the PBM?",7,"That's helpful. Just on the PBM?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","As we said, the PBM, we're going to evaluate, and it's kind of under continued evaluation. We've provided some updates in the past. But the full update will be in the third quarter of this year.",36,"As we said, the PBM, we're going to evaluate, and it's kind of under continued evaluation. We've provided some updates in the past. But the full update will be in the third quarter of this year."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Ana Gupte with Leerink Partners.",10,"Your next question is from Ana Gupte with Leerink Partners."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","So just want to make sure I understand this. I'm a little confused with everything. I'm getting a lot of questions from investors, so I'm pretty confused as well. On retail MLR, what exactly -- this is the underlying Medicare MLR okay, XP YD? And this sor",89,"So just want to make sure I understand this. I'm a little confused with everything. I'm getting a lot of questions from investors, so I'm pretty confused as well. On retail MLR, what exactly -- this is the underlying Medicare MLR okay, XP YD? And this sort of late quarter potential uptick you're seeing? And is the deterioration, which was not great, but it is deteriorating because your HumanaOne individual public exchange product is now going to be much more reliant on reinsurance and were having all these issues?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Yes, again, if you -- Ana, if you look at our retail MERs for the quarter and you adjust them for prior period, they're actually down. So I think that's important to note. As we said, prior period did have a pretty material impact on our numbers. A lot of",101,"Yes, again, if you -- Ana, if you look at our retail MERs for the quarter and you adjust them for prior period, they're actually down. So I think that's important to note. As we said, prior period did have a pretty material impact on our numbers. A lot of it was expected. Some of it wasn't related to the flu and the like. But when you look at the MERs, we feel pretty good about where we are on an incurred basis from an MER perspective. And as I said, they're actually down. So I hope that answers your question."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. So MA is in display. On individual, did you see any improvements in your off exchange ACA-compliant type MLR at all? Your competitors seem to be seeing what they said they would see. And so net-net, on individual, you'd said you'd see margin expansi",58,"Okay. So MA is in display. On individual, did you see any improvements in your off exchange ACA-compliant type MLR at all? Your competitors seem to be seeing what they said they would see. And so net-net, on individual, you'd said you'd see margin expansion ex exchange, publicly exchanges. What's going on in the rest of the book?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Again, we don't break out our ACA complaint, on exchange and off exchange. I think when you adjust for the 3Rs, our MERs in line with our expectation, which is why, as I said in my remarks, that we're going to breakeven or better for 2015. That still is t",80,"Again, we don't break out our ACA complaint, on exchange and off exchange. I think when you adjust for the 3Rs, our MERs in line with our expectation, which is why, as I said in my remarks, that we're going to breakeven or better for 2015. That still is the case. I'm sorry? I was just to say, but the 3Rs clearly help us in that regard and it's higher than we anticipated for the reasons that we went through."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay, one final one, if I may. So then on HumanaOne, might you be in a place where you have some adverse selection last year and as you're raising prices, are you seeing more of that generation of that but because anyone who can afford or is relatively he",62,"Okay, one final one, if I may. So then on HumanaOne, might you be in a place where you have some adverse selection last year and as you're raising prices, are you seeing more of that generation of that but because anyone who can afford or is relatively healthy, migrate someplace else? And so you might have challenges just turning around book?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","As with respect to the State of Georgia, which we have talked about a couple of times. I wouldn't have said that it was adverse selection as opposed to the health condition of the entire population. We just have to price reflective of the health condition",104,"As with respect to the State of Georgia, which we have talked about a couple of times. I wouldn't have said that it was adverse selection as opposed to the health condition of the entire population. We just have to price reflective of the health condition and that may cause some of those members to move onto other plans. But we've got to get our pricing comments rate with the risk conditions that we're assuming. And we think that we've got a pretty good plan in place, not only to increase pricing, but also evaluate some of the products that are in the marketplace."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your final question is from Christine Arnold with Howard.",9,"Your final question is from Christine Arnold with Howard."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm trying to sort through what belongs in this year versus last year. Was there any net prior period negative development in the first quarter of this year related to last year in any products?",36,"I'm trying to sort through what belongs in this year versus last year. Was there any net prior period negative development in the first quarter of this year related to last year in any products?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I'm not sure I understand the question. There was -- the prior period development was positive this quarter based on 2014 and prior results. It was less positive than it was last first quarter in 2014. That was largely expected for the reasons I discussed",101,"I'm not sure I understand the question. There was -- the prior period development was positive this quarter based on 2014 and prior results. It was less positive than it was last first quarter in 2014. That was largely expected for the reasons I discussed, i.e. it was a very high PPD quarter in the first quarter of '14, and we implemented some claims processing changes with front end review and Medicare that drove some of the change. Some of that was unexpected. But -- so there is positive PPD in our numbers just less than there was last year."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. And then payables versus premium. I agree we should exclude PDP. But if we exclude PDP premiums, your payables versus premiums are still upside down in the first quarter. Now this could be because I've got more capitated costs, it could be because o",100,"Okay. And then payables versus premium. I agree we should exclude PDP. But if we exclude PDP premiums, your payables versus premiums are still upside down in the first quarter. Now this could be because I've got more capitated costs, it could be because of other factors. Can you help me understand why, if you're seeing an increase in utilization, I would think you'll be booking more payables through the spring these issues with the individuals book, but it looks like that's not happening. So can you help me sort through what other factors might be at getting for that?"
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","That comparison, change of premium prices change of claims payable, as we've discussed in the past, is not something that we focused on. There are a lot of moving pieces that go into that number. As we've said with regard to utilization, I wouldn't be --",278,"That comparison, change of premium prices change of claims payable, as we've discussed in the past, is not something that we focused on. There are a lot of moving pieces that go into that number. As we've said with regard to utilization, I wouldn't be -- I wouldn't have this statement as boldly as you just made with regard to overall utilization. What we pointed out, because it's important that we point it out to be fully transparent, is that we have seen that slight increase in admits over the recent weeks. And it's something that we're waiting to see how it plays through our claims lags over the coming months. As you know, it takes a few months for those to work through. But I would've made the overall statement that utilization is up. Remember that our admits are actually valid year-over-year. Our trend benders are working, as we've said. And so I wouldn't read into it anything more than that. As you look for balance sheet quality and cash flow quality, the claims -- the process claims and unprocessed claims, on a DCP basis, are actually up, which I know is a measure that you and others look at. And when you look at our cash flow for the year, which is where we focus because of the timing of these working capital issues that I went through, other than the 3Rs, and of course, Concentra, we're actually reasonably in line. As you know, we took up our cash flow last quarter. And I think if were not for some of these other adjustments of that I just discussed, we've be in pretty good stead there."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","We appreciate the support the shareholders are providing us. We recognize that this quarter is a complicated quarter as a result of our Concentra sale, as a result of some of the changes in the comparison. But we do believe it is a quarter that continues",103,"We appreciate the support the shareholders are providing us. We recognize that this quarter is a complicated quarter as a result of our Concentra sale, as a result of some of the changes in the comparison. But we do believe it is a quarter that continues to confirm the organization's strategy around our growth in retail and in addition, the integrated delivery model. 
So in conclusion, as always, we thank our 60,000 associates that helped us bring these results to life every day and we appreciate the shareholder support. So thank you, and we look forward to continuing our conversations later. Thank you."
29618,278392395,796979,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Good morning. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Humana First Quarter 2015 Earnings Call. [Operator Instructions] Thank you.I will now turn the call over to Ms. Regina",51,"Good morning. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Humana First Quarter 2015 Earnings Call. [Operator Instructions] Thank you.
I will now turn the call over to Ms. Regina Nethery. You may begin your conference."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning.In a moment, Humana's senior management team will discuss our first quarter results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be Bruce Broussard, Humana's President and Chief Ex",343,"Thank you, and good morning.
In a moment, Humana's senior management team will discuss our first quarter results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Senior Vice President and Chief Financial Officer. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Joining Bruce and Brian for the Q&A session will be Jim Murray, Executive Vice President and Chief Operating Officer; and Christopher Todoroff, Senior Vice President and General Counsel. We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts.
This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. This call is also being simulcast via the Internet, along with a virtual slide presentation. An Adobe version of today's slide deck has been posted to the Investor Relations section of Humana's website.
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in this morning's earnings press release as well as in our filings with the Securities and Exchange Commission. Today's press release, our historical financial news releases and our filings with the SEC are all available on Humana's Investor Relations website.
Call participants should also note that today's discussion and slide presentation include financial measures that are not in accordance with generally accepted accounting principles. Management's explanation for the use of these non-GAAP measures is included in today's slide presentation, as well as a reconciliation of GAAP to non-GAAP financial measures. Finally, any references to earnings per share or EPS made during this morning's call refer to diluted earnings per common share.
With that, I'll turn the call over to Bruce Broussard."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Good morning, everyone, and thank you for joining us.This morning, Humana announced first quarter 2015 adjusted earnings per share of $2.47, up 5% from the first quarter of last year. Our pretax earnings of $744 million were a record high and we believe",1369,"Good morning, everyone, and thank you for joining us.
This morning, Humana announced first quarter 2015 adjusted earnings per share of $2.47, up 5% from the first quarter of last year. Our pretax earnings of $744 million were a record high and we believe are a clear demonstration on the progress we continue to make as a company. Further, we continue to have confidence in our full year guidance for adjusted earnings of $8.50 to $9 per share.
Our more significant achievements during the quarter included substantial membership growth in our Medicare Advantage, stand-alone PDP and HumanaOne products; the recent launch of our population health technology business, Transcend Insights; announcement of the pending sale of our Concentra business; and completion of our $500 million accelerated share repurchase program. I'll begin with our Medicare Advantage growth.
As we shared with you last quarter, we experienced another successful Medicare enrollment season for 2015. Individual Medicare Advantage membership at March 31, 2015, was up 11% versus the end of the fourth quarter 2014 up 14% year-over-year. We continue to see the positive impact for our members of stability in our value proposition as well as high Star quality ratings. A recent McKinsey study on the 2015 Star ratings concludes that HMO plans perform best on an enrollment-weighted basis. Approximately 56% of our individual members are in HMO plans compared to 53% a year ago. Further, the McKinsey study indicates that plans built around integrated delivery networks achieve higher average Star ratings.
CMS recently eliminated certain fixed thresholds for 4 Star ratings for 2017 bonus year. These changes may result in some pressure on our overall Star ratings, but we believe we will sustain our solid competitive advantage. We expect we will maintain our high-quality ratings due to our successful integrated care delivery model. Our model includes use of data analytics to engage members in preventative measures and wellness programs that close clinical gaps in care.
In sum, we believe the combination of a solid value proposition and a -- high-quality ratings are critical to attracting new membership and retaining our existing membership base. Our projected 2015 net new membership gains of approximately 12%, including a voluntary retention rate of approximately 90%, are all helping to validate this belief.
CMS has also recently released its final Medicare rates for 2016. While we were encouraged by the average rate increase for the first time in 7 years, this average still lags fee-for-service medical cost trends. Additionally, CMS' transition to the new risk adjustment model will negatively impact certain of our markets that are leading the country in value-based reimbursement methods and holistically assisting members with multiple complex chronic conditions, both which are key goals for CMS. As we prepare our Medicare bids for 2016, we will seek to minimize any disruption that rate changes may cause to Medicare beneficiaries while holding firm on our 4.5% to 5% pretax margin target. The continuing investment in our clinical model are expected to provide some offsets to rate pressures that will vary, of course, from market to market. Those investments were highlighted this month by Humana's -- At Home's acquisition of Your Home Advantage, a leading provider of nurse practitioner in home visits. Additionally, we believe our focus on the consumer experience and our proprietary market point distribution channel will be important elements in solidifying our relationship with our members as we face these rate challenges at the market level.
Turning to our stand-alone PDP offerings. We also experienced significant growth for these products, with membership up 10% since the end of 2014 and 14% to the first quarter of last year, primarily in our low-price-point offerings.
I now will spend some time on our investments in health care exchanges and state-based contracts.
We're pleased that HumanaOne membership has continued to grow nicely. While we will continue to project at least breakeven results for our HumanaOne business, our projected increased reliance on the 3Rs is driven primarily by the results for the State of Georgia and our out-of-network provider usage. We believe both are isolated and addressable. Brian will discuss each of these factors in his remarks.
Entering a new customer segment is never an easy task. However, we believe that health care exchanges are a leading example of the ongoing movement to the Retail model, where we have been so effective in Medicare. We continue to be highly targeted in terms of where we will participate in health care exchanges, with a strong emphasis on current Medicare Advantage markets, to enable customer migration as members' life situations change. Our expansions into health care exchanges and our state-based contracts are deepening our partnership with local providers -- local market providers as we develop local market scale through multiple product offerings. State-based Medicaid membership which now includes those members associated with dual demonstration programs is up significantly both on a sequential basis and year-over-year. We continue to monitor the RFP pipeline and plan to pursue other state-based opportunities later in 2015.
These opportunities would not be as viable if it weren't for our integrated care delivery model. Importantly, we continue to show progress in key integrated care delivery model metrics. Some examples include the number of individual Medicare Advantage members covered by value-based arrangements is now more than 54%. This is particularly encouraging giving the substantial increase in membership this quarter. Membership in our Humana Chronic Care Program is up 10% since the end of the year and 56% versus the prior year. Adoption of mail-order pharmacy among our members continues to grow as we highlight this benefit more fully during the sales process and welcome calls. Individual Medicare Advantage mail-order penetration is now, on an average, approaching 35%.
We continue to focus on reaching out to members with gaps in care and have sent over 4 million proactive messages to 2.5 million members to prevent gaps in care. These actions have resulted in a gap closure rate of more than 30%.
As a leader in both the development and execution of value-based payment models and technology-driven population health management analytics, we support trends that encourage care coordination across all payers. In that context, this quarter, we launched Transcend Insights, which leverages the population health capabilities we have developed in our Medicare Advantage business. Our goal is to provide Payer-agnostic tools to our provider partners, allowing more of our members to be in value-based reimbursement models. As we've shared with you in the past, value-based arrangements have proven to lead to higher HEDIS scores, lower medical cost and higher membership satisfaction.
Before closing, I'd like to spend a moment on our recently announced sale of Concentra.
As we've said in previous calls, we review our various businesses on an ongoing basis to ensure each earns its cost of capital and is aligned with our integrated care delivery strategy. The Concentra acquisition was part of a multipronged approach to increase our capabilities of managing risk through primary care physicians. Our subsequent MSO acquisitions and joint venture investments provided a more integrated primary care platform than Concentra. Although it did not ultimately fit strategically, we were able to achieve an attractive price that will result in a gain versus our initial investment. Brian will speak more to the details of this transaction in his remarks.
We expect the transaction will close in the next few weeks. I want to thank all of our Concentra associates for their dedication to the consumer and to our company.
Several of you have asked for an update on our PBM evaluation. That work continues, and we expect to provide a full debriefing on our analysis during the Third Quarter Earnings Call in November.
In summary, we believe our robust organic membership and revenue growth, together with our proven superior clinical operating performance and disciplined capital allocation, all come together to provide our sustainable competitive advantage. Excluding the onetime gains that we expect from the Concentra sale, we continue to expect our full year adjusted earnings per share to be in the range of $8.50 to $9 and look forward to providing you updates as the year progresses.
With that, I'll turn the call over to Brian for a more detailed discussion of our financials."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce. And good morning, everyone.As Bruce mentioned, the first quarter of 2015 produced strong results and continues to demonstrate the successful implementation of our integrated care delivery model. The attractiveness of our product offeri",2216,"Thank you, Bruce. And good morning, everyone.
As Bruce mentioned, the first quarter of 2015 produced strong results and continues to demonstrate the successful implementation of our integrated care delivery model. The attractiveness of our product offerings is resonating with our customers, as demonstrated by the continuing increases in our Medicare Advantage, stand-alone PDP and exchange membership.
Consequently, we have raised full year membership expectations for both stand-alone PDP and HumanaOne. Stand-alone PDP is being driven by higher retention that we are seeing post the open-enrollment period, which is largely the results of fewer auto enrollees being reassigned. I'll speak more to the HumanaOne business shortly. With regard to our Medicare Advantage growth, early indications for our new members are positive as we evaluate individual market growth and performance. Additionally, the growth in our PBM and Humana At Home businesses remains unabated with not only more volume driven by membership growth but also deeper penetration in terms of increased engagement, as well as benefits from scale that are driving results.
First quarter revenues for the Healthcare Services segment rose 26% versus the prior year, and pretax earnings are up 24% year-over-year.
The quarter had several developments that will be the focus of my remarks today. These include the following: the increase in our projected 3R receivables for the year, medical utilization and prior-period development, days in claims payable and cash flows from operations, the earnings implications of the Concentra transaction and capital allocation. Let's begin with our exchange business and the premium stabilization programs commonly called the 3Rs.
Our conviction in our health care exchange strategy remains strong. We continue to focus on our key growth markets by offering high-value networks to drive affordability and access for our customers. We believe that this strategy has been effective in successfully establishing a new growth business while providing a compelling product that our members value. Over time, we believe that HumanaOne will not only contribute meaningfully to our results but it will also, as Bruce emphasized, advance our objectives of local market presence and scale with providers while allowing us to offer a range of products that are relevant to our customers no matter their age or income circumstance.
As with any startup business, we've had our successes as well as our challenges. In terms of successes, our ACA-compliant membership for HumanaOne is up 38% from the end of 2014, well ahead of our previous expectations. This was driven by better-than-forecast sales and lower-than-anticipated attrition. Consequently, we have adjusted our aggregate HumanaOne guidance to reflect higher projected membership in the ACA-compliant business, which we also believe results in us approaching the scale we need for long-term success.
We continue to forecast that we will have at least breakeven results in 2015 and earn a reasonable return on capital in 2016, albeit that achievement of breakeven results this year now includes higher reliance on the 3Rs than previously anticipated coming into 2015. As you've seen from our release, we have increased our net 2015 3R guidance range to $450 million to $550 million, with reinsurance accounting for approximately 75% and risk adjustment and risk corridors accounting for approximately 25% of the total. As we have discussed in the past, there is an interplay between risk adjustment and risk corridors in that, if we don't get the risk adjustment exactly right, a meaningful part of the balance, either positive or negative, is captured through the risk corridors.
As we evaluate our financial performance to date, including runoff claims from 2014, the drivers of the increase in full year receivables related to the 3Rs are quantifiable and addressable. The first 2 Bruce mentioned in his remarks are higher-than-anticipated out-of-network utilization and poor results in our Georgia market. The last driver of the higher receivables is simply a function of having more members than we had previously expected.
I'll start with out-of-network utilization. As the exchanges were rolling out across the nation, we believe there would be a time period during which our members will be getting accustomed to our efficient network products. Consequently, we permitted out-of-network utilization for the small proportion of our members who did not stay in network to avoid disruption, notwithstanding the products designed -- product's design, which underpin the affordability that our members seek. Our provider network team has thoroughly evaluated our networks in light of our membership levels by market, and we are very satisfied in our level of network adequacy. As a consequence, we are in the process of implementing stricter enforcement of network utilization by working closely with nonnetwork providers, as well as educating our members on the products. Higher levels of in-network utilization are anticipated to ensure the continued affordability of our health care exchange offerings as well as aligned with our pricing assumptions for the remainder of the year and for 2016.
After adjusting for the out-of-network usage, our markets across the country, including our largest HumanaOne market in Florida, are performing within expectations, with the notable exception of Georgia. One of the challenges we faced in both 2013 and 2014 was the immaturity of the claims data we had available at the time we set our health care exchange pricing for the following year versus what we would have preferred, specifically, more detail regarding statewide market conditions and health status based on significant exchange claims data. To help address this, we juxtaposed the limited Georgia claims data we had against claims data nationally for states that we believe had similar utilization patterns and mix of likely enrollees to derive assumptions around the population health of each state and, in turn, set our pricing. Recent actuarial claims data for the State of Georgia now indicate that enrollees in the state as a whole are skewing more towards being a less-healthy state population than we had believed and had priced for. Consequently, we are accruing both a risk adjustment and risk corridor receivable.
It's important to recall that this was the original intent behind the premium stabilization programs, namely earlier protection, in this circumstance. We are, of course, incorporating our emerging experience into our actuarial assumptions and are taking the appropriate targeted actions through pricing and product design when we file our 2016 rates in the next few weeks to ensure that Georgia's results will be back on track for 2016 without reliance on the risk corridors.
As I mentioned, the remaining driver of the higher 3R balance relates to higher-than-projected growth of our ACA-compliant business. This will result in higher 2015 receivables than we had expected primarily associated with reinsurance.
Finally, a quick word on our 2014 3R accruals. As you will see, we have decreased reinsurance by approximately $50 million and have increased our risk corridors by around $40 million as an offset. As we've evaluated the runout of our 2014 claims, fewer of our members than anticipated will hit the reinsurance attachment point, which is the reason we have made this change.
Turning to medical utilization. We are watching very closely the hospital ""inpatient admissions per thousand"" data for our Medicare Advantage business. We have seen some of the hospital published data which suggest higher Medicare usage of inpatient services and have also witnessed in the last number of weeks an uptick in inpatient authorizations. For Medicare Advantage, we have projected a decline year-over-year in hospital admissions, and for the first quarter, we have seen that decline bear out. In other words, our trend benders continue to results in lower admissions. However, during the last weeks of the quarter and into April, we are seeing an elevated level of authorizations for hospitals admissions, which although still declining, are slightly higher than we had anticipated. Importantly, we have also seen data throughout the quarter that would suggest our cost per admit is lower than forecast, implying lower-severity conditions are driving the admissions.
While it is too early to draw any conclusions from what I just described, especially as admissions tend to fluctuate, it is something that bears close watching as the actual claims experience develops over the coming months.
As was highlighted in this morning's press release, we did see a lower level of favorable prior-period development than in last year's first quarter. A meaningful portion of the lower prior-period development was anticipated due to the PPD for the first quarter of 2014 having been unusually high and as a result of claims processing changes involving the implementation in early 2014 of a front-end review for Medicare claims. Front-end review enables us to improve the initial accuracy of claim payments, reducing the amount of overpayments recaptured later as part of prior-period development. PPD was also adversely impacted by fourth quarter flu claims that came through in the first quarter of 2015 across our lines of business.
I will now turn to the balance sheet and operating cash flow. I'll start with days in claims payable or DCP.
You will note that we have revised the DCP table to exclude reinsurance associated with the 3Rs. Given that reinsurance reduces benefits expense but does not impact the related benefits payable, it skews DCP trends over the 3-year period of the program.
Days in claims payable during the first quarter of 2015 declined by less than a day, driven primarily by the typical first quarter increase in Part D claims associated with our Medicare Advantage business. That impact is included in the all other category of the DCP roll-forward table in our press release. Recall that our stand-alone PDP business is excluded from our days in claims payable calculation.
Much like our stand-alone PDP offerings, our Medicare Advantage Part D benefit designs generally have the plan picking up substantially all the initial pharmacy claims but covering less of the benefit as the year progresses. While the pharmacy expense associated with these members is in our DCP calculation, the related payable is relatively small due to the speed of processing pharmacy claims. Higher capitation and provider settlements also resulted in a slight decrease to DCP during the quarter, but importantly, this was more than offset by an increase in unprocessed and processed claims inventories.
Cash flow from operations is down versus the first quarter of 2014, as higher net income was more than offset by working capital items. Specifically, the increase in benefits payable, which accompanies growing membership, was smaller year-over-year due to the lower level of overall growth in average membership given the outsized growth we experienced in 2014. This pressured the cash flow from operations on a comparative basis by approximately $250 million in the quarter. Working capital needs for our growing pharmacy business primarily accounted for the remainder of the delta in the first quarter cash flows.
For the year, our operating cash flow guidance is largely unchanged, other than reducing operating cash flow by guidance -- cash flow guidance by approximately $200 million at the midpoint, primarily reflecting the increase in the 3R receivable that I just discussed previously as well as the pending sale of Concentra.
Before closing, I'll spend just a few minutes on capital allocation and earnings guidance. As Bruce said in his remarks, we announced this quarter the sale of our Concentra business. The timing of the signing of the definitive agreement triggered the need to recognize the gain on the establishment of a deferred tax asset. And thus, the $0.35 per share gain was included in our first quarter GAAP results.
We expect this transaction to close in the next few weeks, so we have included the full impact of the transaction in our earnings guidance both from a GAAP and an adjusted perspective. For GAAP, we are including a total projected gain from the sale in the range of $1.35 to $1.45 per share, including the $0.35 tax gain. On an adjusted basis, excluding this onetime gain, we continue to forecast earnings per share in the range of $8.50 to $9 per share.
The sale of Concentra is expected to generate, net of taxes and deal expenses, approximately $1 billion in net proceeds. Before any anticipated use of these proceeds, the sale will results in $0.11 of 2015 EPS dilution. We continue to look for value-enhancing acquisitions such as the Your Home Advantage deal we recently announced that will advance our in-home capabilities, as well as pursue additional share repurchase opportunistically. However, given where we are in the year, it is likely that a good portion of this dilution will persist.
With respect to share repurchase, this quarter, we completed our $500 million accelerated share repurchase program. Additionally, holding true on our commitment to buy back $1 billion of stock by June of this year, we have entered into a 10b5-1 plan that we expect will complete that goal. You will note, however, that we have raised our guidance slightly for the average fully diluted share count due largely to the higher-than-anticipated buyback price, which will have a several-cent negative EPS impact.
Finally, our work around optimizing our portfolio continues to ensure that each of our businesses fits strategically and earns its cost of capital. More generally, we are encouraged by our progress in our prospects, all driven by execution around our integrated care delivery strategy. 
With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your first question comes from Joshua Raskin with Barclays.",9,"Your first question comes from Joshua Raskin with Barclays."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I want to talk a little bit about the utilization trends that you guys are monitoring and just better understand what exactly is driving that. I think you mentioned some public data from some of the hospitals, but I have to assume you're going off of more",81,"I want to talk a little bit about the utilization trends that you guys are monitoring and just better understand what exactly is driving that. I think you mentioned some public data from some of the hospitals, but I have to assume you're going off of more of internal data, so is there any specific lines of service? Are there a specific type of lines? Any geographies for these new members? Just any color on where this utilization is coming from."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Josh, certainly from our own data, that we're seeing a slight uptick in admissions over the last few weeks and into April, there's no specific geography that we would point to. It's something that we continue to evaluate. I would note that, interestingly,",124,"Josh, certainly from our own data, that we're seeing a slight uptick in admissions over the last few weeks and into April, there's no specific geography that we would point to. It's something that we continue to evaluate. I would note that, interestingly, not only are the unit costs of these admits lower, which as I said in my remarks is suggesting lower severity of claims, but also our outpatient utilization seems to be down and our pharmacy utilization is in-line. And so it's very early really to ascertain exactly what this is telling us. It's just something that we thought it would be important to communicate because it's something that we're watching very closely and it's something that we always watch very closely."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Josh, just to build on what Brian talked about and the reason that he specifically addressed it in his opening remarks is, as we saw this, we began to dive into a lot of the information relative to new members and what we call concurrent members. And actu",186,"Josh, just to build on what Brian talked about and the reason that he specifically addressed it in his opening remarks is, as we saw this, we began to dive into a lot of the information relative to new members and what we call concurrent members. And actually, the new members that we -- just joined the plans, which were fairly significant, we're seeing actually better utilization than the concurrent members, so that gives us comfort that there wasn't an issue with any of the markets that we grew in. A lot of the deep dives that we're doing, and there's a lot of work that we're trying to pull together, would suggest that there are some respiratory issues that we're facing. So that lead us somewhat to a conclusion that it's maybe a longer extension of the flu, but a lot of work needs to be done to get our arms around it. But we feel very confident about how it's progressing, and we feel good about a lot of the things that we do from a process perspective. This looks like an isolated incident."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay, that's helpful, Jim. And I guess, just maybe help us understand the magnitude here. If you take holistically this uptick in inpatient utilization but then lower outpatient and Rx in-line, and maybe it's just flu, I mean, if these were to persist thr",75,"Okay, that's helpful, Jim. And I guess, just maybe help us understand the magnitude here. If you take holistically this uptick in inpatient utilization but then lower outpatient and Rx in-line, and maybe it's just flu, I mean, if these were to persist through April, May, June, is this enough to change guidance? Or is this just something that's the pressure point and the reason we're still comfortable in a relatively wide range of EPS?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Yes, Josh, I would say, if this persists as we see it, it's not something that would impact guidance, but it's something that we watch very closely. Obviously, to the extent there was a continued uptick and a greater uptick, that's something that would ha",54,"Yes, Josh, I would say, if this persists as we see it, it's not something that would impact guidance, but it's something that we watch very closely. Obviously, to the extent there was a continued uptick and a greater uptick, that's something that would have an impact, but we're not seeing that right now."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from David Windley from Jefferies.",9,"Your next question is from David Windley from Jefferies."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm going to shift over to HumanaOne. I wanted to understand, if you were changed in, or a lack of change in, age distribution in that book of business in the slide that you presented to us last quarter, yet fairly significant change in metal tier distrib",63,"I'm going to shift over to HumanaOne. I wanted to understand, if you were changed in, or a lack of change in, age distribution in that book of business in the slide that you presented to us last quarter, yet fairly significant change in metal tier distribution, if essentially that adverse selection had anything to do with your additional reliance on 3Rs."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","It's something we continue to evaluate. We certainly evaluate all of our metal tiers and try to understand where the utilization is coming from, particularly in Georgia, where we've seen that. I think it's fair to say that we're going to continue to evalu",102,"It's something we continue to evaluate. We certainly evaluate all of our metal tiers and try to understand where the utilization is coming from, particularly in Georgia, where we've seen that. I think it's fair to say that we're going to continue to evaluate, as we go into 2016, our participation in the various metal tiers. And certainly, our pricing will reflect the increased morbidity that we're seeing in that block. I would also say that the out-of-network utilization is something that we think we can address in short order, and so that will not be a recurring issue going forward."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","And on the out-of-networks, just to follow up on that. Is that something where you were essentially only lightly enforcing the existing policy or rule and now you're going to more stringently enforce? Or do you actually have to change the policy? And is t",50,"And on the out-of-networks, just to follow up on that. Is that something where you were essentially only lightly enforcing the existing policy or rule and now you're going to more stringently enforce? Or do you actually have to change the policy? And is that possible into a year?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I would say the former. It's something that we lightly enforces as we're coming into this program with a new product and with new customers. It was something that they were going to get accustomed to the product design over the next few months. It's somet",141,"I would say the former. It's something that we lightly enforces as we're coming into this program with a new product and with new customers. It was something that they were going to get accustomed to the product design over the next few months. It's something that we will enforce, the policy that exists. And that really, as I said in my remarks, goes both to working with providers -- or I should say, the out-of-network providers in some of the reimbursement levels that we pay them, as well as educating our customers as to the product that they bought. We believe strongly that the strategy that we've pursued is one that allows our customers to have a very affordable and compelling product. And as we educate them, we think we'll be able to get that out-of-network utilization in under control."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from A.J. Rice with UBS.",10,"Your next question comes from A.J. Rice with UBS."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm going to go back to the comments that Bruce have made about there being some pressure from threshold eliminations on the Stars program. Can you give us a little more color on how significant that would be? And are we talking about something that would",70,"I'm going to go back to the comments that Bruce have made about there being some pressure from threshold eliminations on the Stars program. Can you give us a little more color on how significant that would be? And are we talking about something that would impact you essentially in 2017? Is that the right way to think about it? Or is there any reason it would impact earlier?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","This is Jim Murray. It would be 2017. And as many of you know, we're in the process today and for the next several weeks of finalizing a lot of the work related to benefit year 2017. The threshold elimination puts a little bit of pressure, and what that w",175,"This is Jim Murray. It would be 2017. And as many of you know, we're in the process today and for the next several weeks of finalizing a lot of the work related to benefit year 2017. The threshold elimination puts a little bit of pressure, and what that would translate into is the number of members that are enforced our greater plans. A lot of the feedback that we're getting, we have a team of people that comes before us every Friday to talk about the progress, that we're making a lot -- around a lot of the tactical steps that are a part of this whole process that goes over this 2-month period. And we feel very good about where we are positioned. And some pressure related to the elimination, by CMS, of the threshold but, frankly, feel pretty good about how things are playing out this year. And we should be favorably positioned relative to the competition because of a lot of the good work that we do around the Stars program."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","And A.J., I think it's just important to keep in mind that it is a relative measurement. And so our performance is highly predicated on everyone else's performance. And I think, as investors have seen over the past few years, our clinical capabilities has",71,"And A.J., I think it's just important to keep in mind that it is a relative measurement. And so our performance is highly predicated on everyone else's performance. And I think, as investors have seen over the past few years, our clinical capabilities has really outperformed the industry as a whole. And we continue to be confident that we'll be able to continue to outperform even as these changes persist."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Andrew Schenker with Morgan Stanley.",10,"Your next question is from Andrew Schenker with Morgan Stanley."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Yes, I was just hoping to follow up on your comments around maybe some of the moving parts in guidance since we all last spoke. So it sounds like the Concentra deal, as you kind of point out in the press release, well, originally is going to be about an $",120,"Yes, I was just hoping to follow up on your comments around maybe some of the moving parts in guidance since we all last spoke. So it sounds like the Concentra deal, as you kind of point out in the press release, well, originally is going to be about an $0.11 headwind turning this year. You also kind of called out around the pressure on the impact from share repurchases related to the stock appreciation here. Now looking at guidance, it seems like tax rate may have come down a little bit. Just curious what some of the other moving parts where that led you feel confident to maintain your guidance range maybe versus where it was the last quarter."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, I think you outlined some of the major issues that we're focused on. And Concentra will pressure earnings by $0.11. The share repurchase and tax rates and the like, it's probably about $0.04, so it's sort of a $0.15 headwind coming into this quarter",106,"Well, I think you outlined some of the major issues that we're focused on. And Concentra will pressure earnings by $0.11. The share repurchase and tax rates and the like, it's probably about $0.04, so it's sort of a $0.15 headwind coming into this quarterly call. Again, I -- we feel comfortable about reiterating our guidance of $8.50 to $9. And really, what's going to drive that performance, as we said to the first question, is where does utilization ultimately end up. And right now, we feel good about where we are, but that's something we're very focused on that will ultimately drive the year's numbers."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think the important point on the Concentra sale is it is a timing issue for us versus a long-term business problem. And as we think about the sale, we think about it as that we are really allowing the company to redeploy assets that will advance us stra",102,"I think the important point on the Concentra sale is it is a timing issue for us versus a long-term business problem. And as we think about the sale, we think about it as that we are really allowing the company to redeploy assets that will advance us strategically at a price that we feel is -- was a very good value for what we're doing. And now what we can do is take that and redeploy it, whether it's in capital structure alterations such as stock buybacks or acquisitions that will be more accretive long term and strategically much stronger."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Maybe if I can just squeeze one more in real quick. The Healthcare Services segment specifically here, a lot of moving parts related to Concentra, as well as your health -- home health acquisition. If you could just maybe talk about how those kind of offs",91,"Maybe if I can just squeeze one more in real quick. The Healthcare Services segment specifically here, a lot of moving parts related to Concentra, as well as your health -- home health acquisition. If you could just maybe talk about how those kind of offset each other, as well as maybe membership growth that allowed you to kind of maintain revenue guidance. And it seems like the only impact to pretax results was related to the pretax gain. So just making sure I understand the moving parts there as well."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Sure. Well, as you'll see in Healthcare Services segment guidance, we did adjust the revenue numbers and the like to comport with the divestiture of Concentra. I would say more broadly that, as I said in my remarks, that business is performing extremely w",129,"Sure. Well, as you'll see in Healthcare Services segment guidance, we did adjust the revenue numbers and the like to comport with the divestiture of Concentra. I would say more broadly that, as I said in my remarks, that business is performing extremely well. Membership is growing pretty dramatically based on largely our Medicare Advantage and PDP growth. But we're also seeing better engagement with our members both from a mail-older perspective on the pharmacy, which is very important, but also with Humana At Home as our analytical capabilities continue to identify people who would benefit from our Humana At Home capabilities. And so the combination of those is really driving that performance. So we feel very good about the range we have out there for Healthcare Services pretax."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Matthew Borsch with Goldman Sachs.",10,"Your next question is from Matthew Borsch with Goldman Sachs."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Yes, if I could ask a question about the individual market, just with 2 parts. Number one, the extent to which you're seeing inflow of new members coming into the exchanges generally for this year. A peer company of yours earlier today talked about seeing",72,"Yes, if I could ask a question about the individual market, just with 2 parts. Number one, the extent to which you're seeing inflow of new members coming into the exchanges generally for this year. A peer company of yours earlier today talked about seeing less inflow than they had expected. Secondly, just on Georgia, how you reprice in that market and avoid getting stuck in sort of an adverse selection spiral."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think -- as far as new members, I think really it's consistent with what we expected in terms of coming into the market and actually feel reasonably good about the overall pool of what we received. With Georgia, there's no doubt, Matt, that that's somet",98,"I think -- as far as new members, I think really it's consistent with what we expected in terms of coming into the market and actually feel reasonably good about the overall pool of what we received. With Georgia, there's no doubt, Matt, that that's something that we're very focused on as you put in higher price increases or you're going to attract the wrong members. Part of it is going to go to product design and the metal tiers that we participate in, and so we're very cognizant of that risk and we're going to price appropriately."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Peter Costa with Wells Fargo Securities.",11,"Your next question comes from Peter Costa with Wells Fargo Securities."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Getting back to the individual business again. Why do you think you had the problem in Georgia? One of your competitors reported earnings earlier that has a number of low-priced silver plans in Georgia and didn't seem to share the problem that you guys ar",89,"Getting back to the individual business again. Why do you think you had the problem in Georgia? One of your competitors reported earnings earlier that has a number of low-priced silver plans in Georgia and didn't seem to share the problem that you guys are having there. Do you think it's local market related to you? Is it some cost disadvantage that you have in Georgia? And how do we avoid this from happening in another state down the road when the risk corridors and risk reinsurance goes away?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Peter, this is Jim. I'll take your question. And we wondered how long before you would dial in. With respect to Georgia, as Brian said earlier, one of the things that we did at the very beginning was to take our individual legacy business and do relativit",291,"Peter, this is Jim. I'll take your question. And we wondered how long before you would dial in. With respect to Georgia, as Brian said earlier, one of the things that we did at the very beginning was to take our individual legacy business and do relativities to our smaller Group block of business because that was a guarantee issue population. We thought that was fairly close to what might ultimately happen on the exchanges. And after that, and that was done local market by local market, we evaluated morbidities across a national basis with the help of an outside consulting actuarial firm. And as a result of that overall evaluation on a -- from a national perspective, we've lowered some of our markets' expected morbidities. And with respects to Georgia, while other markets turned out just fine relative to that pricing philosophy, Georgia didn't. Another part of the Georgia issue has to do with the platinum plans, which you've asked about in the past. One of the things that we're seeing with the platinum plans is that the philosophy or the strategy that we've enumerated in the past with you and others is that you need to have documentable risk conditions for the members that are heavier utilizers. And as we study the Georgia population as we're doing some of our risk adjustment work, we're seeing that the Georgia population, although heavier utilizers, don't have documentable risk conditions, which doesn't allow us then to get risk adjustment for them. And as a result of that, as Brian said, not only in Georgia but also in other states, we're evaluating that requirement as it respects our platinum plan strategies going forward. And you'll see us take some actions relative to that."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","That's helpful. And what is your strategy for avoiding this going forward in other states?",16,"That's helpful. And what is your strategy for avoiding this going forward in other states?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, now, we have a lot more actual claims information on which to set pricing. And so as we've done with all of our other products over the years, we're using actual claims to set our pricing and so our pricing will be consistent with our desire that th",115,"Well, now, we have a lot more actual claims information on which to set pricing. And so as we've done with all of our other products over the years, we're using actual claims to set our pricing and so our pricing will be consistent with our desire that this block of business will produce a satisfactory return. A lot of what we've done up to this point has been models and estimates based upon other lines of business. Now that we've gotten some real claims information relative to not only '14 but '15, that's how we'll set our pricing going forward. And we feel very confident in our ability to properly set the right rates."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Will you offer platinum plans next year?",7,"Will you offer platinum plans next year?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","We're going to evaluate that market by market. And to the extent that it doesn't make sense because of what I talked about relative to documentable risk conditions, we'll evaluate that and will act accordingly.",36,"We're going to evaluate that market by market. And to the extent that it doesn't make sense because of what I talked about relative to documentable risk conditions, we'll evaluate that and will act accordingly."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Kevin Fischbeck with Bank of America.",11,"Your next question comes from Kevin Fischbeck with Bank of America."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Just wanted to ask a little bit about the commentary on the Medicaid side of the business. The company seems to be more aggressively pursuing RFPs, I guess, as you have in the past. Can you talk a bit about your view kind of what's changed in the last cou",86,"Just wanted to ask a little bit about the commentary on the Medicaid side of the business. The company seems to be more aggressively pursuing RFPs, I guess, as you have in the past. Can you talk a bit about your view kind of what's changed in the last couple of years? And you've pursued RFPs in a couple of different ways, outright or through joint ventures and things like that, so how do you think about the form of these types of participation might take?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I don't think our posture has changed relative to what we look at going forward. I think we continue to believe a partnership model in Medicaid makes sense in most states, if not all states, and we will continue to do that. We do look at states where we h",127,"I don't think our posture has changed relative to what we look at going forward. I think we continue to believe a partnership model in Medicaid makes sense in most states, if not all states, and we will continue to do that. We do look at states where we have existing membership, and as their RFPs come out, we want to participate in those RFPs. And that's really has been a standard direction and strategy for us. And our existing Medicaid results continue to meet expectations and continues to grow quite nicely. And so as we look at that going forward, we continue to believe that the Medicaid platform is a platform that has a partnership model in states that we are operating at within today."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Sarah James with Wedbush.",9,"Your next question comes from Sarah James with Wedbush."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I wanted to go back to the out-of-network utilization portion of the 3R boost. It sounded like this was mainly something that pertained to new members transitioning on to an exchange product. And there has been some stricter network enforcement going on l",102,"I wanted to go back to the out-of-network utilization portion of the 3R boost. It sounded like this was mainly something that pertained to new members transitioning on to an exchange product. And there has been some stricter network enforcement going on lately and, I guess, going forward, so should I think about this as really dipping [ph] into the 3Rs for just the first quarter and that adjusts going forward? Or is this something that's going to continue on through the year? And how can you modify your benefit designs in '16 in a way that would improve this scenario?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, I would say it's going to impact the 3Rs for this year just given where we are with our performance and the like; that when people go out of network, those are higher cost than we had anticipated, and that drives the receivables. As I mentioned in m",143,"Well, I would say it's going to impact the 3Rs for this year just given where we are with our performance and the like; that when people go out of network, those are higher cost than we had anticipated, and that drives the receivables. As I mentioned in my remarks, we are working with these out-of-network providers both in terms of the reimbursable fees that we pay them and the fee schedules, contracting with them and the like. And it's also a matter of educating our members as to their product -- the product that they have. I would say we believe very deeply in the strategy of having these high-value networks that allows us to drive very affordable and attractive pricing to our members. And so those are really the puts and takes. It's a combination of provider and member education, so..."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","So it's more education and less of financial incentives...",10,"So it's more education and less of financial incentives..."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, I would say, with the providers, there's -- there will be financial impacts and financial incentives to ensure that we pay the appropriate levels of reimbursement for our -- for what we call our nonpar or nonparticipating providers. I should note it",141,"Well, I would say, with the providers, there's -- there will be financial impacts and financial incentives to ensure that we pay the appropriate levels of reimbursement for our -- for what we call our nonpar or nonparticipating providers. I should note it's a small number of members that are utilizing the benefit out of network. And to some extent, there might be some product design in terms of higher out-of-pocket costs for members who tend to go out of network, and that's something that we would be evaluating for next year. But I think, the combination of provider education, provider contracting as well as member education and some tweaks in the product design, it's a problem that we think we can get our head around and solve for next year and, frankly, the back half of this year as well."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Scott Fidel with Deutsche Bank.",10,"Your next question is from Scott Fidel with Deutsche Bank."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Just wanted to stick on the individual business. And I know you were talking about Georgia specifically but just interested in how much you think you're going to need to be raising premiums on the exchange business more broadly. If we look at your 3Rs acc",130,"Just wanted to stick on the individual business. And I know you were talking about Georgia specifically but just interested in how much you think you're going to need to be raising premiums on the exchange business more broadly. If we look at your 3Rs accruals now for this year, they're right around $0.5 billion for 2015. And I would calculate that, on your sort of ACA-compliant individual business, that equates to around 13% of revenues. So given that both reinsurance and risk corridors really sort of scale away over the next year or 2, just help us think about how much sort of excess premium increases you're going to need to be implementing in order to reflect the -- this, the expiration of those 2 Rs of the 3Rs."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I mean that's not -- a specific number, for obviously competitive reasons, we wouldn't want to comment on right now. I would say that, certainly, we have the 3Rs squarely in mind as we price for next year. We recognize there's 1 more year to go here with",113,"I mean that's not -- a specific number, for obviously competitive reasons, we wouldn't want to comment on right now. I would say that, certainly, we have the 3Rs squarely in mind as we price for next year. We recognize there's 1 more year to go here with 2 of the 3Rs. And so we're going to price such that, as I said in my remarks, we can earn a attractive return on capital in 2016 and beyond. And so we understand the dynamics of the market and the 3Rs and the pricing required to do that, and we'll take the necessary steps to make sure we get the right financial return."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","To Brian's earlier point, many of the markets are performing well, and we've got some problems in the State of Georgia that were -- we plan to address with our pricing and product design.",35,"To Brian's earlier point, many of the markets are performing well, and we've got some problems in the State of Georgia that were -- we plan to address with our pricing and product design."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. And then just quickly just on the Medicare hospital admissions. How geographically broad based are you seeing that? I mean I'm just trying to tie that into the comments from CMS on their final 2016 rates call, where they said that their actuaries ha",80,"Okay. And then just quickly just on the Medicare hospital admissions. How geographically broad based are you seeing that? I mean I'm just trying to tie that into the comments from CMS on their final 2016 rates call, where they said that their actuaries have also seen some flattening-out of the admissions trends. And I would assume that CMS was highlighting that they were probably more of a broader base, so just interested geographically on how much you're seeing that."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think, as Jim said earlier, we wouldn't call any specific geographies. Where we were very focused was to see where we grew in particular markets and whether that more outsized growth was the cause of this, the slightly higher admits. And while we haven'",65,"I think, as Jim said earlier, we wouldn't call any specific geographies. Where we were very focused was to see where we grew in particular markets and whether that more outsized growth was the cause of this, the slightly higher admits. And while we haven't seen that, they're actually running pretty favorably. So I would suggest it's a broad-based phenomenon that we're watching very closely."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Ralph Giacobbe with CrÃ©dit Suisse.",10,"Your next question comes from Ralph Giacobbe with CrÃ©dit Suisse."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Switching a little bit. You guys reclassified segments, and I guess, within the Group book, you've seen enrollment declines. I guess the question is, how committed are you to this business, I guess, going forward? Is there any strategic overview being con",114,"Switching a little bit. You guys reclassified segments, and I guess, within the Group book, you've seen enrollment declines. I guess the question is, how committed are you to this business, I guess, going forward? Is there any strategic overview being contemplated for this segment? And I guess, step really [ph] just on of the PBM, just want to clarify. You talked about sort of a full debrief on the 3Q call in November. Just hoping to get a little more clarity on that. Is that just a final decision you expect at that point on whether you kind of keep it or come up with some sort of outsourcing arrangement or the like?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","To your question on enrollment declines, we made the strategic decision a year or so ago. And I think we talked about that, that with the large Group business, we were going to wind that down over the next several years because we are not a national playe",279,"To your question on enrollment declines, we made the strategic decision a year or so ago. And I think we talked about that, that with the large Group business, we were going to wind that down over the next several years because we are not a national player and we can't compete in that space. But we are focused on what we call our sweet spot of smaller case sizes. And over the last 6 months, we've performed reasonably well with our sweet spot focus. You may recall that, in the fourth quarter, we grew very nicely with our small or focused business. This past quarter, we have seen some shrinkage in our fully insured smaller-case-size membership as a lot of our competitors are implementing their new rates relative to community rating. And we're seeing a little bit of an aggressive posture in some of the states that we do business. That will ultimately change over time, and we think that, that will work itself out. We feel very confident with our focus on the smaller case size. Over the next several years, we're going to be evaluating our Group business and, again, feel very good about its prospects for continued profitability. And it serves very nicely as a complement to our focus on local market scale. We talk a lot about that with our Medicare business, our individual business, our Medicaid business and our Group business in certain of our -- what we refer to as bold-move markets. So again, we feel very confident in our ability to compete and win in the smaller case size, and hopefully, you'll see that play out over the next several quarters."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think, even as the results showed this quarter, we really have a 3-pronged approach within Group. One is around continuing to increase our efficiency within the Group sector, and you can see that as you see our cost ratios coming down. Second is to focu",154,"I think, even as the results showed this quarter, we really have a 3-pronged approach within Group. One is around continuing to increase our efficiency within the Group sector, and you can see that as you see our cost ratios coming down. Second is to focus on where we probably have better value proposition, and that's in the small Group, as what Jim just talked about, our sweet spot, and begin to start exiting relationships that are not profitable for us. And that traditionally is the larger ASO model. And then the third is to continue to migrate customers to more of a consumer choice model within the markets that we are at, and that would be both the private exchange and public exchanges, as we see that being both a long-term trend and, frankly, I think, where we can even add more value with our Retail capabilities that we've had in the past."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","That's helpful. And just on the PBM?",8,"That's helpful. And just on the PBM?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","As we said, the PBM, we look into -- we're going to evaluate, and it's kind of under a continued evaluation. We've provided some updates in the past, but we -- the full update will be in the third quarter of this year.",43,"As we said, the PBM, we look into -- we're going to evaluate, and it's kind of under a continued evaluation. We've provided some updates in the past, but we -- the full update will be in the third quarter of this year."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Ana Gupte with Leerink Partners.",10,"Your next question is from Ana Gupte with Leerink Partners."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","So I just want to make sure I understand this. I'm a little confused with everything. I'm getting a lot of questions from investors, so I'm pretty confused as well. On Retail MLR, what exactly -- is the underlying Medicare MLR -- okay, x BYD, and the sort",89,"So I just want to make sure I understand this. I'm a little confused with everything. I'm getting a lot of questions from investors, so I'm pretty confused as well. On Retail MLR, what exactly -- is the underlying Medicare MLR -- okay, x BYD, and the sort of late-quarter potential uptick you're seeing? And is the deterioration, which was not great, but it is deteriorating because your HumanaOne individual public exchange product is now going to be much more reliant on reinsurance and you're having all these issues?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Yes, again, if you -- Ana, if you look at our retail MERs for the quarter and you adjust them for prior period, they're actually down. So I think that's important to note. As we said, prior period did have a pretty material impacts on our numbers. A lot o",101,"Yes, again, if you -- Ana, if you look at our retail MERs for the quarter and you adjust them for prior period, they're actually down. So I think that's important to note. As we said, prior period did have a pretty material impacts on our numbers. A lot of it was expected. Some of it wasn't, related to the flu and the like. But when you look at the MERs, we feel pretty good about where we are on an incurred basis from an MER perspective. And as I said, they're actually down. So I hope that answers your question."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. So MA is in good place. On individuals, did you see any improvements in your off-exchange ACA-compliant type MLR at all? Your competitors seem to be seeing what they said they would see. And so net-net, on individual, you had said you'd see margin e",59,"Okay. So MA is in good place. On individuals, did you see any improvements in your off-exchange ACA-compliant type MLR at all? Your competitors seem to be seeing what they said they would see. And so net-net, on individual, you had said you'd see margin expansion x exchange, publicly exchanges. What's going on in the rest of the book?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, again, we don't break out our ACA-complaint off-exchange and on-exchange. I think, when you adjust for the 3Rs, our MER is in line with our expectations, which is why, as I said in my remarks, that we're going to break even or better for 2015. That",73,"Well, again, we don't break out our ACA-complaint off-exchange and on-exchange. I think, when you adjust for the 3Rs, our MER is in line with our expectations, which is why, as I said in my remarks, that we're going to break even or better for 2015. That still is the case. But the 3Rs clearly help us in that regard, and it's higher than we anticipated for the reasons that we went through."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay, one final one, if I may. So then, on HumanaOne, might you be in a place where you had some adverse selection last year? And as you're raising prices, are you seeing more of a deterioration in that book because anyone who can afford or is relatively",63,"Okay, one final one, if I may. So then, on HumanaOne, might you be in a place where you had some adverse selection last year? And as you're raising prices, are you seeing more of a deterioration in that book because anyone who can afford or is relatively healthy migrates someplace else, and so you might have challenges just turning around the book?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","As with respect to the State of Georgia, which we've talked about a couple of times, I wouldn't have said that it was adverse selection as opposed to the health condition of the entire population. We just have to price reflective of the health condition.",103,"As with respect to the State of Georgia, which we've talked about a couple of times, I wouldn't have said that it was adverse selection as opposed to the health condition of the entire population. We just have to price reflective of the health condition. And that may cause some of those members to move on to other plans, but we've got to get our pricing commensurate with the risk conditions that we're assuming. And we think that we've got a pretty good plan in place not only to increase pricing but also evaluate some of the products that are in the marketplace."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","And your final question is from Christine Arnold with Cowen.",10,"And your final question is from Christine Arnold with Cowen."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm trying to sort through what belongs in this year versus last year. Was there any net prior-period negative developments in the first quarter of this year related to last year in any products?",35,"I'm trying to sort through what belongs in this year versus last year. Was there any net prior-period negative developments in the first quarter of this year related to last year in any products?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I'm not sure I understand the question. There was -- the prior-period development was positive this quarter based on 2014 and prior results. It was less positive than it was last, the first quarter in 2014. That was largely expected for the reasons I disc",99,"I'm not sure I understand the question. There was -- the prior-period development was positive this quarter based on 2014 and prior results. It was less positive than it was last, the first quarter in 2014. That was largely expected for the reasons I discussed, i.e. it was a very high-PPD quarter in the first quarter of '14 and we implemented some claims processing changes with front-end review and Medicare that drove some of the change. Some of that was unexpected, but -- so there is positive PPD in our numbers, just less than there was last year."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. And then payables versus premium. I agree we should exclude PDP, but if we exclude PDP premiums, your payables versus premiums are still upside-down in the first quarter. Now this could be because you've got more capitated costs. It could be because",100,"Okay. And then payables versus premium. I agree we should exclude PDP, but if we exclude PDP premiums, your payables versus premiums are still upside-down in the first quarter. Now this could be because you've got more capitated costs. It could be because of other factors. Can you help me understand why? If you're seeing an increase in utilization, I would think you'd be booking more payables [indiscernible] premiums. And you've got these issues with the individual books, but it looks like that's not happening. So can you help me sort through what other factors might be accounting for that?"
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","That comparison, change in premium versus change in claims payables, as we've discussed in the past, is not something that we focused on. There are a lot of moving pieces that go into that number. As we've said with regard to utilization, I wouldn't be as",282,"That comparison, change in premium versus change in claims payables, as we've discussed in the past, is not something that we focused on. There are a lot of moving pieces that go into that number. As we've said with regard to utilization, I wouldn't be as -- I wouldn't have made the statement as boldly as you just made it with regard to overall utilization. What we've pointed out, because it's important that we point it out to be fully transparent, is that we have seen that slight increase in admits over the recent weeks. And it's something that we're waiting to see how it plays through our claims lags over the coming months. As you know, it takes a few months for those to work through, but I wouldn't have made the overall statement that utilization is up. Remember that our admits are actually down year-over-year. Our trend benders are working, as we've said. And so I wouldn't read into it anything more than that. As you look for balance sheet quality and cash flow quality, the claims -- the process claims and unprocessed claims on a days -- DCP basis were actually up, which I know is a measure that you and others look at. And when you look at our cash flow for the year, which is where we focus because of the timing of these working capital issues that I went through, other than the 3Rs and, of course, Concentra, we're actually reasonably in-line. As you know, we took up our cash flow last quarter. And I think, were it not for some of these other adjustments that I just discussed, we'd be in pretty good stead there."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","We appreciate the support the shareholders are providing us. We recognize that this quarter is a complicated quarter as a result of our Concentra sale, as a result of some of the changes in the comparison, but we do believe it is a quarter that continues",101,"We appreciate the support the shareholders are providing us. We recognize that this quarter is a complicated quarter as a result of our Concentra sale, as a result of some of the changes in the comparison, but we do believe it is a quarter that continues to reconfirm the organization's strategy around our growth in Retail and, in addition, the integrated delivery model.
So in conclusion, as always, we thank our 60,000 associates that help us bring these results to life every day. And we appreciate the shareholder support.
So thank you, and we look forward to continuing our conversations later."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Thank you.",2,"Thank you."
29618,278392395,797305,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Good morning. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Humana First Quarter 2015 Earnings Call. [Operator Instructions] Thank you.I will now turn the call over to Ms. Regina",51,"Good morning. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Humana First Quarter 2015 Earnings Call. [Operator Instructions] Thank you.
I will now turn the call over to Ms. Regina Nethery. You may begin your conference."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning.In a moment, Humana's senior management team will discuss our first quarter results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be Bruce Broussard, Humana's President and Chief Ex",343,"Thank you, and good morning.
In a moment, Humana's senior management team will discuss our first quarter results and our updated earnings outlook for 2015. Participating in today's prepared remarks will be Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Senior Vice President and Chief Financial Officer. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Joining Bruce and Brian for the Q&A session will be Jim Murray, Executive Vice President and Chief Operating Officer; and Christopher Todoroff, Senior Vice President and General Counsel. We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts.
This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. This call is also being simulcast via the Internet, along with a virtual slide presentation. An Adobe version of today's slide deck has been posted to the Investor Relations section of Humana's website.
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in this morning's earnings press release as well as in our filings with the Securities and Exchange Commission. Today's press release, our historical financial news releases and our filings with the SEC are all available on Humana's Investor Relations website.
Call participants should also note that today's discussion and slide presentation include financial measures that are not in accordance with generally accepted accounting principles. Management's explanation for the use of these non-GAAP measures is included in today's slide presentation, as well as a reconciliation of GAAP to non-GAAP financial measures. Finally, any references to earnings per share or EPS made during this morning's call refer to diluted earnings per common share.
With that, I'll turn the call over to Bruce Broussard."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Good morning, everyone, and thank you for joining us.This morning, Humana announced first quarter 2015 adjusted earnings per share of $2.47, up 5% from the first quarter of last year. Our pretax earnings of $744 million were a record high and we believe",1367,"Good morning, everyone, and thank you for joining us.
This morning, Humana announced first quarter 2015 adjusted earnings per share of $2.47, up 5% from the first quarter of last year. Our pretax earnings of $744 million were a record high and we believe are a clear demonstration on the progress we continue to make as a company. Further, we continue to have confidence in our full year guidance for adjusted earnings of $8.50 to $9 per share.
Our more significant achievements during the quarter included substantial membership growth in our Medicare Advantage, stand-alone PDP and HumanaOne products; the recent launch of our population health technology business, Transcend Insights; announcement of the pending sale of our Concentra business; and completion of our $500 million accelerated share repurchase program. I'll begin with our Medicare Advantage growth.
As we shared with you last quarter, we experienced another successful Medicare enrollment season for 2015. Individual Medicare Advantage membership at March 31, 2015, was up 11% versus the end of the fourth quarter 2014 up 14% year-over-year. We continue to see the positive impact for our members of stability in our value proposition as well as high Star quality ratings. A recent McKinsey study on the 2015 Star ratings concludes that HMO plans perform best on an enrollment-weighted basis. Approximately 56% of our individual members are in HMO plans compared to 53% a year ago. Further, the McKinsey study indicates that plans built around integrated delivery networks achieve higher average Star ratings.
CMS recently eliminated certain fixed thresholds for 4-Star ratings for 2017 bonus year. These changes may result in some pressure on our overall Star ratings, but we believe we will sustain our solid competitive advantage. We expect we will maintain our high-quality ratings due to our successful integrated care delivery model. Our model includes use of data analytics to engage members in preventative measures and wellness programs that close clinical gaps in care.
In sum, we believe the combination of a solid value proposition and a -- high-quality ratings are critical to attracting new membership and retaining our existing membership base. Our projected 2015 net new membership gains of approximately 12%, including a voluntary retention rate of approximately 90%, are all helping to validate this belief.
CMS has also recently released its final Medicare rates for 2016. While we were encouraged by the average rate increase for the first time in 7 years, this average still lags fee-for-service medical cost trends. Additionally, CMS' transition to the new risk adjustment model will negatively impact certain of our markets that are leading the country in value-based reimbursement methods and holistically assisting members with multiple complex chronic conditions, both which are key goals for CMS. As we prepare our Medicare bids for 2016, we will seek to minimize any disruption that rate changes may cause to Medicare beneficiaries while holding firm on our 4.5% to 5% pretax margin target. The continuing investment in our clinical model are expected to provide some offsets to rate pressures that will vary, of course, from market to market. Those investments were highlighted this month by Humana At Home's acquisition of Your Home Advantage, a leading provider of nurse practitioner in home visits. Additionally, we believe our focus on the consumer experience and our proprietary market point distribution channel will be important elements in solidifying our relationship with our members as we face these rate challenges at the market level.
Turning to our stand-alone PDP offerings. We also experienced significant growth for these products, with membership up 10% since the end of 2014 and 14% to the first quarter of last year, primarily in our low-price-point offerings.
I now will spend some time on our investments in health care exchanges and state-based contracts.
We're pleased that HumanaOne membership has continued to grow nicely. While we will continue to project at least breakeven results for our HumanaOne business, our projected increased reliance on the 3Rs is driven primarily by the results for the State of Georgia and our out-of-network provider usage. We believe both are isolated and addressable. Brian will discuss each of these factors in his remarks.
Entering a new customer segment is never an easy task. However, we believe that health care exchanges are a leading example of the ongoing movement to the Retail model, where we have been so effective in Medicare. We continue to be highly targeted in terms of where we will participate in health care exchanges, with a strong emphasis on current Medicare Advantage markets, to enable customer migration as members' life situations change. Our expansions into health care exchanges and our state-based contracts are deepening our partnership with local providers -- local market providers as we develop local market scale through multiple product offerings. State-based Medicaid membership, which now includes those members associated with dual demonstration programs, is up significantly both on a sequential basis and year-over-year. We continue to monitor the RFP pipeline and plan to pursue other state-based opportunities later in 2015.
These opportunities would not be as viable if it weren't for our integrated care delivery model. Importantly, we continue to show progress in key integrated care delivery model metrics. Some examples include the number of individual Medicare Advantage members covered by value-based arrangements is now more than 54%. This is particularly encouraging giving the substantial increase in membership this quarter. Membership in our Humana Chronic Care Program is up 10% since the end of the year and 56% versus the prior year. Adoption of mail-order pharmacy among our members continues to grow as we highlight this benefit more fully during the sales process and welcome calls. Individual Medicare Advantage mail-order penetration is now, on an average, approaching 35%.
We continue to focus on reaching out to members with gaps in care and have sent over 4 million proactive messages to 2.5 million members to prevent gaps in care. These actions have resulted in a gap closure rate of more than 30%.
As a leader in both the development and execution of value-based payment models and technology-driven population health management analytics, we support trends that encourage care coordination across all payers. In that context, this quarter, we launched Transcend Insights, which leverages the population health capabilities we have developed in our Medicare Advantage business. Our goal is to provide payer-agnostic tools to our provider partners, allowing more of our members to be in value-based reimbursement models. As we've shared with you in the past, value-based arrangements have proven to lead to higher HEDIS scores, lower medical cost and higher membership satisfaction.
Before closing, I'd like to spend a moment on our recently announced sale of Concentra.
As we've said in previous calls, we review our various businesses on an ongoing basis to ensure each earns its cost of capital and is aligned with our integrated care delivery strategy. The Concentra acquisition was part of a multipronged approach to increase our capabilities of managing risk through primary care physicians. Our subsequent MSO acquisitions and joint venture investments provided a more integrated primary care platform than Concentra. Although it did not ultimately fit strategically, we were able to achieve an attractive price that will result in a gain versus our initial investment. Brian will speak more to the details of this transaction in his remarks.
We expect the transaction will close in the next few weeks. I want to thank all of our Concentra associates for their dedication to the consumer and to our company.
Several of you have asked for an update on our PBM evaluation. That work continues, and we expect to provide a full debriefing on our analysis during the third quarter earnings call in November.
In summary, we believe our robust organic membership and revenue growth, together with our proven superior clinical operating performance and disciplined capital allocation, all come together to provide our sustainable competitive advantage. Excluding the onetime gains that we expect from the Concentra sale, we continue to expect our full year adjusted earnings per share to be in the range of $8.50 to $9 and look forward to providing you updates as the year progresses.
With that, I'll turn the call over to Brian for a more detailed discussion of our financials."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce. And good morning, everyone.As Bruce mentioned, the first quarter of 2015 produced strong results and continues to demonstrate the successful implementation of our integrated care delivery model. The attractiveness of our product offeri",2215,"Thank you, Bruce. And good morning, everyone.
As Bruce mentioned, the first quarter of 2015 produced strong results and continues to demonstrate the successful implementation of our integrated care delivery model. The attractiveness of our product offerings is resonating with our customers, as demonstrated by the continuing increases in our Medicare Advantage, stand-alone PDP and exchange membership.
Consequently, we have raised full year membership expectations for both stand-alone PDP and HumanaOne. Stand-alone PDP is being driven by higher retention that we are seeing post the open-enrollment period, which is largely the results of fewer auto-enrollees being reassigned. I'll speak more to the HumanaOne business shortly. With regard to our Medicare Advantage growth, early indications for our new members are positive as we evaluate individual market growth and performance. Additionally, the growth in our PBM and Humana At Home businesses remains unabated with not only more volume driven by membership growth, but also deeper penetration in terms of increased engagement as well as benefits from scale that are driving results.
First quarter revenues for the Healthcare Services segment rose 26% versus the prior year, and pretax earnings are up 24% year-over-year.
The quarter had several developments that will be the focus of my remarks today. These include the following: the increase in our projected 3R receivables for the year, medical utilization and prior-period development, days in claims payable and cash flows from operations, the earnings implications of the Concentra transaction and capital allocation. Let's begin with our exchange business and the premium stabilization programs commonly called the 3Rs.
Our conviction in our health care exchange strategy remains strong. We continue to focus on our key growth markets by offering high-value networks to drive affordability and access for our customers. We believe that this strategy has been effective in successfully establishing a new growth business while providing a compelling product that our members value. Over time, we believe that HumanaOne will not only contribute meaningfully to our results but it will also, as Bruce emphasized, advance our objectives of local market presence and scale with providers while allowing us to offer a range of products that are relevant to our customers no matter their age or income circumstance.
As with any startup business, we've had our successes as well as our challenges. In terms of successes, our ACA-compliant membership for HumanaOne is up 38% from the end of 2014, well ahead of our previous expectations. This was driven by better-than-forecast sales and lower-than-anticipated attrition. Consequently, we have adjusted our aggregate HumanaOne guidance to reflect higher projected membership in the ACA-compliant business, which we also believe results in us approaching the scale we need for long-term success.
We continue to forecast that we will have at least breakeven results in 2015 and earn a reasonable return on capital in 2016, albeit that achievement of breakeven results this year now includes higher reliance on the 3Rs than previously anticipated coming into 2015. As you've seen from our release, we have increased our net 2015 3R guidance range to $450 million to $550 million, with reinsurance accounting for approximately 75% and risk adjustment and risk corridors accounting for approximately 25% of the total. As we have discussed in the past, there is an interplay between risk adjustment and risk corridors in that, if we don't get the risk adjustment exactly right, a meaningful part of the balance, either positive or negative, is captured through the risk corridors.
As we evaluate our financial performance to date, including runoff claims from 2014, the drivers of the increase in full year receivables related to the 3Rs are quantifiable and addressable. The first 2 Bruce mentioned in his remarks are higher-than-anticipated out-of-network utilization and poor results in our Georgia market. The last driver of the higher receivables is simply a function of having more members than we had previously expected.
I'll start with out-of-network utilization. As the exchanges were rolling out across the nation, we believed there would be a time period during which our members would be getting accustomed to our efficient network products. Consequently, we permitted out-of-network utilization for the small proportion of our members who did not stay in network to avoid disruption, notwithstanding the products designed -- product's design, which underpinned the affordability that our members seek. Our provider network team has thoroughly evaluated our networks in light of our membership levels by market, and we are very satisfied in our level of network adequacy. As a consequence, we are in the process of implementing stricter enforcement of network utilization by working closely with nonnetwork providers as well as educating our members on the products. Higher levels of in-network utilization are anticipated to ensure the continued affordability of our health care exchange offerings as well as aligned with our pricing assumptions for the remainder of the year and for 2016.
After adjusting for the out-of-network usage, our markets across the country, including our largest HumanaOne market in Florida, are performing within expectations with the notable exception of Georgia. One of the challenges we faced in both 2013 and 2014 was the immaturity of the claims data we had available at the time we set our health care exchange pricing for the following year versus what we would have preferred, specifically, more detail regarding statewide market conditions and health status based on significant exchange claims data. To help address this, we juxtaposed the limited Georgia claims data we had against claims data nationally for states that we believe had similar utilization patterns and mix of likely enrollees to derive assumptions around the population health of each state and, in turn, set our pricing. Recent actuarial claims data for the State of Georgia now indicate that enrollees in the state as a whole are skewing more towards being a less-healthy state population than we had believed and had priced for. Consequently, we are accruing both a risk adjustment and risk corridor receivable.
It's important to recall that this was the original intent behind the premium stabilization programs, namely earlier protection, in this circumstance. We are, of course, incorporating our emerging experience into our actuarial assumptions and are taking the appropriate targeted actions through pricing and product design when we file our 2016 rates in the next few weeks to ensure that Georgia's results will be back on track for 2016 without reliance on the risk corridors.
As I mentioned, the remaining driver of the higher 3R balance relates to higher-than-projected growth of our ACA-compliant business. This will result in higher 2015 receivables than we had expected, primarily associated with reinsurance.
Finally, a quick word on our 2014 3R accruals. As you will see, we have decreased reinsurance by approximately $50 million and have increased our risk corridors by around $40 million as an offset. As we've evaluated the runout of our 2014 claims, fewer of our members than anticipated will hit the reinsurance attachment point, which is the reason we have made this change.
Turning to medical utilization. We are watching very closely the hospital ""inpatient admissions per thousand"" data for our Medicare Advantage business. We have seen some of the hospital published data which suggest higher Medicare usage of inpatient services and have also witnessed in the last number of weeks an uptick in inpatient authorizations. For Medicare Advantage, we have projected a decline year-over-year in hospital admissions, and for the first quarter, we have seen that decline bear out. In other words, our trend benders continue to results in lower admissions. However, during the last weeks of the quarter and into April, we are seeing an elevated level of authorizations for hospital admissions which, although still declining, are slightly higher than we had anticipated. Importantly, we have also seen data throughout the quarter that would suggest our cost per admit is lower than forecast, implying lower-severity conditions are driving the admissions.
While it is too early to draw any conclusions from what I just described, especially as admissions tend to fluctuate, it is something that bears close watching as the actual claims experience develops over the coming months.
As was highlighted in this morning's press release, we did see a lower level of favorable prior-period development than in last year's first quarter. A meaningful portion of the lower prior-period development was anticipated due to the PPD for the first quarter of 2014 having been unusually high and as a result of claims processing changes involving the implementation in early 2014 of a front-end review for Medicare claims. Front-end review enables us to improve the initial accuracy of claim payments, reducing the amount of overpayments recaptured later as part of prior-period development. PPD was also adversely impacted by fourth quarter flu claims that came through in the first quarter of 2015 across our lines of business.
I will now turn to the balance sheet and operating cash flow. I'll start with days in claims payable or DCP.
You will note that we have revised the DCP table to exclude reinsurance associated with the 3Rs. Given that reinsurance reduces benefits expense but does not impact the related benefits payable, it skews DCP trends over the 3-year period of the program.
Days in claims payable during the first quarter of 2015 declined by less than a day, driven primarily by the typical first quarter increase in Part D claims associated with our Medicare Advantage business. That impact is included in the all other category of the DCP roll-forward table in our press release. Recall that our stand-alone PDP business is excluded from our days in claims payable calculation.
Much like our stand-alone PDP offerings, our Medicare Advantage Part D benefit designs generally have the plan picking up substantially all the initial pharmacy claims, but covering less of the benefit as the year progresses. While the pharmacy expense associated with these members is in our DCP calculation, the related payable is relatively small due to the speed of processing pharmacy claims. Higher capitation and provider settlements also resulted in a slight decrease to DCP during the quarter, but importantly, this was more than offset by an increase in unprocessed and processed claims inventories.
Cash flow from operations is down versus the first quarter of 2014, as higher net income was more than offset by working capital items. Specifically, the increase in benefits payable, which accompanies growing membership, was smaller year-over-year due to the lower level of overall growth in average membership given the outsized growth we experienced in 2014. This pressured the cash flow from operations on a comparative basis by approximately $250 million in the quarter. Working capital needs for our growing pharmacy business primarily accounted for the remainder of the delta in the first quarter cash flows.
For the year, our operating cash flow guidance is largely unchanged, other than reducing operating cash flow by guidance -- cash flow guidance by approximately $200 million at the midpoint, primarily reflecting the increase in the 3R receivable that I just discussed previously as well as the pending sale of Concentra.
Before closing, I'll spend just a few minutes on capital allocation and earnings guidance. As Bruce said in his remarks, we announced this quarter the sale of our Concentra business. The timing of the signing of the definitive agreement triggered the need to recognize the gain on the establishment of a deferred tax asset. And thus, the $0.35 per share gain was included in our first quarter GAAP results.
We expect this transaction to close in the next few weeks, so we have included the full impact of the transaction in our earnings guidance both from a GAAP and an adjusted perspective. For GAAP, we are including a total projected gain from the sale in the range of $1.35 to $1.45 per share, including the $0.35 tax gain. On an adjusted basis, excluding this onetime gain, we continue to forecast earnings per share in the range of $8.50 to $9 per share.
The sale of Concentra is expected to generate, net of taxes and deal expenses, approximately $1 billion in net proceeds. Before any anticipated use of these proceeds, the sale will result in $0.11 of 2015 EPS dilution. We continue to look for value-enhancing acquisitions, such as the Your Home Advantage deal we recently announced that will advance our in-home capabilities, as well as pursue additional share repurchase opportunistically. However, given where we are in the year, it is likely that a good portion of this dilution will persist.
With respect to share repurchase, this quarter, we completed our $500 million accelerated share repurchase program. Additionally, holding true on our commitment to buy back $1 billion of stock by June of this year, we have entered into a 10b5-1 plan that we expect will complete that goal. You will note, however, that we have raised our guidance slightly for the average fully diluted share count due largely to the higher-than-anticipated buyback price, which will have a several-cent negative EPS impact.
Finally, our work around optimizing our portfolio continues to ensure that each of our businesses fits strategically and earns its cost of capital. More generally, we are encouraged by our progress and our prospects, all driven by execution around our integrated care delivery strategy. 
With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your first question comes from Joshua Raskin with Barclays.",9,"Your first question comes from Joshua Raskin with Barclays."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I want to talk a little bit about the utilization trends that you guys are monitoring and just better understand what exactly is driving that. I think you mentioned some public data from some of the hospitals, but I have to assume you're going off of more",81,"I want to talk a little bit about the utilization trends that you guys are monitoring and just better understand what exactly is driving that. I think you mentioned some public data from some of the hospitals, but I have to assume you're going off of more of internal data. So is there any specific lines of service? Are there a specific type of lines? Any geographies for these new members? Just any color on where this utilization is coming from."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Josh, it's certainly from our own data that we're seeing a slight uptick in admissions over the last few weeks and into April. There's no specific geography that we would point to. It's something that we continue to evaluate. I would note that, interestin",125,"Josh, it's certainly from our own data that we're seeing a slight uptick in admissions over the last few weeks and into April. There's no specific geography that we would point to. It's something that we continue to evaluate. I would note that, interestingly, not only are the unit costs of these admits lower, which as I said in my remarks, suggests a lower severity of claims, but also our outpatient utilization seems to be down and our pharmacy utilization is in-line. And so it's very early really to ascertain exactly what this is telling us. It's just something that we thought it would be important to communicate because it's something that we're watching very closely and it's something that we always watch very closely."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Josh, just to build on what Brian talked about and the reason that he specifically addressed it in his opening remarks is, as we saw this, we began to dive into a lot of the information relative to new members and what we call concurrent members. And actu",187,"Josh, just to build on what Brian talked about and the reason that he specifically addressed it in his opening remarks is, as we saw this, we began to dive into a lot of the information relative to new members and what we call concurrent members. And actually, the new members that we -- that just joined the plans, which were fairly significant, we're seeing actually better utilization than the concurrent members. So that gives us comfort that there wasn't an issue with any of the markets that we grew in. A lot of the deep dives that we're doing, and there's a lot of work that we're trying to pull together, would suggest that there are some respiratory issues that we're facing. So that leads us somewhat to a conclusion that it's maybe a longer extension of the flu, but a lot of work needs to be done to get our arms around it. But we feel very confident about how it's progressing, and we feel good about a lot of the things that we do from a process perspective. This looks like an isolated incident."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay, that's helpful, Jim. And I guess, just maybe help us understand the magnitude here. If you take holistically this uptick in inpatient utilization but then lower outpatient and Rx in-line, and maybe it's just flu, I mean, if this were to persist thro",75,"Okay, that's helpful, Jim. And I guess, just maybe help us understand the magnitude here. If you take holistically this uptick in inpatient utilization but then lower outpatient and Rx in-line, and maybe it's just flu, I mean, if this were to persist through April, May, June, is this enough to change guidance? Or is this just something that's a pressure point and the reason we're still comfortable in a relatively wide range of EPS?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Yes, Josh, I would say, if this persists as we see it, it's not something that would impact guidance, but it's something that we watch very closely. Obviously, to the extent there was a continued uptick and a greater uptick, that's something that would ha",54,"Yes, Josh, I would say, if this persists as we see it, it's not something that would impact guidance, but it's something that we watch very closely. Obviously, to the extent there was a continued uptick and a greater uptick, that's something that would have an impact, but we're not seeing that right now."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from David Windley from Jefferies.",9,"Your next question is from David Windley from Jefferies."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm going to shift over to HumanaOne. I wanted to understand, if you were changed in -- or a lack of change in age distribution in that book of business in the slide that you presented to us last quarter, yet fairly significant change in metal tier distri",64,"I'm going to shift over to HumanaOne. I wanted to understand, if you were changed in -- or a lack of change in age distribution in that book of business in the slide that you presented to us last quarter, yet fairly significant change in metal tier distribution, if essentially that adverse selection had anything to do with your additional reliance on 3Rs."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","It's something we continue to evaluate. We certainly evaluate all of our metal tiers and try to understand where the utilization is coming from, particularly in Georgia, where we've seen that. I think it's fair to say that we're going to continue to evalu",102,"It's something we continue to evaluate. We certainly evaluate all of our metal tiers and try to understand where the utilization is coming from, particularly in Georgia, where we've seen that. I think it's fair to say that we're going to continue to evaluate, as we go into 2016, our participation in the various metal tiers. And certainly, our pricing will reflect the increased morbidity that we're seeing in that block. I would also say that the out-of-network utilization is something that we think we can address in short order, and so that will not be a recurring issue going forward."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","And on the out-of-networks, just to follow up on that. Is that something where you were essentially only lightly enforcing the existing policy or rule and now you're going to more stringently enforce? Or do you actually have to change the policy? And is t",48,"And on the out-of-networks, just to follow up on that. Is that something where you were essentially only lightly enforcing the existing policy or rule and now you're going to more stringently enforce? Or do you actually have to change the policy? And is that possible intra-year?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I would say the former. It's something that we lightly enforces as we're coming into this program with a new product and with new customers. It was something that they were going to get accustomed to the product design over the next few months. It's somet",142,"I would say the former. It's something that we lightly enforces as we're coming into this program with a new product and with new customers. It was something that they were going to get accustomed to the product design over the next few months. It's something that we will enforce, the policy that exists. And that really, as I said in my remarks, goes both to working with providers -- or I should say, the out-of-network providers in some of the reimbursement levels that we pay them as well as educating our customers as to the product that they bought. We believe strongly that the strategy that we've pursued is one that allows our customers to have a very affordable and compelling product. And as we educate them, we think we'll be able to get that out-of-network utilization in -- under control."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from A.J. Rice with UBS.",10,"Your next question comes from A.J. Rice with UBS."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm going to go back to the comments that Bruce had made about there being some pressure from threshold eliminations on the Stars program. Can you give us a little more color on how significant that would be? And are we talking about something that would",70,"I'm going to go back to the comments that Bruce had made about there being some pressure from threshold eliminations on the Stars program. Can you give us a little more color on how significant that would be? And are we talking about something that would impact you essentially in 2017? Is that the right way to think about it? Or is there any reason it would impact earlier?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","This is Jim Murray. It would be 2017. And as many of you know, we're in the process today and for the next several weeks of finalizing a lot of the work related to benefit year 2017. The threshold elimination puts a little bit of pressure, and what that w",172,"This is Jim Murray. It would be 2017. And as many of you know, we're in the process today and for the next several weeks of finalizing a lot of the work related to benefit year 2017. The threshold elimination puts a little bit of pressure, and what that would translate into is the number of members that are 4-Star-or-greater plans. A lot of the feedback that we're getting, we have a team of people that comes before us every Friday to talk about the progress that we're making a lot -- around a lot of the tactical steps that are a part of this whole process that goes over this 2-month period. And we feel very good about where we are positioned. Some pressure related to the elimination by CMS of the threshold but, frankly, feel pretty good about how things are playing out this year. And we should be favorably positioned relative to the competition because of a lot of the good work that we do around the Stars program."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","And A.J., I think it's just important to keep in mind that it is a relative measurement. And so our performance is highly predicated on everyone else's performance. And I think, as investors have seen over the past few years, our clinical capabilities has",71,"And A.J., I think it's just important to keep in mind that it is a relative measurement. And so our performance is highly predicated on everyone else's performance. And I think, as investors have seen over the past few years, our clinical capabilities has really outperformed the industry as a whole. And we continue to be confident that we'll be able to continue to outperform even as these changes persist."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Andrew Schenker with Morgan Stanley.",10,"Your next question is from Andrew Schenker with Morgan Stanley."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Yes, I was just hoping to follow up on your comments around maybe some of the moving parts in guidance since we all last spoke. So it sounds like the Concentra deal, as you kind of point out in the press release, was originally going to be about an $0.11",120,"Yes, I was just hoping to follow up on your comments around maybe some of the moving parts in guidance since we all last spoke. So it sounds like the Concentra deal, as you kind of point out in the press release, was originally going to be about an $0.11 headwind to earnings this year. You also kind of called out around the pressure on the impact from share repurchases related to the stock appreciation here. Now looking at guidance, it seems like tax rate may have come down a little bit. Just curious what some of the other moving parts were that let you feel confident to maintain your guidance range maybe versus where it was the last quarter."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, I think you outlined some of the major issues that we're focused on. Concentra will pressure earnings by $0.11. The share repurchase and tax rates and the like, it's probably about $0.04. So it's sort of a $0.15 headwind coming into this quarterly c",105,"Well, I think you outlined some of the major issues that we're focused on. Concentra will pressure earnings by $0.11. The share repurchase and tax rates and the like, it's probably about $0.04. So it's sort of a $0.15 headwind coming into this quarterly call. Again, I -- we feel comfortable about reiterating our guidance of $8.50 to $9. And really, what's going to drive that performance, as we said to the first question, is where does utilization ultimately end up. And right now, we feel good about where we are, but that's something we're very focused on that will ultimately drive the year's numbers."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think the important point on the Concentra sale is it is a timing issue for us versus a long-term business problem. And as we think about the sale, we think about it as that we are really allowing the company to redeploy assets that will advance us stra",103,"I think the important point on the Concentra sale is it is a timing issue for us versus a long-term business problem. And as we think about the sale, we think about it as that we are really allowing the company to redeploy assets that will advance us strategically at a price that we feel is -- was a very good value for what we're doing. And now what we can do is take that and redeploy it, whether it's in capital structure alterations such as stock buybacks or acquisitions that will be more accretive long term and strategically much, much stronger."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Maybe if I can just squeeze one more in real quick. The Healthcare Services segment specifically here, a lot of moving parts related to Concentra as well as your health -- home health acquisition. If you could just maybe talk about how those kind of offse",91,"Maybe if I can just squeeze one more in real quick. The Healthcare Services segment specifically here, a lot of moving parts related to Concentra as well as your health -- home health acquisition. If you could just maybe talk about how those kind of offset each other as well as maybe membership growth that allowed you to kind of maintain revenue guidance. And it seems like the only impact to pretax results was related to the pretax gain. So just making sure I understand the moving parts there as well."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Sure. Well, as you'll see in Healthcare Services segment guidance, we did adjust the revenue numbers and the like to comport with the divestiture of Concentra. I would say more broadly that, as I said in my remarks, that business is performing extremely w",129,"Sure. Well, as you'll see in Healthcare Services segment guidance, we did adjust the revenue numbers and the like to comport with the divestiture of Concentra. I would say more broadly that, as I said in my remarks, that business is performing extremely well. Membership is growing pretty dramatically based on largely our Medicare Advantage and PDP growth. But we're also seeing better engagement with our members both from a mail-older perspective on the pharmacy, which is very important, but also with Humana At Home as our analytical capabilities continue to identify people who would benefit from our Humana At Home capabilities. And so the combination of those is really driving that performance. So we feel very good about the range we have out there for Healthcare Services pretax."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Matthew Borsch with Goldman Sachs.",10,"Your next question is from Matthew Borsch with Goldman Sachs."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Yes, if I could ask a question about the individual market, just with 2 parts. Number one, the extent to which you're seeing inflow of new members coming into the exchanges generally for this year? A peer company of yours earlier today talked about seeing",72,"Yes, if I could ask a question about the individual market, just with 2 parts. Number one, the extent to which you're seeing inflow of new members coming into the exchanges generally for this year? A peer company of yours earlier today talked about seeing less inflow than they had expected. Secondly, just on Georgia, how you reprice in that market and avoid getting stuck in sort of an adverse selection spiral?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think -- as far as new members, I think really it's consistent with what we expected in terms of coming into the market and actually feel reasonably good about the overall pool of what we received. With Georgia, there's no doubt, Matt, that, that's some",98,"I think -- as far as new members, I think really it's consistent with what we expected in terms of coming into the market and actually feel reasonably good about the overall pool of what we received. With Georgia, there's no doubt, Matt, that, that's something that we're very focused on as you put in higher price increases or you're going to attract the wrong members. Part of that is going to go to product design and the metal tiers that we participate in, and so we're very cognizant of that risk and we're going to price appropriately."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Peter Costa with Wells Fargo Securities.",11,"Your next question comes from Peter Costa with Wells Fargo Securities."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Getting back to the individual business again. Why do you think you had the problem in Georgia? One of your competitors reported earnings earlier that has a number of low-priced silver plans in Georgia and didn't seem to share the problem that you guys ar",89,"Getting back to the individual business again. Why do you think you had the problem in Georgia? One of your competitors reported earnings earlier that has a number of low-priced silver plans in Georgia and didn't seem to share the problem that you guys are having there. Do you think it's local market related to you? Is it some cost disadvantage that you have in Georgia? And how do we avoid this from happening in another state down the road when the risk corridors and risk reinsurance goes away?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Peter, this is Jim. I'll take your question. And we wondered how long before you would dial in. With respect to Georgia, as Brian said earlier, one of the things that we did at the very beginning was to take our individual legacy business and do relativit",291,"Peter, this is Jim. I'll take your question. And we wondered how long before you would dial in. With respect to Georgia, as Brian said earlier, one of the things that we did at the very beginning was to take our individual legacy business and do relativities to our smaller Group block of business because that was a guarantee issue population. We thought that was fairly close to what might ultimately happen on the exchanges. And after that, and that was done local market by local market, we evaluated morbidities across a national basis with the help of an outside consulting actuarial firm. And as a result of that overall evaluation on a -- from a national perspective, we've lowered some of our markets' expected morbidities. And with respects to Georgia, while other markets turned out just fine relative to that pricing philosophy, Georgia didn't. Another part of the Georgia issue has to do with the platinum plans, which you've asked about in the past. One of the things that we're seeing with the platinum plans is that the philosophy or the strategy that we've enumerated in the past with you and others is that you need to have documentable risk conditions for the members that are heavier utilizers. And as we study the Georgia population as we're doing some of our risk adjustment work, we're seeing that the Georgia population, although heavier utilizers, don't have documentable risk conditions, which doesn't allow us then to get risk adjustment for them. And as a result of that, as Brian said, not only in Georgia but also in other states, we're evaluating that requirement as it respects our platinum plan strategies going forward. And you'll see us take some actions relative to that."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","That's helpful. And what is your strategy for avoiding this going forward in other states?",16,"That's helpful. And what is your strategy for avoiding this going forward in other states?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, now, we have a lot more actual claims information on which to set pricing. And so as we've done with all of our other products over the years, we're using actual claims to set our pricing and so our pricing will be consistent with our desire that th",115,"Well, now, we have a lot more actual claims information on which to set pricing. And so as we've done with all of our other products over the years, we're using actual claims to set our pricing and so our pricing will be consistent with our desire that this block of business will produce a satisfactory return. A lot of what we've done up to this point has been models and estimates based upon other lines of business. Now that we've gotten some real claims information relative to not only '14 but '15, that's how we'll set our pricing going forward. And we feel very confident in our ability to properly set the right rates."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Will you offer platinum plans next year?",7,"Will you offer platinum plans next year?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","We're going to evaluate that market by market. And to the extent that it doesn't make sense because of what I talked about relative to documentable risk conditions, we'll evaluate that and will act accordingly.",36,"We're going to evaluate that market by market. And to the extent that it doesn't make sense because of what I talked about relative to documentable risk conditions, we'll evaluate that and will act accordingly."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Kevin Fischbeck with Bank of America.",11,"Your next question comes from Kevin Fischbeck with Bank of America."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Just wanted to ask a little bit about the commentary on the Medicaid side of the business. The company seems to be more aggressively pursuing RFPs, I guess, as you have in the past. Can you talk a bit about your view, kind of what's changed in the last co",86,"Just wanted to ask a little bit about the commentary on the Medicaid side of the business. The company seems to be more aggressively pursuing RFPs, I guess, as you have in the past. Can you talk a bit about your view, kind of what's changed in the last couple of years? And you've pursued RFPs in a couple of different ways, outright or through joint ventures and things like that, so how do you think about the form of these types of participation might take?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I don't think our posture has changed relative to what we look at going forward. I think we continue to believe a partnership model in Medicaid makes sense in most states, if not all states, and we will continue to do that. We do look at states where we h",127,"I don't think our posture has changed relative to what we look at going forward. I think we continue to believe a partnership model in Medicaid makes sense in most states, if not all states, and we will continue to do that. We do look at states where we have existing membership, and as their RFPs come out, we want to participate in those RFPs. And that's really has been a standard direction and strategy for us. And our existing Medicaid results continue to meet expectations and continues to grow quite nicely. And so as we look at that going forward, we continue to believe that the Medicaid platform is a platform that has a partnership model in states that we are operating at within today."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Sarah James with Wedbush.",9,"Your next question comes from Sarah James with Wedbush."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'd like to go back to the out-of-network utilization portion of the 3R boost. It sounded like this was mainly something that pertained to new members transitioning on to an exchange product. And there has been some stricter network enforcement going on l",101,"I'd like to go back to the out-of-network utilization portion of the 3R boost. It sounded like this was mainly something that pertained to new members transitioning on to an exchange product. And there has been some stricter network enforcement going on lately and, I guess, going forward, so should I think about this as really dipping  into the 3Rs for just the first quarter and it's addressed going forward? Or is this something that's going to continue on through the year? And how can you modify your benefit designs in '16 in a way that would improve this scenario?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, I would say it's going to impact the 3Rs for this year just given where we are with our performance and the like; that when people go out of network, those are higher costs than we had anticipated, and that drives the receivables. As I mentioned in",143,"Well, I would say it's going to impact the 3Rs for this year just given where we are with our performance and the like; that when people go out of network, those are higher costs than we had anticipated, and that drives the receivables. As I mentioned in my remarks, we are working with these out-of-network providers both in terms of the reimbursable fees that we pay them and the fee schedules, contracting with them and the like. And it's also a matter of educating our members as to their product -- the product that they have. I would say we believe very deeply in the strategy of having these high-value networks that allows us to drive very affordable and attractive pricing to our members. And so those are really the puts and takes. It's a combination of provider and member education, so..."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","So it's more education and less of financial incentives kind of...",12,"So it's more education and less of financial incentives kind of..."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, I would say, with the providers, there's -- there will be financial impacts and financial incentives to ensure that we pay the appropriate levels of reimbursement for our -- for what we call our nonpar or nonparticipating providers. I should note it",141,"Well, I would say, with the providers, there's -- there will be financial impacts and financial incentives to ensure that we pay the appropriate levels of reimbursement for our -- for what we call our nonpar or nonparticipating providers. I should note it's a small number of members that are utilizing the benefit out of network. And to some extent, there might be some product design in terms of higher out-of-pocket costs for members who tend to go out of network, and that's something that we would be evaluating for next year. But I think the combination of provider education, provider contracting as well as member education and some tweaks in the product design, it's a problem that we think we can get our head around and solve for next year and, frankly, the back half of this year as well."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Scott Fidel with Deutsche Bank.",10,"Your next question is from Scott Fidel with Deutsche Bank."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Just wanted to stick on the individual business. And I know you were talking about Georgia specifically, but just interested in how much you think you're going to need to be raising premiums on the exchange business more broadly. If we look at your 3Rs ac",128,"Just wanted to stick on the individual business. And I know you were talking about Georgia specifically, but just interested in how much you think you're going to need to be raising premiums on the exchange business more broadly. If we look at your 3Rs accruals now for this year, they're right around $0.5 billion for 2015. And I would calculate that, on your sort of ACA-compliant individual business, that equates to around 13% of revenues. So given that both reinsurance and risk corridors really sort of scale away over the next year or 2, just help us think about how much sort of excess premium increases you're going to need to be implementing in order to reflect this, the expiration of those 2 Rs of the 3Rs."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I mean that's not a specific number, for obviously competitive reasons, we wouldn't want to comment on right now. I would say that, certainly, we have the 3Rs squarely in mind as we price for next year. We recognize there's 1 more year to go here with 2 o",112,"I mean that's not a specific number, for obviously competitive reasons, we wouldn't want to comment on right now. I would say that, certainly, we have the 3Rs squarely in mind as we price for next year. We recognize there's 1 more year to go here with 2 of the 3Rs. And so we're going to price such that, as I said in my remarks, we can earn a attractive return on capital in 2016 and beyond. And so we understand the dynamics of the market and the 3Rs and the pricing required to do that, and we'll take the necessary steps to make sure we get the right financial return."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","To Brian's earlier point, many of the markets are performing well, and we've got some problems in the State of Georgia that were -- we plan to address with our pricing and product design.",35,"To Brian's earlier point, many of the markets are performing well, and we've got some problems in the State of Georgia that were -- we plan to address with our pricing and product design."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. And then, just quickly just on the Medicare hospital admissions. How geographically broad based are you seeing that? I mean, I'm just trying to tie that into the comments from CMS on their final 2016 rates call, where they said that their actuaries",82,"Okay. And then, just quickly just on the Medicare hospital admissions. How geographically broad based are you seeing that? I mean, I'm just trying to tie that into the comments from CMS on their final 2016 rates call, where they said that their actuaries have also seen some flattening-out of the admissions trends. And I would assume if CMS was highlighting that, that it would probably be more of a broader base. So just interested geographically on how much you're seeing that."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think, as Jim said earlier, we wouldn't call any specific geographies. Where we were very focused was to see where we grew in particular markets and whether that more outsized growth was the cause of this, the slightly higher admits. And we haven't seen",64,"I think, as Jim said earlier, we wouldn't call any specific geographies. Where we were very focused was to see where we grew in particular markets and whether that more outsized growth was the cause of this, the slightly higher admits. And we haven't seen that. They're actually running pretty favorably. So I would suggest it's a broad-based phenomenon that we're watching very closely."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question comes from Ralph Giacobbe with CrÃ©dit Suisse.",10,"Your next question comes from Ralph Giacobbe with CrÃ©dit Suisse."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Switching a little bit. You guys reclassified segments, and I guess, within the Group book, you've seen enrollment declines. I guess the question is, how committed are you to this business, I guess, going forward? Is there any strategic review being conte",113,"Switching a little bit. You guys reclassified segments, and I guess, within the Group book, you've seen enrollment declines. I guess the question is, how committed are you to this business, I guess, going forward? Is there any strategic review being contemplated for this segment? And then, I guess, separately just on of the PBM, just want to clarify. You talked about sort of a full debrief on the 3Q call in November. Just hoping to get a little more clarity on that. Is that just a final decision you expect at that point on whether you kind of keep it or come up with some sort of outsourcing arrangement or the like?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","To your question on enrollment declines, we made the strategic decision a year or so ago. And I think we talked about that, that with the large Group business, we were going to wind that down over the next several years because we are not a national playe",279,"To your question on enrollment declines, we made the strategic decision a year or so ago. And I think we talked about that, that with the large Group business, we were going to wind that down over the next several years because we are not a national player and we can't compete in that space. But we are focused on what we call our sweet spot of smaller case sizes. And over the last 6 months, we've performed reasonably well with our sweet spot focus. You may recall that, in the fourth quarter, we grew very nicely with our small or focused business. This past quarter, we have seen some shrinkage in our fully insured smaller-case-size membership as a lot of our competitors are implementing their new rates relative to community rating. And we're seeing a little bit of an aggressive posture in some of the states that we do business. That will ultimately change over time, and we think that, that will work itself out. We feel very confident with our focus on the smaller case size. Over the next several years, we're going to be evaluating our Group business and, again, feel very good about its prospects for continued profitability. And it serves very nicely as a complement to our focus on local market scale. We talk a lot about that with our Medicare business, our individual business, our Medicaid business and our Group business in certain of our -- what we refer to as bold-move markets. So again, we feel very confident in our ability to compete and win in the smaller case size, and hopefully, you'll see that play out over the next several quarters."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I think, even as the results showed this quarter, we really have a 3-pronged approach within Group. One is around continuing to increase our efficiency within the Group sector, and you can see that as you see our cost ratios coming down. Second is to focu",154,"I think, even as the results showed this quarter, we really have a 3-pronged approach within Group. One is around continuing to increase our efficiency within the Group sector, and you can see that as you see our cost ratios coming down. Second is to focus on where we probably have better value proposition, and that's in the small Group, as what Jim just talked about, our sweet spot, and begin to start exiting relationships that are not profitable for us. And that traditionally is the larger ASO model. And then, the third is to continue to migrate customers to more of a consumer choice model within the markets that we are at, and that would be both the private exchange and public exchanges, as we see that being both a long-term trend and, frankly, I think, where we can even add more value with our Retail capabilities that we've had in the past."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","That's helpful. And just on the PBM?",8,"That's helpful. And just on the PBM?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","As we said, the PBM, we will -- we're going to evaluate, and it's under a continued evaluation. We've provided some updates in the past, but we -- the full update will be in the third quarter of this year.",40,"As we said, the PBM, we will -- we're going to evaluate, and it's under a continued evaluation. We've provided some updates in the past, but we -- the full update will be in the third quarter of this year."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","Your next question is from Ana Gupte with Leerink Partners.",10,"Your next question is from Ana Gupte with Leerink Partners."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","So I just want to make sure I understand this. I'm a little confused with everything. I'm getting a lot of questions from investors, so I'm pretty confused as well. On Retail MLR, what exactly -- is the underlying Medicare MLR okay, x BYD, and the sort of",89,"So I just want to make sure I understand this. I'm a little confused with everything. I'm getting a lot of questions from investors, so I'm pretty confused as well. On Retail MLR, what exactly -- is the underlying Medicare MLR okay, x BYD, and the sort of late-quarter potential uptick you're seeing? And is this the deterioration, which was not great, but it is deteriorating because your HumanaOne individual public exchange product is now going to be much more reliant on reinsurance and you're having all these issues?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Yes, again, if you -- Ana, if you look at our retail MERs for the quarter and you adjust them for prior period, they're actually down. So I think that's important to note. As we said, prior period did have a pretty material impact on our numbers. A lot of",101,"Yes, again, if you -- Ana, if you look at our retail MERs for the quarter and you adjust them for prior period, they're actually down. So I think that's important to note. As we said, prior period did have a pretty material impact on our numbers. A lot of it was expected. Some of it wasn't, related to the flu and the like. But when you look at the MERs, we feel pretty good about where we are on an incurred basis from an MER perspective. And as I said, they're actually down. So I hope that answers your question."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. So MA is in good place. On individual, did you see any improvements in your off-exchange ACA-compliant type MLR at all? Your competitors seem to be seeing what they said they would see. And so net-net, on individual, you had said you'd see margin ex",59,"Okay. So MA is in good place. On individual, did you see any improvements in your off-exchange ACA-compliant type MLR at all? Your competitors seem to be seeing what they said they would see. And so net-net, on individual, you had said you'd see margin expansion x exchange, public exchanges. What's going on in the rest of the book?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","Well, again, we don't break out our ACA-complaint off-exchange and on-exchange. I think, when you adjust for the 3Rs, our MER is in line with our expectations, which is why, as I said in my remarks, that we're going to break even or better for 2015. That",73,"Well, again, we don't break out our ACA-complaint off-exchange and on-exchange. I think, when you adjust for the 3Rs, our MER is in line with our expectations, which is why, as I said in my remarks, that we're going to break even or better for 2015. That still is the case. But the 3Rs clearly help us in that regard, and it's higher than we anticipated for the reasons that we went through."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay, one final one, if I may. So then, on HumanaOne, might you be in a place where you had some adverse selection last year? And as you're raising prices, are you seeing more of a deterioration in that book because anyone who can afford or is relatively",63,"Okay, one final one, if I may. So then, on HumanaOne, might you be in a place where you had some adverse selection last year? And as you're raising prices, are you seeing more of a deterioration in that book because anyone who can afford or is relatively healthy migrates someplace else, and so you might have challenges just turning around the book?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","As with respect to the State of Georgia, which we've talked about a couple of times, I wouldn't have said that it was adverse selection as opposed to the health condition of the entire population. We just have to price reflective of the health condition.",103,"As with respect to the State of Georgia, which we've talked about a couple of times, I wouldn't have said that it was adverse selection as opposed to the health condition of the entire population. We just have to price reflective of the health condition. And that may cause some of those members to move on to other plans, but we've got to get our pricing commensurate with the risk conditions that we're assuming. And we think that we've got a pretty good plan in place not only to increase pricing, but also evaluate some of the products that are in the marketplace."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","And your final question is from Christine Arnold with Cowen.",10,"And your final question is from Christine Arnold with Cowen."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","I'm trying to sort through what belongs in this year versus last year. Was there any net prior-period negative developments in the first quarter of this year related to last year in any products?",35,"I'm trying to sort through what belongs in this year versus last year. Was there any net prior-period negative developments in the first quarter of this year related to last year in any products?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","I'm not sure I understand the question. There was -- the prior-period development was positive this quarter based on 2014 and prior results. It was less positive than it was last first quarter in 2014. That was largely expected for the reasons I discussed",98,"I'm not sure I understand the question. There was -- the prior-period development was positive this quarter based on 2014 and prior results. It was less positive than it was last first quarter in 2014. That was largely expected for the reasons I discussed, i.e. it was a very high-PPD quarter in the first quarter of '14, and we implemented some claims processing changes with front-end review and Medicare that drove some of the change. Some of that was unexpected, but -- so there is positive PPD in our numbers, just less than there was last year."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Analysts","Okay. And then payables versus premium. I agree we should exclude PDP, but if we exclude PDP premiums, your payables versus premiums are still upside-down in the first quarter. Now this could be because you've got more capitated costs. It could be because",100,"Okay. And then payables versus premium. I agree we should exclude PDP, but if we exclude PDP premiums, your payables versus premiums are still upside-down in the first quarter. Now this could be because you've got more capitated costs. It could be because of other factors. Can you help me understand why? If you're seeing an increase in utilization, I would think you'd be booking more payables relative to premiums. And plus these issues with the individual books, but it looks like that's not happening. So can you help me sort through what other factors might be accounting for that?"
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","That comparison, change in premium versus change in claims payables, as we've discussed in the past, is not something that we focused on. There are a lot of moving pieces that go into that number. As we've said with regard to utilization, I wouldn't be as",282,"That comparison, change in premium versus change in claims payables, as we've discussed in the past, is not something that we focused on. There are a lot of moving pieces that go into that number. As we've said with regard to utilization, I wouldn't be as -- I wouldn't have made the statement as boldly as you just made it with regard to overall utilization. What we've pointed out, because it's important that we point it out to be fully transparent, is that we have seen that slight increase in admits over the recent weeks. And it's something that we're waiting to see how it plays through our claims lags over the coming months. As you know, it takes a few months for those to work through, but I wouldn't have made the overall statement that utilization is up. Remember that our admits are actually down year-over-year. Our trend benders are working, as we've said. And so I wouldn't read into it anything more than that. As you look for balance sheet quality and cash flow quality, the claims -- the process claims and unprocessed claims on a days -- DCP basis are actually up, which I know is a measure that you and others look at. And when you look at our cash flow for the year, which is where we focus because of the timing of these working capital issues that I went through, other than the 3Rs and, of course, Concentra, we're actually reasonably in-line. As you know, we took up our cash flow last quarter. And I think, were it not for some of these other adjustments that I just discussed, we'd be in pretty good stead there."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Executives","We appreciate the support the shareholders are providing us. We recognize that this quarter is a complicated quarter as a result of our Concentra sale, as a result of some of the changes in the comparison, but we do believe it is a quarter that continues",103,"We appreciate the support the shareholders are providing us. We recognize that this quarter is a complicated quarter as a result of our Concentra sale, as a result of some of the changes in the comparison, but we do believe it is a quarter that continues to reconfirm the organization's strategy around our growth in Retail and, in addition, the integrated delivery model.
So in conclusion, as always, we thank our 60,000 associates that help us bring these results to life every day. And we appreciate the shareholder support.
So thank you, and we look forward to continuing our conversations later. Thank you."
29618,278392395,797547,"Humana Inc., Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Humana Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
